NZ749301B2 - Heteroaromatic modulators of the retinoid-related orphan receptor gamma - Google Patents
Heteroaromatic modulators of the retinoid-related orphan receptor gamma Download PDFInfo
- Publication number
- NZ749301B2 NZ749301B2 NZ749301A NZ74930117A NZ749301B2 NZ 749301 B2 NZ749301 B2 NZ 749301B2 NZ 749301 A NZ749301 A NZ 749301A NZ 74930117 A NZ74930117 A NZ 74930117A NZ 749301 B2 NZ749301 B2 NZ 749301B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- methyl
- phenyl
- amino
- dimethyl
- alkyl
- Prior art date
Links
- 125000001072 heteroaryl group Chemical group 0.000 title claims abstract description 41
- 230000000051 modifying Effects 0.000 title claims abstract description 15
- 101710005817 RORC Proteins 0.000 title claims description 7
- 102100017734 RORC Human genes 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 413
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 105
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract description 81
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 80
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 61
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims abstract description 61
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims abstract description 56
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 44
- 125000005843 halogen group Chemical group 0.000 claims abstract description 37
- 229910004664 ORa Inorganic materials 0.000 claims abstract description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims abstract description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 330
- -1 chloro, methyl Chemical group 0.000 claims description 315
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 216
- 125000000217 alkyl group Chemical group 0.000 claims description 157
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 129
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 88
- 239000000203 mixture Substances 0.000 claims description 75
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 66
- 125000001424 substituent group Chemical group 0.000 claims description 64
- 150000002367 halogens Chemical class 0.000 claims description 48
- 125000003944 tolyl group Chemical group 0.000 claims description 46
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 claims description 45
- 239000011780 sodium chloride Substances 0.000 claims description 39
- 150000003839 salts Chemical class 0.000 claims description 36
- CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 claims description 34
- 201000010099 disease Diseases 0.000 claims description 28
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 24
- 239000012453 solvate Substances 0.000 claims description 21
- 150000004677 hydrates Chemical class 0.000 claims description 19
- 206010003816 Autoimmune disease Diseases 0.000 claims description 16
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 16
- 125000001188 haloalkyl group Chemical group 0.000 claims description 16
- 200000000018 inflammatory disease Diseases 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 15
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 15
- UMGDCJDMYOKAJW-UHFFFAOYSA-N Thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 14
- 201000004681 psoriasis Diseases 0.000 claims description 14
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 14
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 13
- 239000003937 drug carrier Substances 0.000 claims description 10
- ZPJZSEHCMJYUPI-UHFFFAOYSA-N methyl piperazine-1-carboxylate Chemical compound COC(=O)N1CCNCC1 ZPJZSEHCMJYUPI-UHFFFAOYSA-N 0.000 claims description 10
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims description 9
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims description 8
- 229910004755 ORb Inorganic materials 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 6
- KCOPAESEGCGTKM-UHFFFAOYSA-N 1,3-oxazol-4-one Chemical group O=C1COC=N1 KCOPAESEGCGTKM-UHFFFAOYSA-N 0.000 claims description 5
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 5
- 230000002730 additional Effects 0.000 claims description 5
- TUCNEACPLKLKNU-UHFFFAOYSA-N ethanone Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 claims description 5
- 230000003405 preventing Effects 0.000 claims description 5
- ZXDUPDQEFOYLOM-UHFFFAOYSA-O propylideneazanium Chemical group [CH2-]CC=[NH2+] ZXDUPDQEFOYLOM-UHFFFAOYSA-O 0.000 claims description 5
- 239000003981 vehicle Substances 0.000 claims description 5
- SYBYTAAJFKOIEJ-UHFFFAOYSA-N Methyl isopropyl ketone Chemical compound CC(C)C(C)=O SYBYTAAJFKOIEJ-UHFFFAOYSA-N 0.000 claims description 4
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 claims description 4
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 3
- FVSKHRXBFJPNKK-UHFFFAOYSA-N Propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 211
- 239000000543 intermediate Substances 0.000 abstract description 40
- 238000002560 therapeutic procedure Methods 0.000 abstract description 5
- 102000001691 Member 3 Group F Nuclear Receptor Subfamily 1 Human genes 0.000 abstract 2
- 108010029279 Member 3 Group F Nuclear Receptor Subfamily 1 Proteins 0.000 abstract 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 185
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 128
- 230000002829 reduced Effects 0.000 description 115
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 104
- 239000000243 solution Substances 0.000 description 98
- 238000005481 NMR spectroscopy Methods 0.000 description 89
- 239000007787 solid Substances 0.000 description 83
- 239000011541 reaction mixture Substances 0.000 description 73
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 65
- 238000004140 cleaning Methods 0.000 description 62
- 238000000034 method Methods 0.000 description 55
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 52
- 238000010438 heat treatment Methods 0.000 description 46
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 45
- 150000001412 amines Chemical class 0.000 description 43
- 235000019439 ethyl acetate Nutrition 0.000 description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 43
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 42
- 239000002253 acid Substances 0.000 description 40
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 40
- ZMANZCXQSJIPKH-UHFFFAOYSA-N N,N-Diethylethanamine Substances CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 37
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 37
- 239000000047 product Substances 0.000 description 36
- 235000002639 sodium chloride Nutrition 0.000 description 33
- 239000012044 organic layer Substances 0.000 description 32
- 238000004440 column chromatography Methods 0.000 description 31
- 239000000741 silica gel Substances 0.000 description 31
- 229910002027 silica gel Inorganic materials 0.000 description 31
- 125000004432 carbon atoms Chemical group C* 0.000 description 29
- 239000003921 oil Substances 0.000 description 29
- 235000019198 oils Nutrition 0.000 description 28
- 238000006243 chemical reaction Methods 0.000 description 25
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 25
- 239000002904 solvent Substances 0.000 description 25
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 24
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 24
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 24
- 238000002953 preparative HPLC Methods 0.000 description 24
- 102000005962 receptors Human genes 0.000 description 24
- 108020003175 receptors Proteins 0.000 description 24
- 125000003277 amino group Chemical compound 0.000 description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 22
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 22
- 150000001299 aldehydes Chemical class 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 20
- 125000005842 heteroatoms Chemical group 0.000 description 20
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 19
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 19
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 17
- 239000000010 aprotic solvent Substances 0.000 description 17
- HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 17
- 229910052938 sodium sulfate Inorganic materials 0.000 description 16
- 235000011152 sodium sulphate Nutrition 0.000 description 16
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 15
- 238000004166 bioassay Methods 0.000 description 15
- 238000003756 stirring Methods 0.000 description 15
- 125000001309 chloro group Chemical group Cl* 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 14
- 229910052757 nitrogen Inorganic materials 0.000 description 14
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 14
- 239000004480 active ingredient Substances 0.000 description 13
- 230000035492 administration Effects 0.000 description 13
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 13
- 125000001153 fluoro group Chemical group F* 0.000 description 13
- 150000002828 nitro derivatives Chemical class 0.000 description 13
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 13
- 150000003254 radicals Chemical class 0.000 description 13
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical compound C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-Toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 10
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 10
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L mgso4 Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 10
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- CSJLBAMHHLJAAS-UHFFFAOYSA-N Diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 9
- 102100008982 IL17A Human genes 0.000 description 9
- 101710003110 IL17A Proteins 0.000 description 9
- 238000007792 addition Methods 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 9
- 210000004027 cells Anatomy 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 9
- 125000006633 tert-butoxycarbonylamino group Chemical group 0.000 description 9
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 9
- 239000005864 Sulphur Chemical group 0.000 description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N Thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
- BRWIZMBXBAOCCF-UHFFFAOYSA-N aminothiourea Chemical compound NNC(N)=S BRWIZMBXBAOCCF-UHFFFAOYSA-N 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 8
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 8
- 235000019253 formic acid Nutrition 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Substances [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 8
- 239000012048 reactive intermediate Substances 0.000 description 8
- 206010012442 Dermatitis contact Diseases 0.000 description 7
- 210000003819 Peripheral blood mononuclear cell Anatomy 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 7
- 231100000080 dermatitis contact Toxicity 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 230000000699 topical Effects 0.000 description 7
- 239000003643 water by type Substances 0.000 description 7
- 210000004369 Blood Anatomy 0.000 description 6
- 239000004215 Carbon black (E152) Substances 0.000 description 6
- JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 description 6
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 6
- 230000002378 acidificating Effects 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 125000002393 azetidinyl group Chemical group 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 6
- 125000003566 oxetanyl group Chemical group 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 6
- 238000002821 scintillation proximity assay Methods 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- PFKFTWBEEFSNDU-UHFFFAOYSA-N 1,1'-Carbonyldiimidazole Substances C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 5
- 208000010247 Contact Dermatitis Diseases 0.000 description 5
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 5
- 210000001853 Microsomes, Liver Anatomy 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 125000004429 atoms Chemical group 0.000 description 5
- 150000002431 hydrogen Chemical class 0.000 description 5
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 125000000842 isoxazolyl group Chemical group 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- 125000006431 methyl cyclopropyl group Chemical group 0.000 description 5
- VQGISNOMGHCEPX-UHFFFAOYSA-N propanenitrile Chemical compound C[CH]C#N VQGISNOMGHCEPX-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Inorganic materials [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 125000001113 thiadiazolyl group Chemical group 0.000 description 5
- 125000001425 triazolyl group Chemical group 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 239000007832 Na2SO4 Substances 0.000 description 4
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 4
- UCPYLLCMEDAXFR-UHFFFAOYSA-N Triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 4
- ZBKFYXZXZJPWNQ-UHFFFAOYSA-N [N-]=C=S Chemical compound [N-]=C=S ZBKFYXZXZJPWNQ-UHFFFAOYSA-N 0.000 description 4
- 125000001743 benzylic group Chemical group 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- 230000000155 isotopic Effects 0.000 description 4
- 108020001756 ligand binding domains Proteins 0.000 description 4
- 125000002757 morpholinyl group Chemical group 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 125000003386 piperidinyl group Chemical group 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 235000015320 potassium carbonate Nutrition 0.000 description 4
- 230000001681 protective Effects 0.000 description 4
- 239000003586 protic polar solvent Substances 0.000 description 4
- AGGHKNBCHLWKHY-UHFFFAOYSA-N sodium;triacetyloxyboron(1-) Chemical compound [Na+].CC(=O)O[B-](OC(C)=O)OC(C)=O AGGHKNBCHLWKHY-UHFFFAOYSA-N 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
- NLOLSXYRJFEOTA-OWOJBTEDSA-N (E)-1,1,1,4,4,4-hexafluorobut-2-ene Chemical compound FC(F)(F)\C=C\C(F)(F)F NLOLSXYRJFEOTA-OWOJBTEDSA-N 0.000 description 3
- 208000004631 Alopecia Areata Diseases 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- 206010011401 Crohn's disease Diseases 0.000 description 3
- 210000004185 Liver Anatomy 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N Methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 3
- XBXCNNQPRYLIDE-UHFFFAOYSA-M N-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 3
- 241000658540 Ora Species 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 206010037162 Psoriatic arthropathy Diseases 0.000 description 3
- ODHCTXKNWHHXJC-VKHMYHEASA-N Pyroglutamic acid Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 3
- ZWZVWGITAAIFPS-UHFFFAOYSA-N Thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- BMJXMAAIWXBKBD-UHFFFAOYSA-N aniline;dihydrochloride Chemical compound Cl.Cl.NC1=CC=CC=C1 BMJXMAAIWXBKBD-UHFFFAOYSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000875 corresponding Effects 0.000 description 3
- 239000006184 cosolvent Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- TXWOGHSRPAYOML-UHFFFAOYSA-N cyclobutanecarboxylic acid Chemical compound OC(=O)C1CCC1 TXWOGHSRPAYOML-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000002592 echocardiography Methods 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- AWISGSJZNFRYNE-UHFFFAOYSA-N ethanol;dihydrochloride Chemical compound Cl.Cl.CCO AWISGSJZNFRYNE-UHFFFAOYSA-N 0.000 description 3
- 230000002349 favourable Effects 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- HPQVWDOOUQVBTO-UHFFFAOYSA-N lithium aluminum hydride Chemical compound [Li+].[Al-] HPQVWDOOUQVBTO-UHFFFAOYSA-N 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 150000002829 nitrogen Chemical group 0.000 description 3
- 125000000160 oxazolidinyl group Chemical group 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 201000001263 psoriatic arthritis Diseases 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-Hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 2
- UJZBSAONPRVEIJ-UHFFFAOYSA-N 2,2,2-trifluoroethyl carbonochloridate Chemical compound FC(F)(F)COC(Cl)=O UJZBSAONPRVEIJ-UHFFFAOYSA-N 0.000 description 2
- WGDYYIQUKVJLTK-UHFFFAOYSA-N 2-(oxolan-2-yl)-1,3,4-oxadiazole Chemical compound C1CCOC1C1=NN=CO1 WGDYYIQUKVJLTK-UHFFFAOYSA-N 0.000 description 2
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 2
- ZMSIFDIKIXVLDF-UHFFFAOYSA-N 2-methyl-1,3,4-oxadiazole Chemical compound CC1=NN=CO1 ZMSIFDIKIXVLDF-UHFFFAOYSA-N 0.000 description 2
- INBGSXNNRGWLJU-ZHHJOTBYSA-N 25-hydroxycholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCCC(C)(C)O)C)[C@@]1(C)CC2 INBGSXNNRGWLJU-ZHHJOTBYSA-N 0.000 description 2
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-Dimethylaminophenol Substances CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- 208000002029 Allergic Contact Dermatitis Diseases 0.000 description 2
- 230000036643 Apparent clearance Effects 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- XAEXSWVTEJHRMH-UHFFFAOYSA-N Chlorothen Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=C(Cl)S1 XAEXSWVTEJHRMH-UHFFFAOYSA-N 0.000 description 2
- 230000037250 Clearance Effects 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- HCUYBXPSSCRKRF-UHFFFAOYSA-N Diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 description 2
- 241000400611 Eucalyptus deanei Species 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- LJQLCJWAZJINEB-UHFFFAOYSA-N Hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F LJQLCJWAZJINEB-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 229910010082 LiAlH Inorganic materials 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N Methyl iodide Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 229960002900 Methylcellulose Drugs 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 description 2
- 108009000071 Non-small cell lung cancer Proteins 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N Oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N Phosphoryl chloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- OKBMCNHOEMXPTM-UHFFFAOYSA-M Potassium peroxymonosulfate Chemical compound [K+].OOS([O-])(=O)=O OKBMCNHOEMXPTM-UHFFFAOYSA-M 0.000 description 2
- 241001506308 Potato virus T Species 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N Pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- 229910006124 SOCl2 Inorganic materials 0.000 description 2
- 229940032147 Starch Drugs 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- VXUYXOFXAQZZMF-UHFFFAOYSA-N Titanium isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N Trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- ONDSBJMLAHVLMI-UHFFFAOYSA-N Trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- CKDWPUIZGOQOOM-UHFFFAOYSA-N carbamoyl chloride Chemical compound NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 229950005434 chloropyrilene Drugs 0.000 description 2
- 229940047645 chlorothen Drugs 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000035512 clearance Effects 0.000 description 2
- 230000001808 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 2
- RUYNTLUDGSFPFZ-UHFFFAOYSA-N cyclobutanol Chemical compound OC1[CH]CC1 RUYNTLUDGSFPFZ-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-O hydron;urea Chemical compound NC([NH3+])=O XSQUKJJJFZCRTK-UHFFFAOYSA-O 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 230000000622 irritating Effects 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- SJRJJKPEHAURKC-UHFFFAOYSA-N n-methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 2
- 239000007908 nanoemulsion Substances 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 230000003000 nontoxic Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 125000004430 oxygen atoms Chemical group O* 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920002102 polyvinyl toluene Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propanol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 230000000069 prophylaxis Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000010956 selective crystallization Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000000707 stereoselective Effects 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 201000006704 ulcerative colitis Diseases 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- PNFVIPIQXAIUAY-ZCFIWIBFSA-N (2R)-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC[C@H](C(O)=O)NC(=O)OC(C)(C)C PNFVIPIQXAIUAY-ZCFIWIBFSA-N 0.000 description 1
- QVHJQCGUWFKTSE-RXMQYKEDSA-N (2R)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound OC(=O)[C@@H](C)NC(=O)OC(C)(C)C QVHJQCGUWFKTSE-RXMQYKEDSA-N 0.000 description 1
- SZYCXFJWSGHCLZ-ZETCQYMHSA-N (2S)-2-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-1-carboxylic acid Chemical compound CC(C)(C)OC(=O)[C@@H]1CCCN1C(O)=O SZYCXFJWSGHCLZ-ZETCQYMHSA-N 0.000 description 1
- NBSJCAVRXHCOAD-UHFFFAOYSA-N 1,1-difluoro-3-methylcyclopentane Chemical compound CC1CCC(F)(F)C1 NBSJCAVRXHCOAD-UHFFFAOYSA-N 0.000 description 1
- GFTBMBHVZZFGCK-UHFFFAOYSA-N 1,2,5-thiadiazole-3-carboxylic acid Chemical compound OC(=O)C=1C=NSN=1 GFTBMBHVZZFGCK-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 150000000094 1,4-dioxanes Chemical compound 0.000 description 1
- CSCPPACGZOOCGX-MICDWDOJSA-N 1-deuteriopropan-2-one Chemical compound [2H]CC(C)=O CSCPPACGZOOCGX-MICDWDOJSA-N 0.000 description 1
- DFPYXQYWILNVAU-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1.C1=CC=C2N(O)N=NC2=C1 DFPYXQYWILNVAU-UHFFFAOYSA-N 0.000 description 1
- XCBNHDSVRQZWLH-UHFFFAOYSA-N 1-hydroxycyclobutane-1-carboxylic acid Chemical compound OC(=O)C1(O)CCC1 XCBNHDSVRQZWLH-UHFFFAOYSA-N 0.000 description 1
- BSXPDVKSFWQFRT-UHFFFAOYSA-N 1-hydroxytriazolo[4,5-b]pyridine Chemical compound C1=CC=C2N(O)N=NC2=N1 BSXPDVKSFWQFRT-UHFFFAOYSA-N 0.000 description 1
- JREJQAWGQCMSIY-UHFFFAOYSA-N 1-methyl-pyrazole-5-carboxylic acid Chemical compound CN1N=CC=C1C(O)=O JREJQAWGQCMSIY-UHFFFAOYSA-N 0.000 description 1
- GMQPIGJXSZAXSJ-UHFFFAOYSA-N 1-methylsulfonylpyrrolidine Chemical compound CS(=O)(=O)N1CCCC1 GMQPIGJXSZAXSJ-UHFFFAOYSA-N 0.000 description 1
- SFBMENHESNKIKS-UHFFFAOYSA-N 1-oxa-2,3-diazacyclopent-2-en-4-yne Chemical compound O1N=NC#C1 SFBMENHESNKIKS-UHFFFAOYSA-N 0.000 description 1
- RHQDFWAXVIIEBN-UHFFFAOYSA-N 2,2,2-trifluoroethyl alcohol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
- SBSKRVZFWQPJID-UHFFFAOYSA-N 2,2-difluorobutanoic acid Chemical compound CCC(F)(F)C(O)=O SBSKRVZFWQPJID-UHFFFAOYSA-N 0.000 description 1
- SNIIADHYLUSXJJ-UHFFFAOYSA-N 2,5-dimethyl-3-nitrobenzaldehyde Chemical compound CC1=CC(C=O)=C(C)C([N+]([O-])=O)=C1 SNIIADHYLUSXJJ-UHFFFAOYSA-N 0.000 description 1
- CXGZFDGAQVAGHA-UHFFFAOYSA-N 2,5-dimethyl-3-nitrobenzoic acid Chemical compound CC1=CC(C(O)=O)=C(C)C([N+]([O-])=O)=C1 CXGZFDGAQVAGHA-UHFFFAOYSA-N 0.000 description 1
- XZRHNAFEYMSXRG-UHFFFAOYSA-N 2,5-dimethylbenzoic acid Chemical compound CC1=CC=C(C)C(C(O)=O)=C1 XZRHNAFEYMSXRG-UHFFFAOYSA-N 0.000 description 1
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-Bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
- AFENDNXGAFYKQO-UHFFFAOYSA-N 2-Hydroxybutyric acid Chemical compound CCC(O)C(O)=O AFENDNXGAFYKQO-UHFFFAOYSA-N 0.000 description 1
- FQRMJJJRCOMBKG-UHFFFAOYSA-N 2-cyclobutylacetic acid Chemical compound OC(=O)CC1CCC1 FQRMJJJRCOMBKG-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- APOYTRAZFJURPB-UHFFFAOYSA-N 2-methoxy-N-(2-methoxyethyl)-N-(trifluoro-$l^{4}-sulfanyl)ethanamine Chemical compound COCCN(S(F)(F)F)CCOC APOYTRAZFJURPB-UHFFFAOYSA-N 0.000 description 1
- JJKWHOSQTYYFAE-UHFFFAOYSA-N 2-methoxyacetyl chloride Chemical compound COCC(Cl)=O JJKWHOSQTYYFAE-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- AYEGPMGNMOIHDL-UHFFFAOYSA-N 2-methylcyclopropane-1-carboxylic acid Chemical compound CC1CC1C(O)=O AYEGPMGNMOIHDL-UHFFFAOYSA-N 0.000 description 1
- MMIWDPMBWOTICQ-UHFFFAOYSA-M 2-methylpiperazine-1-carboxylate Chemical compound CC1CNCCN1C([O-])=O MMIWDPMBWOTICQ-UHFFFAOYSA-M 0.000 description 1
- IIVWHGMLFGNMOW-UHFFFAOYSA-N 2-methylpropane Chemical group C[C](C)C IIVWHGMLFGNMOW-UHFFFAOYSA-N 0.000 description 1
- YNYLYAXLIWRIMX-UHFFFAOYSA-N 2-oxoazetidine-1-carboxylic acid Chemical compound OC(=O)N1CCC1=O YNYLYAXLIWRIMX-UHFFFAOYSA-N 0.000 description 1
- DXLZFZGHXIZHFB-UHFFFAOYSA-N 3,3-difluorocyclopentane-1-carboxylic acid Chemical compound OC(=O)C1CCC(F)(F)C1 DXLZFZGHXIZHFB-UHFFFAOYSA-N 0.000 description 1
- CPOFFCWAFRUKDX-UHFFFAOYSA-N 3-(2-oxoethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(CC=O)=C1 CPOFFCWAFRUKDX-UHFFFAOYSA-N 0.000 description 1
- FTPAHNNMUYOHOB-UHFFFAOYSA-N 3-(bromomethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(CBr)=C1 FTPAHNNMUYOHOB-UHFFFAOYSA-N 0.000 description 1
- WUKANDNCRFGEHC-UHFFFAOYSA-N 3-(dimethylamino)propyl-(ethyliminomethylidene)azanium;chloride;hydrochloride Chemical compound Cl.Cl.CCN=C=NCCCN(C)C WUKANDNCRFGEHC-UHFFFAOYSA-N 0.000 description 1
- FDPIMTJIUBPUKL-UHFFFAOYSA-N 3-Pentanone Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 1
- CXKBIGPGKSLGAP-UHFFFAOYSA-N 4-[(3,5-difluorophenyl)methylamino]-3-nitrobenzoic acid Chemical compound [O-][N+](=O)C1=CC(C(=O)O)=CC=C1NCC1=CC(F)=CC(F)=C1 CXKBIGPGKSLGAP-UHFFFAOYSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical group OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 description 1
- GAIAHHRZVGJYQW-UHFFFAOYSA-N 4-methyl-1,2,5-oxadiazole-3-carboxylic acid Chemical compound CC1=NON=C1C(O)=O GAIAHHRZVGJYQW-UHFFFAOYSA-N 0.000 description 1
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N AcOH acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229940023476 Agar Drugs 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N Ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229940092782 Bentonite Drugs 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N Benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- VICSZNBZFBGDGP-UHFFFAOYSA-N C1(CCC1)C(=O)C1N(CCNC1)C Chemical compound C1(CCC1)C(=O)C1N(CCNC1)C VICSZNBZFBGDGP-UHFFFAOYSA-N 0.000 description 1
- IXRAQYMAEVFORF-UTLNTRLCSA-N C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(O)[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(O)[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 IXRAQYMAEVFORF-UTLNTRLCSA-N 0.000 description 1
- NDLDEHVIJLFWSU-QMMMGPOBSA-N CC(C)(C)OC(=O)N[C@@](C)(O)C(O)=O Chemical compound CC(C)(C)OC(=O)N[C@@](C)(O)C(O)=O NDLDEHVIJLFWSU-QMMMGPOBSA-N 0.000 description 1
- FJNSWFUWMAXJQL-UHFFFAOYSA-N CC1=C(C=C(C=C1[N+](=O)[O-])C)CO Chemical compound CC1=C(C=C(C=C1[N+](=O)[O-])C)CO FJNSWFUWMAXJQL-UHFFFAOYSA-N 0.000 description 1
- ARQRPTNYUOLOGH-UHFFFAOYSA-N CHCl3 Chloroform Chemical compound ClC(Cl)Cl.ClC(Cl)Cl ARQRPTNYUOLOGH-UHFFFAOYSA-N 0.000 description 1
- 229910014455 Ca-Cb Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L Calcium hydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Carbodicyclohexylimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229940105329 Carboxymethylcellulose Drugs 0.000 description 1
- 229940112822 Chewing Gum Drugs 0.000 description 1
- JGBQPTVKJQOFBS-UHFFFAOYSA-N ClS(Cl)=O.ClP(Cl)(Cl)=O Chemical compound ClS(Cl)=O.ClP(Cl)(Cl)=O JGBQPTVKJQOFBS-UHFFFAOYSA-N 0.000 description 1
- 229960001681 Croscarmellose Sodium Drugs 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229960000913 Crospovidone Drugs 0.000 description 1
- MLIREBYILWEBDM-UHFFFAOYSA-N Cyanoacetic acid Chemical compound OC(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N DCM Dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N DMSO dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 230000037287 ELIMINATION RATE CONSTANT Effects 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N EtOAc EtOAc Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N Ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 240000000437 Eucalyptus leucoxylon Species 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 230000036218 HEPATIC EXTRACTION RATIO Effects 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 210000002216 Heart Anatomy 0.000 description 1
- 229960002897 Heparin Drugs 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 family Proteins 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N Isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 101710009221 LD Proteins 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L Magnesium hydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N MeCN acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N MeOH methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N Meta-Chloroperoxybenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- 230000036650 Metabolic stability Effects 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N Methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- VSPPONOIKZXUBJ-UHFFFAOYSA-N N,N-diethylethanamine;oxolane Chemical compound C1CCOC1.CCN(CC)CC VSPPONOIKZXUBJ-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N N,N-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-N Nicotinamide adenine dinucleotide phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 1
- ODUCDPQEXGNKDN-UHFFFAOYSA-N Nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 1
- 108020005497 Nuclear hormone receptors Proteins 0.000 description 1
- 102000007399 Nuclear hormone receptors Human genes 0.000 description 1
- 239000012425 OXONE® Substances 0.000 description 1
- 230000035536 Oral bioavailability Effects 0.000 description 1
- 102000016978 Orphan receptors Human genes 0.000 description 1
- 108070000031 Orphan receptors Proteins 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229940068968 Polysorbate 80 Drugs 0.000 description 1
- 229940068965 Polysorbates Drugs 0.000 description 1
- 239000007759 RPMI Media 1640 Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 229940005550 Sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M Sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M Sodium stearate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N Sulfamic acid Chemical compound NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-Lymphocytes Anatomy 0.000 description 1
- UJJLJRQIPMGXEZ-UHFFFAOYSA-N Tetrahydro-2-furoic acid Chemical compound OC(=O)C1CCCO1 UJJLJRQIPMGXEZ-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N Tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 210000001541 Thymus Gland Anatomy 0.000 description 1
- 229940116362 Tragacanth Drugs 0.000 description 1
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 1
- 229960001727 Tretinoin Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- HWKQNAWCHQMZHK-UHFFFAOYSA-N Trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 description 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- BIVUUOPIAYRCAP-UHFFFAOYSA-N aminoazanium;chloride Chemical compound Cl.NN BIVUUOPIAYRCAP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 150000003939 benzylamines Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 229910000090 borane Inorganic materials 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 125000004773 chlorofluoromethyl group Chemical group [H]C(F)(Cl)* 0.000 description 1
- LKYXEULZVGJVTG-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH] LKYXEULZVGJVTG-UHFFFAOYSA-N 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000005712 crystallization Effects 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 1
- 230000002939 deleterious Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- DMJZZSLVPSMWCS-UHFFFAOYSA-N diborane Chemical compound B1[H]B[H]1 DMJZZSLVPSMWCS-UHFFFAOYSA-N 0.000 description 1
- BTFSVBAFIHSVBO-UHFFFAOYSA-N dichloromethane;1,4-dioxane Chemical compound ClCCl.C1COCCO1 BTFSVBAFIHSVBO-UHFFFAOYSA-N 0.000 description 1
- 125000005046 dihydronaphthyl group Chemical group 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide DMF Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- IKYOVSVBLHGFMA-UHFFFAOYSA-N dipyridin-2-yloxymethanethione Chemical compound C=1C=CC=NC=1OC(=S)OC1=CC=CC=N1 IKYOVSVBLHGFMA-UHFFFAOYSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol EtOH Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 1
- KCCKZVUDDJTOFK-UHFFFAOYSA-N hydrazine;hydrate;hydrochloride Chemical compound O.Cl.NN KCCKZVUDDJTOFK-UHFFFAOYSA-N 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- NONOKGVFTBWRLD-UHFFFAOYSA-N isocyanatosulfanylimino(oxo)methane Chemical compound O=C=NSN=C=O NONOKGVFTBWRLD-UHFFFAOYSA-N 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003041 laboratory chemical Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VASIZKWUTCETSD-UHFFFAOYSA-N manganese(II) oxide Inorganic materials [Mn]=O VASIZKWUTCETSD-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002609 media Substances 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000003228 microsomal Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 229940113083 morpholine Drugs 0.000 description 1
- UULYVBBLIYLRCU-UHFFFAOYSA-N myristyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC UULYVBBLIYLRCU-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 230000036220 oral bioavailability Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 150000004866 oxadiazoles Chemical class 0.000 description 1
- SOWBFZRMHSNYGE-UHFFFAOYSA-N oxamic acid Chemical compound NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- UJJLJRQIPMGXEZ-UHFFFAOYSA-M oxolane-2-carboxylate Chemical compound [O-]C(=O)C1CCCO1 UJJLJRQIPMGXEZ-UHFFFAOYSA-M 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 230000000737 periodic Effects 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 230000003285 pharmacodynamic Effects 0.000 description 1
- 230000000275 pharmacokinetic Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920001888 polyacrylic acid Polymers 0.000 description 1
- 229920001690 polydopamine Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001184 potassium carbonate Substances 0.000 description 1
- HVAHYVDBVDILBL-UHFFFAOYSA-M potassium;oxidooxy hydrogen sulfate Chemical compound [K+].OS(=O)(=O)OO[O-] HVAHYVDBVDILBL-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive Effects 0.000 description 1
- UGBJIKLMXYATRX-QMMMGPOBSA-N propan-2-yl (2S)-2-methylpiperazine-1-carboxylate Chemical compound CC(C)OC(=O)N1CCNC[C@@H]1C UGBJIKLMXYATRX-QMMMGPOBSA-N 0.000 description 1
- 230000001185 psoriatic Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- AOJFQRQNPXYVLM-UHFFFAOYSA-M pyridine;chloride Chemical compound [Cl-].C1=CC=NC=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-M 0.000 description 1
- 150000003222 pyridines Chemical compound 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 230000002285 radioactive Effects 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- NGBNXJUWQPLNGM-UHFFFAOYSA-N silver;azane Chemical compound N.[Ag+] NGBNXJUWQPLNGM-UHFFFAOYSA-N 0.000 description 1
- UKHWJBVVWVYFEY-UHFFFAOYSA-M silver;hydroxide Chemical compound [OH-].[Ag+] UKHWJBVVWVYFEY-UHFFFAOYSA-M 0.000 description 1
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Substances [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2R,3R,4S,5S,6R)-2-[(2R,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
- ODGROJYWQXFQOZ-UHFFFAOYSA-N sodium;boron(1-) Chemical compound [B-].[Na+] ODGROJYWQXFQOZ-UHFFFAOYSA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001954 sterilising Effects 0.000 description 1
- 101710011036 stiI Proteins 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 239000000700 tracer Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003442 weekly Effects 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
Abstract
The present invention relates to a compound according to general formula (I) wherein X represents N or CH; R1 is -CN, (C1–C6)alkyl, (C3–C7)cycloalkyl, (3-7 membered)heterocycloalkyl, (5-6 membered)heteroaryl, (C3–C7)cycloalkyl(C1–C4)alkyl, (3-7 membered)heterocycloalkyl-(C1–C4)alkyl or (5-6 membered)heteroaryl-(C1–C4)alkyl; R2 is halogen, cyano, (C1–C4)alkyl or (C3–C7)cycloalkyl; R3 is halogen, cyano, (C1–C4)alkyl, (C1–C4)haloalkyl or (C3–C7)cycloalkyl; R4 is (C1–C4)alkyl or (C1–C4)haloalkyl; R5 is (C1–C6)alkyl, (C3–C7)cycloalkyl, (C1–C6)alkyl-(C3–C7)cycloalkyl, (C3–C7)cycloalkyl-(C1–C6)alkyl, (3-7 membered)heterocycloalkyl, phenyl, (5-6 membered)heteroaryl or -ORa. Said compounds are useful as ROR-gamma modulators. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds and to intermediates for preparation of said compounds. )heteroaryl-(C1–C4)alkyl; R2 is halogen, cyano, (C1–C4)alkyl or (C3–C7)cycloalkyl; R3 is halogen, cyano, (C1–C4)alkyl, (C1–C4)haloalkyl or (C3–C7)cycloalkyl; R4 is (C1–C4)alkyl or (C1–C4)haloalkyl; R5 is (C1–C6)alkyl, (C3–C7)cycloalkyl, (C1–C6)alkyl-(C3–C7)cycloalkyl, (C3–C7)cycloalkyl-(C1–C6)alkyl, (3-7 membered)heterocycloalkyl, phenyl, (5-6 membered)heteroaryl or -ORa. Said compounds are useful as ROR-gamma modulators. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds and to intermediates for preparation of said compounds.
Description
HETEROAROMATIC MODULATORS OF THE RETINOID-RELATED ORPHAN
RECEPTOR GAMMA
FIELD OF THE INVENTION
This invention relates to compounds which are ROR-gamma (ROR γ) modulators, to
intermediates for the preparation thereof, to said compounds for use in therapy and to
pharmaceutical compositions comprising said compounds and to methods of treating
diseases with said compounds.
BACKGROUND OF THE INVENTION
The Retinoic acid-related orphan receptor (ROR) gene family is part of the nuclear
hormone receptor super-family and consists of three members ROR alpha, ROR beta and
ROR gamma (ROR α, ROR β and ROR γ). Each ROR gene is expressed in different isoforms;
the isoforms differ in their pattern of tissue-specific expression and can regulate distinct
physiological processes and target genes. More specifically two isoforms of ROR γ have
been identified; ROR γ1 and ROR γ2 (known as ROR γt). ROR γ1 is expressed in multiple
tissues, such as heart, brain, kidney, lung, liver and muscle; whereas ROR γt is restricted
to the cells of the immune system and is expressed in lymphoid organs, such as the
thymus (Jetten, A. M.; Adv. Dev. Biol. (2006), 16, 313-355).
ROR γt has been shown to be crucial for the development of T helper 17 cells (T 17 cells)
(Ivanov et.a l., Cell (2006), 126, 1121-1133). TH17 cells, which produce IL-17, IL-21
and IL-22, have an essential role in the development of many autoimmune and
inflammatory disorders, such as multiple sclerosis, psoriasis and rheumatoid arthritis.
(Betelli, E. et al., Nature Immunol. (2007), 8, 345-350; Fouser, L. et al. Immunol. Rev.
(2008), 226, 87-102); suggesting that development of ROR γ modulators may be
beneficial for treatment of autoimmune and inflammatory diseases (Kojetin, D. et al.;
Nature Rev Drug Discovery (2014) 13, 197-215).
Recently, Proof-of-Concept was shown with an oral ROR γt inhibitor (VTP 43742) in a
Phase 2a clinical trial in psoriatic patients.
Several other compounds modulating ROR γt have been reported, for example;
WO2014/086894 discloses ‘Modulators of the retinoid-related orphan receptor gamma
(ROR-gamma) for use in the treatment of autoimmune and inflammatory diseases.’
WO2015/180612, WO2015/180613 and WO2015/180614 disclose novel retinoid-related
orphan receptor gamma (ROR-gamma) modulators and their use in the treatment of
autoimmune and inflammatory diseases.
Thus it is desirable to provide compounds that modulate the activity of ROR γ for use in
the treatment of autoimmune and inflammatory disorders. It is an object of the present
invention to go some way to satisfying this desideratum; and/or to at least provide the
public with a useful choice.
SUMMARY OF THE INVENTION
The inventors have surprisingly found that novel compounds of the present invention
exhibit modulating effect on ROR-gamma and may be useful as therapeutic agents for
diseases mediated by ROR-gamma, including autoimmune or inflammatory diseases
such as psoriasis, psoriatic arthritis, multiple sclerosis, rheumatoid arthritis, Crohns
disease, ulcerative colitis, alopecia areata, contact dermatitis, including irritative contact
dermatitis and allergic contact dermatitis, spondyloarthritis; and cancers, including
prostate cancer and non-small cell lung cancer.
Compounds of the present invention may have favourable pharmacokinetic and
pharmacodynamic properties such as favourable oral bioavailability, solubility,
absorption and metabolic stability or a favourable toxicity profile.
Compounds of the present invention may have low clearance in human liver microsomes
thus making them suitable for oral use; or compounds of the present invention may
have high clearance in human liver microsomes thus making them suitable for topical
use as they may have reduced systemic side-effects while retaining the topical anti-
inflammatory efficacy.
Accordingly, the present invention relates to a compound according to general formula
wherein X represents N or CH;
R is selected from the group consisting of -CN, (C –C )alkyl, (C –C )cycloalkyl, (3-7
1 1 6 3 7
membered)heterocycloalkyl, (5-6 membered)heteroaryl, (C3–C7)cycloalkyl(C1–C4)alkyl,
(3-7 membered)heterocycloalkyl-(C1–C4)alkyl and (5-6 membered)heteroaryl-(C1–
C4)alkyl, wherein said (C1–C6)alkyl, (C3–C7)cycloalkyl, (3-7 membered)heterocycloalkyl,
(5membered)heteroaryl, (C3–C7)cycloalkyl(C1–C4)alkyl, (3-7
membered)heterocycloalkyl-(C –C )alkyl and (5-6 membered)heteroaryl-(C –C )alkyl is
1 4 1 4
optionally substituted with one or more substituents independently selected from R ;
R is selected from the group consisting of halogen, cyano, (C –C )alkyl and (C –
2 1 4 3
C )cycloalkyl, wherein said (C –C )alkyl and (C –C )cycloalkyl is optionally substituted
7 1 4 3 7
with one or more substituents independently selected from –OH and halogen;
R3 is selected from the group consisting of halogen, cyano, (C1–C4)alkyl, (C1–
C4)haloalkyl and (C3–C7)cycloalkyl;
R is selected from the group consisting of (C –C )alkyl and (C –C )haloalkyl;
4 1 4 1 4
R is selected from the group consisting of (C –C )alkyl, (C –C )cycloalkyl, (C –C )alkyl-
1 6 3 7 1 6
(C –C )cycloalkyl, (C –C )cycloalkyl-(C –C )alkyl, (3-7 membered)heterocycloalkyl,
3 7 3 7 1 6
phenyl, (5-6 membered)heteroaryl and -OR ; wherein said (C –C )alkyl, (C –
a 1 6 3
C7)cycloalkyl, (C1–C6)alkyl-(C3–C7)cycloalkyl, (C3–C7)cycloalkyl-(C1–C6)alkyl, (3-7
membered)heterocycloalkyl, phenyl, (5-6 membered)heteroaryl and -ORa is optionally
substituted with one or more substituents independently selected from R7;
R represents the group consisting of –OH, -CN, halogen, =O, -S(O) R , -NR R , -
6 2 b c d
NR C(O)R , -C(O)NR R , -S(O) NR R , -NR S(O) R , -OR -C(O)R , (C –C )alkyl,
c d c d 2 c d c 2 b b b 1 4
hydroxy(C1–C4)alkyl, halo(C1–C4)alkyl, (C3–C7)cycloalkyl, (3-7
membered)heterocycloalkyl and (5-6 membered)heteroaryl;
R7 represents the group consisting of –OH, -CN, halogen, (C1–C4)alkyl, (C3-C7)cycloalkyl
and (C1–C6)alkyl-(C3–C7)cycloalkyl-;
R represents (C –C )alkyl, (C –C )cycloalkyl, (C –C )alkyl-(C –C )cycloalkyl- or (C –C )-
a 1 6 3 7 1 6 3 7 3 7
–C )alkyl;
cycloalkyl(C1 6
Rb represents (C1–C6)alkyl or (C3–C7)cycloalkyl;
Rc and Rd each independently represents H, (C1–C6)alkyl or (C3–C7)cycloalkyl;
or pharmaceutically acceptable salts, hydrates or solvates thereof.
In another aspect, the invention relates to a compound of general formula (I) for use as
a medicament.
In yet another aspect, the invention relates to a compound of general formula (I) for use
in treatment of autoimmune or inflammatory diseases.
In yet another aspect, the invention relates to a pharmaceutical composition comprising
a compound according to general formula (I) together with a pharmaceutically
acceptable vehicle or excipient or pharmaceutically acceptable carrier(s).
In yet another aspect, the invention relates to use of a compound according to general
formula (I) in the manufacture of a medicament for use in treatment of autoimmune or
inflammatory diseases.
In yet another aspect, the invention relates to use of a compound according to according
to general formula (I), optionally together with a pharmaceutically acceptable carrier or
one or more excipients, in the manufacture of a medicament for preventing, treating or
ameliorating psoriasis, wherein the medicament is optionally formulated for
administration in combination with other therapeutically active compounds.
In yet another aspect, the invention relates to use of a compound according general
formula (I) in the manufacture of a medicament for use in treatment of a disease,
disorder or condition, which disease, disorder or condition is responsive of modulation of
RORgamma.
In another aspect the invention relates to a compound according to general formula (II)
(II)
wherein
R is selected from the group consisting of halogen and (C –C )alkyl, wherein said (C –
2 1 4 1
C )alkyl is optionally substituted with one or more substituents independently selected
from halogen;
R3 is selected from (C1–C4)alkyl;
R is selected from the group (C –C )alkyl;
4 1 4
R5 is selected from the group consisting of (C1–C6)alkyl, (C3–C7)cycloalkyl, phenyl and -
OR ; wherein said (C –C )alkyl, (C –C )cycloalkyl, phenyl and -OR is optionally
a 1 6 3 7 a
substituted with one or more substituents independently selected from halogen.
In yet another aspect, the invention relates to a compound according to general formula
(IX)
(IX)
wherein
R is selected from the group consisting of halogen and (C –C )alkyl, wherein said (C –
2 1 4 1
C )alkyl is optionally substituted with one or more substituents independently selected
from halogen;
R3 is selected from (C1–C4)alkyl;
R is selected from the group (C –C )alkyl;
4 1 4
R is selected from the group consisting of (C –C )alkyl, (C –C )cycloalkyl, phenyl and -
1 6 3 7
; wherein said (C –C )alkyl, (C –C )cycloalkyl, phenyl and -OR is optionally
ORa 1 6 3 7 a
substituted with one or more substituents independently selected from halogen.
Also described is a compound according to general formula (II), which is useful as
intermediate for the preparation of a compound of general formula (I),
(II)
wherein
R is selected from the group consisting of halogen, cyano, (C –C )alkyl and (C –
2 1 4 3
C )cycloalkyl, wherein said (C –C )alkyl and (C –C )cycloalkyl is optionally substituted
7 1 4 3 7
with one or more substituents independently selected from –OH and halogen;
R is selected from the group consisting of halogen, cyano, (C –C )alkyl, (C –
3 1 4 1
C )haloalkyl and (C –C )cycloalkyl;
4 3 7
R4 is selected from the group consisting of (C1–C4)alkyl and (C1–C4)haloalkyl;
R5 is selected from the group consisting of (C1–C6)alkyl, (C3–C7)cycloalkyl, (C1–C6)alkyl-
(C –C )cycloalkyl, (C –C )cycloalkyl-(C –C )alkyl, (3-7 membered)heterocycloalkyl,
3 7 3 7 1 6
phenyl, (5-6 membered)heteroaryl and -OR ; wherein said (C –C )alkyl, (C –
a 1 6 3
C )cycloalkyl, (C –C )alkyl-(C –C )cycloalkyl, (C –C )cycloalkyl-(C –C )alkyl, (3-7
7 1 6 3 7 3 7 1 6
membered)heterocycloalkyl, phenyl, (5-6 membered)heteroaryl and -OR is optionally
substituted with one or more substituents independently selected from R ;
R7 represents the group consisting of –OH, -CN, halogen, (C1–C4)alkyl, (C3-C7)cycloalkyl
and (C1–C6)alkyl-(C3–C7)cycloalkyl-.
Also described is a compound according to general formula (IX), which is useful as
intermediate for the preparation of a compound of general formula (I),
(IX)
wherein
R2 is selected from the group consisting of halogen, cyano, (C1–C4)alkyl and (C3–
C7)cycloalkyl, wherein said (C1–C4)alkyl and (C3–C7)cycloalkyl is optionally substituted
with one or more substituents independently selected from –OH and halogen;
R is selected from the group consisting of halogen, cyano, (C –C )alkyl, (C –
3 1 4 1
)haloalkyl and (C –C )cycloalkyl;
C4 3 7
R4 is selected from the group consisting of (C1–C4)alkyl and (C1–C4)haloalkyl;
R5 is selected from the group consisting of (C1–C6)alkyl, (C3–C7)cycloalkyl, (C1–C6)alkyl-
(C –C )cycloalkyl, (C –C )cycloalkyl-(C –C )alkyl, (3-7 membered)heterocycloalkyl,
3 7 3 7 1 6
phenyl, (5-6 membered)heteroaryl and -OR ; wherein said (C –C )alkyl, (C –
a 1 6 3
C7)cycloalkyl, (C1–C6)alkyl-(C3–C7)cycloalkyl, (C3–C7)cycloalkyl-(C1–C6)alkyl, (3-7
membered)heterocycloalkyl, phenyl, (5-6 membered)heteroaryl and -OR is optionally
substituted with one or more substituents independently selected from R ;
R7 represents the group consisting of –OH, -CN, halogen, (C1–C4)alkyl, (C3-C7)cycloalkyl
and (C1–C6)alkyl-(C3–C7)cycloalkyl-.
Also described is a method of preventing, treating or ameliorating psoriasis, the method
comprising administering to a person suffering from psoriasis an effective amount of one
or more compounds according to general formula (I), optionally together with a
pharmaceutically acceptable carrier or one or more excipients, optionally in combination
with other therapeutically active compounds.
In the description in this specification reference may be made to subject matter which is
not within the scope of the appended claims. That subject matter should be readily
identifiable by a person skilled in the art and may assist in putting into practice the
invention as defined in the appended claims.
DETAILED DESCRIPTION OF THE INVENTION
Definitions
The term “alkyl” is intended to indicate a radical obtained when one hydrogen atom is
removed from a branched or linear hydrocarbon. Said alkyl comprises 1-6, preferably 1-
4, such as 1-3, such as 2-3 or such as 1-2 carbon atoms. The term includes the
subclasses normal alkyl (n-alkyl), secondary and tertiary alkyl, such as methyl, ethyl, n-
propyl, isopropyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl,
neopentyl, n-hexyl and isohexyl.
The term “alkylcycloalkyl” is intended to indicate an alkyl radical appended to the parent
molecular moiety through a cycloalkyl group, as defined herein.
The term “(C –C )alkyl-(C –C )cycloalkyl” is intended to indicate an “(C –C )alkyl radical
1 6 3 7 1 6
appended to the parent molecular moiety through a (C –C )cycloalkyl group, as defined
herein.
The term “alkylheteroaryl” is intended to indicate an alkyl radical appended to the parent
molecular moiety through a heteroaryl group, as defined herein.
The term “alkylheterocycloalkyl” is intended to indicate an alkyl radical appended to the
parent molecular moiety through a heterocycloalkyl group, as defined herein.
The terms “alkyloxy” and “alkoxy” are intended to indicate a radical of the formula –OR,
wherein R is alkyl as indicated herein, wherein the alkyl group is appended to the parent
molecular moiety through an oxygen atom, e.g. methoxy (-OCH3), ethoxy (-OCH2CH3),
n-propoxy, isopropoxy, butoxy, tert-butoxy, and the like.
The term “aryl” is intended to indicate a radical of aromatic carbocyclic rings comprising
6-13 carbon atoms, such as 6-9 carbon atoms, such as 6 carbon atoms, in particular 5-
or 6-membered rings, including fused carbocyclic rings with at least one aromatic ring. If
the aryl group is a fused carbocyclic ring, the point of attachment of the aryl group to
the parent molecular moiety may be through an aromatic or through an aliphatic carbon
atom within the aryl group. Representative examples of aryl include, but are not limited
to phenyl, naphthyl, indenyl, indanyl, dihydronaphthyl, tetrahydronaphthyl and fluorenyl.
The term “comprising” as used in this specification and claims means “consisting at least
in part of”. When interpreting statements in this specification and claims which include
the term “comprising”, other features besides the features prefaced by this term in each
statement can also be present. Related terms such as “comprise” and “comprises” are to
be interpreted in similar manner.
The term “cyano” is intended to indicate a –CN group attached to the parent molecular
moiety through the carbon atom.
The term “cycloalkyl” is intended to indicate a saturated cycloalkane hydrocarbon
radical, including polycyclic radicals such as bicyclic radicals, comprising 3-7 carbon
atoms, preferably 3-6 carbon atoms, such as 3-5 carbon atoms or such as 3-4 carbon
atoms, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl.
The term “cycloalkylalkyl” is intended to indicate a cycloalkyl radical appended to the
parent molecular moiety through an alkyl group, as defined herein.
The term “(C3–C7)cycloalkyl(C1–C4)alkyl” is intended to indicate a (C3–C7)cycloalkyl
radical appended to the parent molecular moiety through an (C1–C4)alkyl group, as
defined herein.
The term “(C3–C7)cycloalkyl(C1–C6)alkyl” is intended to indicate a (C3–C7)cycloalkyl
radical appended to the parent molecular moiety through an (C –C )alkyl group, as
defined herein.
The term “haloalkyl” is intended to indicate an alkyl group as defined herein substituted
with one or more halogen atoms as defined herein, e.g. fluoro or chloro, such as
difluoromethyl or trifluoromethyl.
“(C -C )haloalkyl” is intended to indicate a (C -C )alkyl group as defined herein
1 4 1 4
substituted with one or more halogen atoms as defined herein, e.g. fluoro or chloro,
such as difluoromethyl or trifluoromethyl.
The term “halogen” is intended to indicate a substituent from the 7 main group of the
periodic table, such as fluoro, chloro and bromo.
The term “heteroaryl” is intended to indicate radicals of monocyclic heteroaromatic rings.
The term “(5-6 membered)heteroaryl” is intended to indicate radicals of monocyclic
heteroaromatic rings, comprising 5- or 6-membered rings, i.e. having a ring size of 5 or
6 atoms, which contain from 1-5 carbon atoms and from 1-5 heteroatoms selected from
oxygen, sulphur and nitrogen, such as 1 heteroatom, such as 1-2 heteroatoms, such as
1-3 heteroatoms, such as 1-4 heteroatoms selected from oxygen, sulphur and nitrogen.
The heteroaryl radical may be connected to the parent molecular moiety through a
carbon atom or a nitrogen atom contained anywhere within the heteroaryl group.
Representative examples of (5-6 membered)heteroaryl groups include, but are not
limited to furanyl, imidazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, pyrazinyl,
pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, thiadiazolyl, thiazolyl,
thienyl, triazolyl.
The term “(5 - membered)heteroaryl” is intended to indicate radicals of monocyclic
heteroaromatic rings, comprising 5- membered rings, i.e. having a ring size of 5 atoms,
which contain from 1-4 carbon atoms and from 1-4 heteroatoms selected from oxygen,
sulphur and nitrogen, such as 1 heteroatom, such as 1-2 heteroatoms, such as 1-3
heteroatoms, such as 1-4 heteroatoms selected from oxygen, sulphur and nitrogen. The
heteroaryl radical may be connected to the parent molecular moiety through a carbon
atom or a nitrogen atom contained anywhere within the heteroaryl group.
Representative examples of (5-membered)heteroaryl groups include, but are not limited
to furanyl, imidazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, pyrazolyl, pyrrolyl,
tetrazolyl, thiadiazolyl, thiazolyl, thienyl, triazolyl.
The term “heteroarylalkyl” is intended to indicate a heteroaryl radical appended to the
parent molecular moiety through an alkyl group, as defined herein.
The term “(5-6 membered)heteroaryl-(C –C )alkyl” is intended to indicate a “(5-6
membered)heteroaryl radical appended to the parent molecular moiety through an (C –
C )alkyl group, as defined herein.
The term ”heterocycloalkyl” is intended to indicate a cycloalkane radical as described
herein, wherein one or more carbon atoms are replaced by heteroatoms.
The term “(3-7 membered)heterocycloalkyl” is intended to indicate a cycloalkane radical
as described herein, wherein one or more carbon atoms are replaced by heteroatoms,
having a ring size of 3-7 atoms, comprising 1-6 carbon atoms, e.g. 2-5 or 2-4 carbon
atoms, further comprising 1-6 heteroatoms, preferably 1, 2, or 3 heteroatoms, selected
from O, N, or S, such as 1 heteroatom or such as 1-2 heteroatoms selected from O, N,
or S ; such as 4-membered heterocycloalkyl comprising 3 carbon atoms and 1
heteroatom selected from oxygen, nitrogen and sulphur; such as (5-6
membered)heterocycloalkyl comprising 3-5 carbon atoms and 1-2 heteroatoms selected
from oxygen, nitrogen and sulphur, such as (5-membered)heterocycloalkyl comprising 4
carbon atoms and 1 heteroatom selected from oxygen, nitrogen and sulphur, such as (6-
membered)heterocycloalkyl comprising 4-5 carbon atoms and 1-2 heteroatoms selected
from oxygen, nitrogen and sulphur. The heterocycloalkyl radical may be connected to
the parent molecular moiety through a carbon atom or a nitrogen atom contained
anywhere within the heterocycloalkyl group. Representative examples of (3-7
membered)heterocycloalkyl groups include, but are not limited to azepanyl, azetidinyl,
aziridinyl, dioxolanyl, dioxolyl, imidazolidinyl, morpholinyl, oxetanyl, piperazinyl,
piperidinyl, pyrrolidinyl tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl,
tetrahydrothiopyranyl, thietanyl.
The term “heterocycloalkylalkyl” is intended to indicate a heterocycloalkyl radical
appended to the parent molecular moiety through an alkyl group, as defined herein.
The term “(3-7 membered)heterocycloalkyl-(C1–C4)alkyl” is intended to indicate a “(3-7
membered)heterocycloalkyl appended to the parent molecular moiety through an (C –
C )alkyl group, as defined herein.
The term “hydrocarbon radical” is intended to indicate a radical containing only hydrogen
and carbon atoms, it may contain one or more double and/or triple carbon-carbon
bonds, and it may comprise cyclic moieties in combination with branched or linear
moieties. Said hydrocarbon comprises 1-10 carbon atoms, and preferably comprises 1-8,
e.g. 1-6, e.g. 1-4, e.g. 1-3, e.g. 1-2 carbon atoms. The term includes alkyl, alkenyl,
cycloalkyl, cycloalkenyl, alkynyl and aryl, as indicated herein.
The number of carbon atoms in a hydrocarbon radical (e.g. alkyl and cycloalkyl, as
indicated below) is indicated by the prefix “(Ca-Cb)”, wherein a is the minimum number
and b is the maximum number of carbons in the hydrocarbon radical. Thus, for example
(C1-C4)alkyl is intended to indicate an alkyl radical comprising from 1 to 4 carbon atoms,
(C -C )alkyl is intended to indicate an alkyl radical comprising from 1 to 6 carbon atoms
and (C -C )cycloalkyl is intended to indicate a cycloalkyl radical comprising from 3 to 7
carbon ring atoms.
The term “hydroxyalkyl” is intended to indicate an alkyl group as defined above
substituted with one or more hydroxy, e.g. hydroxymethyl, hydroxyethyl,
hydroxypropyl.
The term “oxo” is intended to indicate an oxygen atom which is connected to the parent
molecular moiety via a double bond (=O).
When two or more of the above defined terms are used in combination, such as
arylalkyl, heteroarylalkyl, cycloalkylalkyl and the like, it is to be understood that the first
mentioned radical is a substituent on the latter mentioned radical, where the point of
attachment to the parent molecular moiety is on the latter radical.
The group C(O) is intended to represent a carbonyl group (C=O)
If substituents are described as being independently selected from a group, each
substituent is selected independent of the other. Each substituent may therefore be
identical or different from the other substituent(s).
The term “optionally substituted” means “unsubstituted or substituted”, and therefore
the general formulas described herein encompasses compounds containing the specified
optional substituent(s) as well as compounds that do not contain the optional
substituent(s).
The term ”pharmaceutically acceptable salt” is intended to indicate salts prepared by
reacting a compound of formula I, which comprise a basic moiety, with a suitable
inorganic or organic acid, such as hydrochloric, hydrobromic, hydroiodic, sulfuric, nitric,
phosphoric, formic, acetic, 2,2-dichloroacetic, adipic, ascorbic, L-aspartic, L-glutamic,
galactaric, lactic, maleic, L-malic, phthalic, citric, propionic, benzoic, glutaric, gluconic,
D-glucuronic, methanesulfonic, salicylic, succinic, malonic, tartaric, benzenesulfonic,
ethane-1,2-disulfonic, 2-hydroxy ethanesulfonic acid, toluenesulfonic, sulfamic, fumaric
and ethylenediaminetetraacetic acid. Pharmaceutically acceptable salts of compounds of
formula I comprising an acidic moiety may also be prepared by reaction with a suitable
base such as sodium hydroxide, potassium hydroxide, magnesium hydroxide, calcium
hydroxide, silver hydroxide, ammonia or the like, or suitable non-toxic amines, such as
lower alkylamines, hydroxy-lower alkylamines, cycloalkylamines, or benzylamines, or L-
arginine or L-lysine. Further examples of pharmaceutical acceptable salts are listed in
Berge, S.M.; J. Pharm. Sci.; (1977), 66(1), 1-19, which is incorporated herein by
reference.
The terms “ROR gamma” and “ROR γ” are used to describe ROR γ1 and/or ROR γt
The term “solvate” is intended to indicate a species formed by interaction between a
compound, e.g. a compound of formula I, and a solvent, e.g. alcohol, glycerol or water,
wherein said species are in an amorphous or in a crystalline form. When water is the
solvent, said species is referred to as a hydrate.
The term “protic solvent” is intended to indicate a solvent which has an acidic hydrogen,
such as water, or such as alcohols, e.g. methanol, ethanol or isopropanol.
The term “aprotic solvent” is intended to indicate a solvent which does not have an
acidic hydrogen, such as for example dichloromethane, acetonitrile, dimethylformamide,
dimethyl sulfoxide or acetone.
The term “treatment” as used herein means the management and care of a patient for
the purpose of combating a disease, disorder or condition. The term is intended to
include the delaying of the progression of the disease, disorder or condition, the
amelioration, alleviation or relief of symptoms and complications, and/or the cure or
elimination of the disease, disorder or condition. The term may also include prevention
of the condition, wherein prevention is to be understood as the management and care of
a patient for the purpose of combating the disease, condition or disorder and includes
the administration of the active compounds to prevent the onset of the symptoms or
complications. Nonetheless, prophylactic (preventive) and therapeutic (curative)
treatments are two separate aspects.
Unless otherwise indicated, all exact values provided herein are representative of
corresponding approximate values, e.g. exact exemplary values provided with respect to
a particular measurement can be considered to also provide a corresponding
approximate measurement, modified by “about” where appropriate.
All references, including publications, patent applications and patents, cited herein are
hereby incorporated by reference in their entirety and to the same extent as if each
reference were individually and specifically indicated to be incorporated by reference,
regardless of any separately provided incorporation of particular documents made
elsewhere herein.
Embodiments of the invention
In one or more embodiments of the invention X represents N.
In one or more embodiments of the invention X represents CH.
represents –CN, methyl, ethyl, propyl,
In one or more embodiments of the invention R1
cyclopropyl, cyclobutyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl,
pyrrolidinyl, oxazolidinyl, morpholinyl, piperidinyl, triazolyl, pyrrazolyl, isoxazolyl,
thiadiazolyl or oxadiazolyl.
In one or more embodiments of the invention R represents chloro, methyl or
difluoromethyl.
In one or more embodiments of the invention R3 represents methyl.
In one or more embodiments of the invention R4 represents methyl.
In one or more embodiments of the invention R5 represents phenyl, propyl, butyl,
ethoxy, iso-propyloxy, tert-butyloxy, cyclopropyl, cyclobutyl, cyclopentyl,
methylcyclopropyl or cyclobutylmethyl.
In one or more embodiments of the invention R6 represents -OH, -CN, fluoro, -NH2, =O,
-S(O)2CH3, methyl, methoxy or hydroxymethyl.
In one or more embodiments of the invention R represents fluoro or –OH.
In one or more embodiments of the invention the compound of general formula (I) is
selected from the list consisting of
-[3-[[(3S)benzoylmethyl-piperazinyl]methyl]chloromethyl-anilino]-
1,3,4-oxadiazolecarbonitrile,
[(2S)[[5-chloro[[5-(methoxymethyl)-1,3,4-oxadiazolyl]amino]methyl-
phenyl]methyl]methyl-piperazinyl]-phenyl-methanone,
[(2S)[[5-chloromethyl[(5-tetrahydrofuranyl-1,3,4-oxadiazol
yl)amino]phenyl]methyl]methyl-piperazinyl]-phenyl-methanone,
[(2S)[[5-chloromethyl[(5-tetrahydrofuranyl-1,3,4-oxadiazol
yl)amino]phenyl]methyl]methyl-piperazinyl]-phenyl-methanone
[(2S)[[5-chloro[(5-cyclopropyl-1,3,4-oxadiazolyl)amino]methyl-
phenyl]methyl]methyl-piperazinyl]-phenyl-methanone,
[(2S)[[5-chloro[[5-(1-hydroxycyclopropyl)-1,3,4-oxadiazolyl]amino]methyl-
phenyl]methyl]methyl-piperazinyl]-phenyl-methanone,
3-[5-[3-[[(3S)benzoylmethyl-piperazinyl]methyl]chloromethyl-anilino]-
1,3,4-oxadiazolyl]propanenitrile,
3-[5-[3-[[(3S)benzoylmethyl-piperazinyl]methyl]chloromethyl-anilino]-
1,3,4-oxadiazolyl]propanenitrile,
1-[(2S)[[5-chloro[[5-(methoxymethyl)-1,3,4-oxadiazolyl]amino]methyl-
phenyl]methyl]methyl-piperazinyl]-2,2-difluoro-butanone,
[(2S)[[5-chloro[[5-(methoxymethyl)-1,3,4-oxadiazolyl]amino]methyl-
phenyl]methyl]methyl-piperazinyl]-(2-fluorophenyl)methanone,
[(2S)[[5-chloro[[5-(methoxymethyl)-1,3,4-oxadiazolyl]amino]methyl-
phenyl]methyl]methyl-piperazinyl]-(3,3-difluorocyclopentyl)methanone,
(2S)[(2S)[[5-chloro[[5-(methoxymethyl)-1,3,4-oxadiazolyl]amino]
methyl-phenyl]methyl]methyl-piperazinyl]methyl-butanone,
[(2S)[[5-chloro[[5-(methoxymethyl)-1,3,4-oxadiazolyl]amino]methyl-
phenyl]methyl]methyl-piperazinyl]-cyclobutyl-methanone,
[(2S)[[5-chloro[[5-(methoxymethyl)-1,3,4-oxadiazolyl]amino]methyl-
phenyl]methyl]methyl-piperazinyl]-cyclopentyl-methanone,
cyclobutyl-[(2S)[[2,5-dimethyl[(5-methyl-1,3,4-oxadiazol
yl)amino]phenyl]methyl]methyl-piperazinyl]methanone,
2-[5-[3-[[(3S)(cyclobutanecarbonyl)methyl-piperazinyl]methyl]-2,5-dimethyl-
anilino]-1,3,4-oxadiazolyl]acetonitrile,
2-[5-[3-[[(3S)(cyclopropanecarbonyl)methyl-piperazinyl]methyl]-2,5-dimethyl-
anilino]-1,3,4-oxadiazolyl]acetonitrile,
2-[5-[3-[[(3S)(3,3-difluorocyclopentanecarbonyl)methyl-piperazinyl]methyl]-
2,5-dimethyl-anilino]-1,3,4-oxadiazolyl]acetonitrile,
2-[5-[5-chloro[[4-(cyclopentanecarbonyl)methyl-piperazinyl]methyl]methyl-
anilino]-1,3,4-oxadiazolyl]acetonitrile,
cyclobutyl-[(2S)[[3-[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5-
dimethyl-phenyl]methyl]methyl-piperazinyl]methanone,
cyclobutyl-[(2S)[[3-[[5-[(1S)hydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5-
dimethyl-phenyl]methyl]methyl-piperazinyl]methanone,
2,2-difluoro[(2S)[[3-[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5-
dimethyl-phenyl]methyl]methyl-piperazinyl]butanone,
cyclopropyl-[(2S)[[3-[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5-
dimethyl-phenyl]methyl]methyl-piperazinyl]methanone,
[(2S)[[3-[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5-dimethyl-
phenyl]methyl]methyl-piperazinyl]-(2-methylcyclopropyl)methanone,
cyclopentyl-[(2S)[[3-[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5-
dimethyl-phenyl]methyl]methyl-piperazinyl]methanone,
(3,3-difluorocyclopentyl)-[(2S)[[3-[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazol
yl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinyl]methanone,
2-cyclobutyl[(2S)[[3-[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5-
dimethyl-phenyl]methyl]methyl-piperazinyl]ethanone,
cyclobutyl-[(2S)[[5-(difluoromethyl)[[5-[(1S)hydroxyethyl]-1,3,4-oxadiazol
yl]amino]methyl-phenyl]methyl]methyl-piperazinyl]methanone,
tert-butyl (2S)[[3-[[5-[(1S)hydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5-
dimethyl-phenyl]methyl]methyl-piperazinecarboxylate,
tert-butyl (2S)[[3-[[5-(3-hydroxycyclobutyl)-1,3,4-oxadiazolyl]amino]-2,5-
dimethyl-phenyl]methyl]methyl-piperazinecarboxylate,
tert-butyl (2S)[[2,5-dimethyl[[5-(3-methyltriazolyl)-1,3,4-oxadiazol
yl]amino]phenyl]methyl]methyl-piperazinecarboxylate,
tert-butyl (2S)[[2,5-dimethyl[[5-(2-methylpyrazolyl)-1,3,4-oxadiazol
yl]amino]phenyl]methyl]methyl-piperazinecarboxylate,
tert-butyl (2S)[[3-[(5-isoxazolyl-1,3,4-oxadiazolyl)amino]-2,5-dimethyl-
phenyl]methyl]methyl-piperazinecarboxylate,
tert-butyl (2S)[[2,5-dimethyl[[5-(1,2,5-thiadiazolyl)-1,3,4-oxadiazol
yl]amino]phenyl]methyl]methyl-piperazinecarboxylate,
tert-butyl (2S)[[2,5-dimethyl[[5-(4-methyl-1,2,5-oxadiazolyl)-1,3,4-oxadiazol-
2-yl]amino]phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[2,5-dimethyl[(5-methyl-1,3,4-oxadiazol
yl)amino]phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[3-[[5-[(1S)aminohydroxy-ethyl]-1,3,4-oxadiazolyl]amino]-
2,5-dimethyl-phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[3-[[5-(3-hydroxycyclobutyl)-1,3,4-oxadiazolyl]amino]-2,5-
dimethyl-phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[3-[[5-[(1S)aminopropyl]-1,3,4-oxadiazolyl]amino]chloro
methyl-phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[5-chloro[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazolyl]amino]
methyl-phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[5-chloromethyl[[5-(oxetanyl)-1,3,4-oxadiazol
yl]amino]phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[3-[[5-[(1S,2R)aminohydroxy-propyl]-1,3,4-oxadiazol
yl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[3-[[5-(cyanomethyl)-1,3,4-oxadiazolyl]amino]-2,5-dimethyl-
phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[5-(difluoromethyl)[[5-[(1S)hydroxyethyl]-1,3,4-oxadiazol
yl]amino]methyl-phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[5-chloromethyl[(5-tetrahydropyranyl-1,3,4-oxadiazol
yl)amino]phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[5-chloro[[5-(1-hydroxycyclopropyl)-1,3,4-oxadiazolyl]amino]-
2-methyl-phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[5-chloro[[5-[1-(hydroxymethyl)cyclopropyl]-1,3,4-oxadiazol
yl]amino]methyl-phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[5-chloromethyl[[5-(2,2,2-trifluorohydroxy-ethyl)-1,3,4-
oxadiazolyl]amino]phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[5-chloromethyl[[5-(2-oxopyrrolidinyl)-1,3,4-oxadiazol
yl]amino]phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[3-[[5-[(1S)aminoethyl]-1,3,4-oxadiazolyl]amino]-2,5-dimethyl-
phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[5-(difluoromethyl)[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazol
yl]amino]methyl-phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[2,5-dimethyl[[5-(5-oxopyrrolidinyl)-1,3,4-oxadiazol
yl]amino]phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[2,5-dimethyl[[5-[(5S)oxooxazolidinyl]-1,3,4-oxadiazol
yl]amino]phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[5-chloromethyl[[5-[(2S)oxoazetidinyl]-1,3,4-oxadiazol
yl]amino]phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[2,5-dimethyl[[5-(4-methyl-1,2,5-oxadiazolyl)-1,3,4-oxadiazol-
2-yl]amino]phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[2,5-dimethyl[[5-[(3S)-morpholinyl]-1,3,4-oxadiazol
yl]amino]phenyl]methyl]methyl-piperazinecarboxylate dihydrochloride,
isopropyl (2S)[[3-[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5-
dimethyl-phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[2,5-dimethyl[[5-[(2R)-3,3,3-trifluorohydroxy-propyl]-1,3,4-
oxadiazolyl]amino]phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[2,5-dimethyl[[5-(2-oxopiperidyl)-1,3,4-oxadiazol
yl]amino]phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[2,5-dimethyl[[5-(2-methylpyrazolyl)-1,3,4-oxadiazol
yl]amino]phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[3-[[5-[(2S)hydroxypropyl]-1,3,4-oxadiazolyl]amino]-2,5-
dimethyl-phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[3-[[5-[(2R)hydroxypropyl]-1,3,4-oxadiazolyl]amino]-2,5-
dimethyl-phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[3-[[5-[(1S)hydroxypropyl]-1,3,4-oxadiazolyl]amino]-2,5-
dimethyl-phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[5-chloro[[5-[(1S)hydroxyethyl]-1,3,4-oxadiazolyl]amino]
methyl-phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[5-chloro[[5-(3-hydroxycyclobutyl)-1,3,4-oxadiazolyl]amino]
methyl-phenyl]methyl]methyl-piperazinecarboxylate
isopropyl (2S)[[2,5-dimethyl[[5-[(2S)methylsulfonylpyrrolidinyl]-1,3,4-
oxadiazolyl]amino]phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[3-[[5-[(1S)hydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5-
dimethyl-phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[5-chloromethyl[[5-(5-oxopyrrolidinyl)-1,3,4-oxadiazol
yl]amino]phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[3-[[5-[(1R)aminoethyl]-1,3,4-oxadiazolyl]amino]-2,5-dimethyl-
phenyl]methyl]methyl-piperazinecarboxylate
2,2,2-trifluoroethyl (2S)[[5-chloro[[5-(cyanomethyl)-1,3,4-oxadiazolyl]amino]-
2-methyl-phenyl]methyl]methyl-piperazinecarboxylate,
2,2,2-trifluoroethyl (2S)[[3-[[5-(3-hydroxycyclobutyl)-1,3,4-oxadiazolyl]amino]-
2,5-dimethyl-phenyl]methyl]methyl-piperazinecarboxylate,
ethyl (2S)[[3-[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5-dimethyl-
phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[3-[[5-[(1S)-1,2-dihydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5-
dimethyl-phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[5-chloromethyl[(5-morpholinyl-1,3,4-oxadiazol
yl)amino]phenyl]methyl]methyl-piperazinecarboxylate and
tert-butyl (2S)[[5-chloro[[5-(hydroxymethyl)oxazolyl]amino]methyl-
phenyl]methyl]methyl-piperazinecarboxylate
or pharmaceutically acceptable salts, hydrates or solvates thereof.
Any combination of two or more embodiments described herein is considered within the
scope of the present invention.
The present invention includes all embodiments wherein R , R , R , R , R , R and R are
1 2 3 4 5 6 7
combined in any combination as anywhere described herein.
The compounds of formula I may be obtained in crystalline form either directly by
concentration from an organic solvent or by crystallisation or recrystallisation from an
organic solvent or mixture of said solvent and a cosolvent that may be organic or
inorganic, such as water. The crystals may be isolated in essentially solvent-free form or
as a solvate, such as a hydrate. The invention covers all crystalline forms, such as
polymorphs and pseudopolymorphs, and also mixtures thereof.
If nothing else is indicated the term ‘solid’ in the description of the examples means that
the compound of the invention was prepared as a non-crystalline compound.
Compounds of formula I comprise asymmetrically substituted (chiral) carbon atoms
which give rise to the existence of isomeric forms, e.g. enantiomers and possibly
diastereomers. The present invention relates to all such isomers, either in optically pure
form or as mixtures thereof (e.g. racemic mixtures or partially purified optical mixtures).
Pure stereoisomeric forms of the compounds and the intermediates of this invention may
be obtained by the application of procedures known in the art. The various isomeric
forms may be separated by physical separation methods such as selective crystallization
and chromatographic techniques, e.g. high pressure liquid chromatography using chiral
stationary phases. Enantiomers may be separated from each other by selective
crystallization of their diastereomeric salts which may be formed with optically active
acids. Optically purified compounds may subsequently be liberated from said purified
diastereomeric salts. Enantiomers may also be resolved by the formation of
diastereomeric derivatives. Alternatively, enantiomers may be separated by
chromatographic techniques using chiral stationary phases. Pure stereoisomeric forms
may also be derived from the corresponding pure stereoisomeric forms of the
appropriate starting materials, provided that the reaction occur stereoselectively or
stereospecifically. Preferably, if a specific stereoisomer is desired, said compound will be
synthesized by stereoselective or stereospecific methods of preparation. These methods
will advantageously employ chiral pure starting materials.
In the compounds of general Formula I, the atoms may exhibit their natural isotopic
abundances, or one or more of the atoms may be artificially enriched in a particular
isotope having the same atomic number, but an atomic mass or mass number different
from the atomic mass or mass number found in nature. The present invention is meant
to include all suitable isotopic variations of the compounds of general Formula I. For
1 2 3
example, different isotopic forms of hydrogen include H, H and H and different isotopic
12 13 14 2
forms of carbon include C, C and C. Enriching for deuterium ( H) may for example
increase in-vivo half-life or reduce dosage regiments, or may provide a compound useful
as a standard for characterization of biological samples. Isotopically enriched compounds
within general formula I can be prepared by conventional techniques well known to a
person skilled in the art or by processes analogous to those described in the general
procedures and examples herein using appropriate isotopically enriched reagents and/or
intermediates.
In one or more embodiments of the present invention, the compounds of general
as defined above are useful in therapy and in particular for use in the
formula (I)
treatment of psoriasis.
In one or more embodiments of the present invention, the compounds of general
formula (I) as defined above are useful in treatment of a disease, disorder or condition,
which disease, disorder or condition is responsive of modulation of ROR-gamma.
In one or more embodiments of present invention provides a pharmaceutical
composition comprising a compound according to general formula (I) together with one
or more other therapeutically active compound(s) together with a pharmaceutically
acceptable vehicle or excipient or pharmaceutically acceptable carrier(s).
In one or more embodiments of the present invention, the compounds of general
formula (I) are useful in the manufacture of a medicament for the prophylaxis,
treatment or amelioration of autoimmune or inflammatory diseases.
In one or more embodiments of the present invention, the compounds of general
formula (I) are useful in the manufacture of a medicament for the prophylaxis,
treatment or amelioration of psoriasis.
In one or more embodiments of the present invention, the compounds of general
formula (I) are useful in a method of preventing, treating or ameliorating autoimmune or
inflammatory diseases or conditions, the method comprising administering to a person
suffering from at least one of said diseases an effective amount of one or more
compounds according to according to general formula (I), optionally together with a
pharmaceutically acceptable carrier or one or more excipients, optionally in combination
with other therapeutically active compounds.
Besides being useful for human treatment, the compounds of the present invention may
also be useful for veterinary treatment of animals including mammals such as horses,
cattle, sheep, pigs, dogs, and cats.
Pharmaceutical Compositions of the Invention
For use in therapy, compounds of the present invention are typically in the form of a
pharmaceutical composition. The invention therefore relates to a pharmaceutical
composition comprising a compound of formula I, optionally together with one or more
other therapeutically active compound(s), together with a pharmaceutically acceptable
excipient, vehicle or carrier(s). The excipient must be "acceptable" in the sense of being
compatible with the other ingredients of the composition and not deleterious to the
recipient thereof.
Conveniently, the active ingredient comprises from 0.0001-50 % by weight of the
formulation.
In the form of a dosage unit, the compound may be administered one or more times a
day at appropriate intervals, always depending, however, on the condition of the patient,
and in accordance with the prescription made by the medical practitioner. Conveniently,
a dosage unit of a formulation contain between 0.001 mg and 1000 mg, preferably
between 0.01 mg and 250 mg, such as 50-200 mg of a compound of formula I.
A suitable dosage of the compound of the invention will depend, inter alia, on the age
and condition of the patient, the severity of the disease to be treated and other factors
well known to the practising physician. The compound may be administered either orally,
parenterally, topically, transdermally or interdermally + other routes according to
different dosing schedules, e.g. daily, weekly or with monthly intervals. In general a
single dose will be in the range from 0.001 to 400 mg/kg body weight. The compound
may be administered as a bolus (i.e. the entire daily dose is administered at once) or in
divided doses two or more times a day.
In the context of topical treatment it may be more appropriate to refer to a “usage unit”,
which denotes a single dose which is capable of being administered to a patient, and
which may be readily handled and packed, remaining as a physically and chemically
stable unit dose comprising either the active material as such or a mixture of it with
solid, semisolid or liquid pharmaceutical diluents or carriers.
The term “usage unit” in connection with topical use means a unitary, i.e. a single dose,
capable of being administered topically to a patient in an application per square
centimetre of the treatment area of from 0.001 microgram to 1 mg and preferably from
0.05 microgram to 0.5 mg of the active ingredient in question.
It is also envisaged that in certain treatment regimes, administration with longer
intervals, e.g. every other day, every week, or even with longer intervals may be
beneficial.
If the treatment involves administration of another therapeutically active compound it is
recommended to consult Goodman & Gilman’s The Pharmacological Basis of
Therapeutics, 12 Ed., L. L. Brunton (Ed.), McGraw-Hill 2010, for useful dosages of said
compounds.
The administration of a compound of the present invention with one or more other active
compounds may be either concomitantly or sequentially.
The formulations include e.g. those in a form suitable for oral, rectal, parenteral
(including subcutaneous, intraperitoneal, intramuscular, intraarticular and intravenous),
transdermal, intradermal, ophthalmic, topical, nasal, sublingual or buccal administration.
The formulations may conveniently be presented in dosage unit form and may be pre-
pared by but not restricted to any of the methods well known in the art of pharmacy,
e.g. as disclosed in Remington, The Science and Practice of Pharmacy, 22nd ed., 2013.
All methods include the step of bringing the active ingredient into association with the
carrier, which constitutes one or more accessory ingredients. In general, the formula-
tions are prepared by uniformly and intimately bringing the active ingredient into
association with a liquid carrier, semisolid carrier or a finely divided solid carrier or
combinations of these, and then, if necessary, shaping the product into the desired
formulation.
Formulations of the present invention suitable for oral and buccal administration may be
in the form of discrete units as capsules, sachets, tablets, chewing gum or lozenges,
each containing a predetermined amount of the active ingredient; in the form of a
powder, granules or pellets; in the form of a solution or a suspension in an aqueous
liquid or non-aqueous liquid, such as ethanol or glycerol; or in the form of a gel, a nano-
or microemulsion, an oil-in-water emulsion, a water-in-oil emulsion or other dispensing
systems. The oils may be edible oils, such as but not restricted to e.g. cottonseed oil,
sesame oil, coconut oil or peanut oil. Suitable dispersing or suspending agents for
aqueous suspensions include synthetic or natural surfactants and viscosifying agents
such as but not restricted to tragacanth, alginate, acacia, dextran, sodium
carboxymethylcellulose, gelatin, methylcellulose, hydroxypropylmethylcellulose,
hydroxypropylcellulose, carbomers, polyvinylpyrrolidone, polysorbates, sorbitan fatty
acid esters,. The active ingredients may also be administered in the form of a bolus,
electuary or paste.
A tablet may be made by compressing, moulding or freeze drying the active ingredient
optionally with one or more accessory ingredients. Compressed tablets may be prepared
by compressing, in a suitable machine, the active ingredient(s) in a free-flowing form
such as a powder or granules, optionally mixed by a binder and/or filler, such as e.g.
lactose, glucose, mannitol starch, gelatine, acacia gum, tragacanth gum, sodium
alginate, calcium phosphates, microcrystalline cellulose, carboxymethylcellulose,
methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, ethylcellulose,
hydroxyethylcellulose, polyethylene glycol, waxes or the like; a lubricant such as e.g.
sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate,
sodium chloride or the like; a disintegrating agent such as e.g. starch, methylcellulose,
agar, bentonite, croscarmellose sodium, sodium starch glycollate, crospovidone or the
like or a dispersing agent, such as polysorbate 80. Moulded tablets may be made by
moulding, in a suitable machine, a mixture of the powdered active ingredient and
suitable carrier moistened with an inert liquid diluent. Freeze dried tablets may be
formed in a freeze-dryer from a solution of the drug substance. Suitable filler can be
included.
Formulations for rectal administration may be in the form of suppositories in which the
compound of the present invention is admixed with low melting point, water soluble or
insoluble solids such as cocoa butter, hydrogenated vegetable oils, polyethylene glycol or
fatty acids esters of polyethylene glycols, while elixirs may be prepared using myristyl
palmitate.
Formulations suitable for parenteral administration conveniently comprise a sterile oily
or aqueous preparation of the active ingredients, which is preferably isotonic with the
blood of the recipient, e.g. isotonic saline, isotonic glucose solution or buffer solution.
Furthermore, the formulation may contain cosolvent, solubilising agent and/or
complexation agents. The formulation may be conveniently sterilised by for instance
filtration through a bacteria retaining filter, addition of sterilising agent to the
formulation, irradiation of the formulation or heating of the formulation. Liposomal
formulations as disclosed in e.g. Encyclopedia of Pharmaceutical Technology, vol.9,
1994, are also suitable for parenteral administration.
Alternatively, the compounds of formula I may be presented as a sterile, solid
preparation, e.g. a freeze-dried powder, which is readily dissolved in a sterile solvent
immediately prior to use.
Transdermal formulations may be in the form of a plaster, patch, microneedles,
liposomal or nanoparticulate delivery systems or other cutaneous formulations applied to
the skin.
Formulations suitable ophthalmic administration may be in the form of a sterile aqueous
preparation of the active ingredients, which may be in microcrystalline form, for
example, in the form of an aqueous microcrystalline suspension. Liposomal formulations
or biodegradable polymer systems e.g. as disclosed in Encyclopedia of Pharmaceutical
Technology, vol.2, 1989, may also be used to present the active ingredient for ophthal-
mic administration.
Formulations suitable for topical, such as dermal, intradermal or ophthalmic admi-
nistration include liquid or semi-solid preparations such as liniments, lotions, gels,
applicants, sprays, foams, film forming systems, microneedles, micro- or nano-
emulsions, oil-in-water or water-in-oil emulsions such as creams, ointments or pastes;
or solutions or suspensions such as drops.
For topical administration, the compound of formula I may typically be present in an
amount of from 0.001 to 20% by weight of the composition, such as 0.01% to about 10
%, but may also be present in an amount of up to about 100% of the composition.
Formulations suitable for nasal or buccal administration include powder, self-propelling
and spray formulations, such as aerosols and atomisers. Such formulations are disclosed
in greater detail in e.g. Modern Pharmaceutics, 2 ed., G.S. Banker and C.T. Rhodes
(Eds.), page 427-432, Marcel Dekker, New York; Modern Pharmaceutics, 3 ed., G.S.
Banker and C.T. Rhodes (Eds.), page 618-619 and 718-721, Marcel Dekker, New York
and Encyclopedia of Pharmaceutical Technology, vol. 10, J. Swarbrick and J.C. Boylan
(Eds), page 191-221, Marcel Dekker, New York.
In addition to the aforementioned ingredients, the formulations of a compound of
formula I may include one or more additional ingredients such as diluents, buffers,
flavouring agents, colourant, surface active agents, thickeners, penetration enhancing
agents, solubility enhancing agents preservatives, e.g. methyl hydroxybenzoate (in-
cluding anti-oxidants), emulsifying agents and the like.
When the active ingredient is administered in the form of salts with pharmaceutically
acceptable non-toxic acids or bases, preferred salts are for instance easily water-soluble
or slightly soluble in water, in order to obtain a particular and appropriate rate of
absorption.
The pharmaceutical composition may additionally comprise one or more other active
components conventionally used in the treatment of autoimmune or inflammatory
diseases such as psoriasis, psoriatic arthritis, multiple sclerosis, rheumatoid arthritis,
crohns disease, alopecia areata, contact dermatitis, spondyloarthritis; and cancers.
METHODS OF PREPARATION
The compounds of the present invention can be prepared in a number of ways well
known to those skilled in the art of synthesis. The compounds of formula I may for
example be prepared using the reactions and techniques outlined below together with
methods known in the art of synthetic organic chemistry, or variations thereof as
appreciated by those skilled in the art. Preferred methods include, but are not limited to,
those described below. The reactions are carried out in solvents appropriate to the
reagents and materials employed and suitable for the transformations being effected.
Also, in the synthetic methods described below, it is to be understood that all proposed
reaction conditions, including choice of solvent, reaction atmosphere, reaction
temperature, duration of experiment and work-up procedures, are chosen to be
conditions of standard for that reaction, which should be readily recognized by one
skilled in the art. Not all compounds falling into a given class may be compatible with
some of the reaction conditions required in some of the methods described. Such
restrictions to the substituents which are compatible with the reaction conditions will be
readily apparent to one skilled in the art and alternative methods can be used. The
compounds of the present invention or any intermediate may be purified if required
using standard methods well known to a synthetic organist chemist, e.g. methods
described in “Purification of Laboratory Chemicals”, 6 ed. 2009, W. Amarego and C.
Chai, Butterworth-Heinemann. Starting materials are either known compounds,
commercially available, or they may be prepared by routine synthetic methods well
known to a person skilled in the art.
Synthetic routes
The following schemes illustrate the preparation of compounds of the formula (I),
throughout which R1, R2, R3, R4, R5 are as described above:
When X =N,
(III)
(II) (I)
Scheme 1
Acids suitable for use as compound (III) are commercially available, are known in the
literature or can be prepared by standard methods.
Step (a): Acid (III) is reacted with aminothiourea (II) to give the compound of formula
(I). This reaction is carried out by standard methods.
Coupling may be undertaken by using either;
(i) The acid chloride derivative of acid (III) + aminothiourea (II), with an excess of base
in a suitable solvent, then desulfurative cyclisation with WSCDI or DCC in DCM, THF
or DMSO with or without heating; or tosyl chloride and excess pyridine in THF at 65
(ii) The acid (III) + aminothiourea (II), with WSCDI or DCC in DCM, THF or DMSO with
or without heating; or tosyl chloride and excess pyridine in THF at 65 C .
Typically the conditions are as follows:
(i) acid chloride of acid (III) (generated in-situ or commercial), an excess of
aminothiourea (II), optionally with an excess of tertiary amine such as TEA,
Hünig's base or NMM, in DCM or THF, without heating for 1 to 24 hrs, then
WSDCI in DCM or THF without heating for 1 to 16 hrs
(ii) acid (III), WSCDI or DCC, aminothiourea (II), in THF, DCM without heating or in
DMSO at 60 C for 1 to 16 hrs; or, acid (III), aminothiourea (II), with an excess of
pyridine and tosyl chloride in THF at 65 C for 1-2 hrs.
The preferred conditions are: 1.2 eq. acid (III), 1 eq. aminothiourea (II), 4 eq. WSCDI in
DCM at room temperature for up to 16 hours.
Alternatively, when X = N or CH:
Compound (I) can be prepared as outlined in scheme 1.1
(IV)
Scheme 1.1
Acids suitable for use as compound (V) are commercially available or known in the
literature.
Step (b): Acid (V) is reacted with amine (IV) to give the compound of formula (I). This
reaction is carried out by standard methods.
Coupling may be undertaken by using either;
(i) The acid chloride derivative of acid (V) + amine (IV), with an excess of base in
a suitable solvent, or
(ii) acid (V), amine (IV), HATU with an excess of NMM, TEA, Hünig's base in THF or
DMF at room temperature for 4 to 16 hrs; or acid (V), WSCDI /DCC and HOBT
/HOAT, amine (IV), with an excess of NMM, TEA, Hünig's base in THF, DCM or
EtOAc, at room temperature for 4 to 16 hrs.
The preferred conditions are: 1.0 eq. acid (V), 1.0 eq. amine (IV), 1.5 eq. HATU and an
excess of in DMF at room temperature for up to 16 hours.
Alternatively, when X= N or CH and R5 = ORa:
Compound (I) can be prepared as outlined in scheme 1.2
(VI)
(VII)
(VI')
(IV)
Scheme 1.2
Alcohols suitable for use as compound (VI) are commercially available or are known in
the literature.
LG represents a leaving group, typically chloro, compounds suitable for use as compound
(VII) are known in the literature or commercially available.
Step (c): The alcohol (IV) is transformed in situ to the reactive intermediate (IV’), if LG
is chloro then (IV’) is a carbamoyl chloride.
Typical conditions are,
(i) The alcohol (VI) in a suitable aprotic solvent with phosgene, triphosgene,
diphosgene or CDI in the presence of a tertiary base, without heating for 1
to 24hr.
Preferred conditions are: The alcohol (VI) in DCM with triphosgene (0.4 eq) with Hunig’s
base (2 eq.), without heating for 2 hr.
Step (d): The reactive intermediate (VI’) is reacted with amine (IV). Typical conditions
are,
(i) The reactive intermediate (IV’) in a suitable aprotic solvent with amine
(IV) in the presence of a tertiary base like NMM, Hunig’s base, TEA without
heating for 1 to 24hr.
Preferred conditions are: The reactive intermediate (VI’) (1.3 eq.) with amine (IV) in
with Hunig’s base (3 eq) in DCM at low temperature for 2hr.
When X = N or CH,
(a*)
(IV)
(IV*)
Scheme 1.2*
PG represents a suitable protecting group for nitrogen. Standard methodology for
nitrogen protecting groups is used, described in for example “Greene’s Protective Groups
in Organic Synthesis” Fifth edition, Wiley, Ed. P. G. M. Wuts.
Those skilled in the art will appreciate that the compounds of formula (IV*) can have,
but are not limited to, structures of the same formula as compound (I). (e.g. R is O-
tert-butyl or O-benzyl)
Step (a*): Deprotection of compound (IX) is undertaken using standard methodology, as
described in “Greene’s Protective Groups in Organic Synthesis” Fifth edition, Wiley, Ed.
P. G. M. Wuts.
Preferred conditions are: when PG is Boc the is hydrogen chloride in a suitable solvent
such as 1,4-dioxane at room temperature for 1-16 hours, or a solution of trifluoroacetic
acid in dichloromethane for 1-2 hours.
(VIII)
(VII)
(IX)
PG-HNNH2
(f) H NNH
(II)
Scheme 2
PG represents a suitable protecting group for nitrogen. Standard methodology for
nitrogen protecting groups is used, such as that found in textbooks, e.g. “Greene’s
Protective Groups in Organic Synthesis” Fifth edition, Wiley, Ed. P. G. M. Wuts.
LG represents a leaving group, typically chloro, compounds suitable for use as compound
(VII) are known in the literature or commercially available.
Step (e): Amine (VII) is reacted with thiocarbonyl compounds (VIII) to give compounds
of formula (IX). This reaction is carried out by standard methods.
Typical conditions are,
(i) Amine (II) in a suitable aprotic solvent with thiocarbonyl dichloride, optionally in
the prescence of base, without heating for 1-24 hrs.
(ii) Amine (II) in a suitable aprotic solvent with bis(2-pyridyloxy)methanethione and
DMAP, without heating for 1-3hrs.
Preferred conditions are: The amine and thiocarbonyl dichloride (1 eq) in chloroform and
aqueous sodium hydrogen carbonate without heating for 1 hr.
Step (f): Isothiocyanate (IX) is reacted with commercially available hydrazine
compositions, such as hydrazine hydrate or hydrazine hydrochloride, to give compounds
of formula (II). This reaction is carried out by standard methods.
Preferred conditions are: Isothiocyanate with hydrazine hydrate (1.05 eq) in CHCl ,
without heating for 1-16 hrs.
Alternatively,
Compound (II) can be accessed via
Step (g): Isothiocyanate (IX) is reacted with commercially available protected hydrazine
to give compounds of formula (II). This reaction is carried out by standard methods.
Preferred conditions are: Isothiocyanate with hydrazine hydrate (1.05 eq) in CHCl3
without heating for 1-16 hrs.
Step (h): Deprotection of compound (IX) is undertaken using standard methodology, as
described in “Greene’s Protective Groups in Organic Synthesis” Fifth edition, Wiley, Ed.
P. G. M. Wuts.
When PG is Boc the preferred method is hydrogen chloride in a suitable solvent such as
1,4-dioxane at room temperature for 1-16 hours, or a solution of trifluoroacetic acid in
dichloromethane for 1-2 hours.
(VII)
(XI)
Scheme 3
Step (i): Nitro compound (XI) is reacted under reducing conditions to give compounds of
formula (VII). This reaction is carried out by standard methods.
Typical conditions are,
(i) Nitro compound (XI) and a suitable Pd catalyst in a protic solvent such as EtOH
under a pressure of hydrogen gas, with heating for 4-24 hrs.
(ii) Nitro compound (XI) and Zn or Fe in AcOH with or without aprotic co-solvent
without heating for 4-24 hrs.
Preferred conditions are: Nitro compound (XI) and Fe powder (2 eq) in AcOH without
heating for 16 hrs.
(XII)
(XIII)
(XV)
(XV)
(XI)
(XIV)
Scheme 4
Step (j): Benzylic alcohol (XII) is reacted with a activating reagent to give compounds of
the formula (XIII). If LG is a chloro, then (XIII) is a benzyl chloride. If LG is OSO2CH3,
then (XIII) is a methanesulfonate.
Typical conditions are,
(i) Benzylic alcohol (XII) and thionyl chloride in a suitable solvent such as THF or
DMF, with a base such as TEA or Hunig’s base with or without heating for 1- 24
hrs.
(ii) Benzylic alcohol (XII) and thionyl chloride in pyridine with or without heating for
1- 24 hrs.
(iii) Benzylic alcohol (XII) and methanesulfonyl chloride in a suitable aprotic solvent
with a base such as TEA or Hunig’s base without heating for 1- 24 hrs.
Preferred conditions are: Benzylic alcohol (XII), methanesulfonyl chloride (2 eq) and TEA
(3 eq) in DCM at 0-5 C.
Step (k): Benzylic chloride or methanesulfonate (XIII) is reacted with amine (XV) to give
compounds of the formula (XI).
Typical conditions are,
(i) Benzylic chloride (XIII), amine (XV) and TEA, Hunig’s base, NMM or K2CO3 in
suitable aprotic solvent, optionally with KI, with or without heating for 1-24 hrs.
(ii) Benzylic methanesulfonate (XIII), amine (XV) and TEA, Hunig’s base, NMM or
K CO in suitable aprotic solvent with or without heating for 1-24 hrs.
Preferred conditions are: Benzylic methanesulfonate (XIII), amine (XV), K2CO3 (3 eq) in
MeCN from 0-75 C for 16 hrs.
Alternatively
Compound (II) can be accessed via
Step (l): Benzylic alcohol (XII) is reacted to give compounds of the formula (XIV).
Typical conditions are,
(i) Benzylic alcohol (XII) and MnO in a suitable aprotic solvent with or without
heating for 1-24 hrs.
(ii) Benzylic alcohol (XII), oxalyl chloride, DMSO and TEA in DCM at -78 C.
(iii) Benzylic alcohol (XII), PCC in a suitable aprotic solvent with or without heating
for 1-24 hrs.
Preferred conditions are: Benzylic alcohol (XII) and PCC (1.3 eq) in DCM without heating
for 3 hrs.
Step (m): Aldehyde (XIV) is reacted with amine (XV) to give compounds of formula (XI).
Typical conditions are,
(i) Aldehyde (XIV), amine (XV), Ti(OPr-i) and NaBH in a protic solvent such as
MeOH without heating for 1-24 hrs.
(ii) Aldehyde (XIV), amine (XV) with NaHB(OAc)3 in DCM without heating for 1-24
hrs.
Preferred conditions are: Aldehyde (XIV), amine (XV) (1.1 eq) and NaHB(OAc)3 (2 eq) in
DCM without heating for 4 hrs.
(VI)
(VII)
(VI')
(XVII)
(XV)
(XVI)
Scheme 5
LG represents a leaving group, typically chloro, compounds suitable for use as compound
(VII) are known in the literature or commercially available.
Step (c): The alcohol (IV) is transformed in situ to the reactive intermediate (IV’), if LG
is chloro then (IV’) is a carbamoyl chloride.
Typical conditions are,
(i) The alcohol (VI) in a suitable aprotic solvent with phosgene, triphosgene,
diphosgene or CDI in the presence of a tertiary base, without heating for 1
to 24hr.
Preferred conditions are: The alcohol (VI) in DCM with triphosgene (0.4 eq) with Hunig’s
base (2 eq.), without heating for 2 hr.
Step (d): The reactive intermediate (VI’) is reacted with amine (XVI). Typical conditions
are,
(i) The reactive intermediate (IV’) in a suitable aprotic solvent with amine
(XVI) in the presence of a tertiary base like NMM, Hunig’s base, TEA
without heating for 1 to 24hr.
Preferred conditions are: The reactive intermediate (VI’) (1.3 eq.) with amine (XVI) in
with Hunig’s base (3 eq) in DCM at low temperature for 2hr.
Step (n): Carbamate (XVII) is reacted to give compounds of the formula (XV)
Typical conditions are,
(i) Carbamate (XVII) in a solution of trifluoroacetic acid in dichloromethane for 1-2
hours.
(ii) Carbamate (XVII) and hydrogen chloride in either DCM or 1,4-dioxane for 1-16
hrs.
Preferred conditions are: Carbamate (XVII) and an excess of HCl in 1,4-dioxane, without
heating for 16 hrs.
(XVIII)
(XII)
Scheme 6
Acids suitable for use as compounds (XVIII) are commercially available, known in the
literature or can be prepared from commercially available intermediates using methods
outlined in, amongst others, Kuntz et al., J. Med. Chem (2016), 59, 1556-1564, Sun et
al., PCT 2004073612, Jackson Bioorg Med Chem Lett. (2011), 21, 3227-3231, or defined
as in Scheme 7.
Step (o): Acid (XVIII) is reacted to give compounds of the formula (XII).
Typical conditions are,
(i) Acid (XVIII) and borane.tetrahyrofuran complex in suitable aprotic solvent such
as THF with heating for 3-16 hrs.
(ii) Acid (XVIII) and LiAlH in a suitable aprotic solvent without heating for 1-24 hrs.
Preferred conditions are: Acid (XVIII) and borane THF complex (3 eq) in THF with heat
for 3 hrs.
3 R O
(XIX)
(XX)
(XXI)
R O 3
O N 2
(XXII) (XVIII)
Scheme 7
Step (p): Acid (XIX) is reacted to give compounds of formula (XX)
Typical conditions are,
(i) Acid (XIX), c.H SO and c.HNO without heating for 1-3 hrs.
2 4 3
(ii) Acid (XIX), c.H SO and KNO with heating for 2-16 hrs.
2 4 3
Preferred conditions are: Acid (XIX) in c.H SO with mixture of c.HNO /c.H SO without
2 4 3 2 4
heating for 1 hr.
Step (q): Acid (XX) is reacted to give compounds of formula (XXI)
Typical conditions are,
(i) Acid (XX), TMSCHN2 in a suitable aprotic solvent with MeOH and without heating
for 2-16 hrs.
(ii) Acid (XX), MeI and K2CO3 or Na2CO3 in a suitable aprotic solvent without heating
for 3-24 hrs.
Preferred conditions are: Acid (XX), MeI (2 eq) and K CO (3 eq) in DMF at 0°C for 3 hrs.
Step (r): Aldehyde (XXI) is reacted to give compounds of formula (XXII)
Typical conditions are,
(i) Aldehyde (XXI) and DAST in a suitable solvent such as DCM without heating for
2-24 hrs
(ii) Aldehyde (XXI) and Deoxyfluor in a suitable solvent such as DCM, optionally with
protic solvent such as EtOH, with or without heating.
Preferred conditions are: Aldehyde (XXI) and DAST (2 eq) in DCM without heating for 16
hrs.
Step (s): Ester (XXII) is reacted to give compounds of formula (XVIII)
Deprotection of compound (XXII) is undertaken using standard methodology, as
described in “Greene’s Protective Groups in Organic Synthesis” Fifth edition, Wiley, Ed.
P. G. M. Wuts.
Preferred conditions are: Ester (XXII) with LiOH in aqueous THF without heating for 5
hrs.
The following scheme illustrates the preparation of compounds of the formula (XXIII)
with R1, R2, R3, R4 and R5 as hereinbefore defined:
When X = CH,
(XXIV)
(VII)
Scheme 8
LG represents a leaving group, typically chloro, compounds suitable for use as compound
(XXIV) are known in the literature or commercially available, or can be prepared from
commercially available intermediates using methods outlined in the literature.
Step (t): Amine (VII) is reacted with oxazole (XXIV) to give compounds of formula (I’)
When LG is chloro or bromo, typical conditions are,
(i) Amine (VII), oxazole (XXIV) in a suitable solvent with heating for 0.5-24 hrs.
(ii) Amine (VII), oxazole (XXIV) in a suitable aprotic solvent, with strong base such
as NaH, with heating for 1-24 hrs.
When LG is sulfur, typical conditions are,
(i) Amine (VII), oxazole (XXIV), POCl3 or SOCl2 with base such as TEA or pyridine
with heating for 1-24 hrs.
(ii) Amine (VII), oxazole (XXIV) with mcpba or Oxone in suitable solvent with heating
for 1-24 hrs.
Preferred conditions are: LG is chloro: Amine (VII) and oxazole (XXIV) in IPA with
microwave irradiation for 30 min.
GENERAL PROCEDURES, PREPARATIONS AND EXAMPLES
H nuclear magnetic resonance (NMR) spectra were recorded at 300 MHz unless
otherwise specified. Chemical shift values ( δ, in ppm) are quoted relative to internal
tetramethylsilane ( δ = 0.00) standards. The value of a multiplet, either defined doublet
(d), triplet (t), quartet (q)) or not (m) at the approximate midpoint is given unless a
range is quoted. (br) indicates a broad peak, whilst (s) indicates a singlet. All NMR
spectra are recorded in DMSO-d6 unless another solvent is stated.
The organic solvents used were usually anhydrous. The solvent ratios indicated refer to
vol:vol unless otherwise noted.
LCMS Method 1: KINETEX-1.7u XB-C18 column, 0.05% FA in water with acetonitrile
LCMS Method 2: ACQUITY UPLC BEH C18 column, 0.05% FA in water with acetonitrile
LCMS Method 3: Xbridge C18 column, 0.01M NH4CO3 in water with acetonitrile
UPLC-MS Method 4:
Column: Waters Acquity UPLC HSS T3 1.8µm, 2.1 x 50 mm.
Column temperature: 60 C.
UV: PDA 210-400 nm.
Injection volume: 2µl.
Eluents: A: 10 mM Ammonium acetate with 0.1% formic acid.
B: 100% Acetonitrile with 0.1% formic acid.
Gradient: Time A% B% Flow
0.0 95 5 1.2
0.9 5 95 1.2
0.91 5 95 1.3
1.2 5 95 1.3
1.21 5 95 1.2
1.4 95 5 1.2
MS: Electrospray switching between positive and negative ionisation.
Instruments: Waters Aquity UPLC, Waters SQD
UPLC-MS Method 5:
Column: Acquity UPLC HSS T3 1.8µm; 2.1 x 50mm
Flow: 0.7ml/min
Column temp: 40°C
Mobile phases: A: 10 mM Ammonium acetate + 0.1% formic acid
B: 100% Acetonitrile + 0.1% formic acid
UV: 240-400 nm
Injection volume: 2µl
Gradient: Time A% B%
0.0 99% A 1% B
0.5 94% A 6% B
1.0 94% A 6% B
2.6 5% A 95% B
3.8 5% A 95% B
3.81 99% A 1% B
4.8 99% A 1% B
UPLC (inlet method): XE Metode 7 CM
MS – method: PosNeg_50_1000
Instruments: Waters Acquity UPLC, Waters LCT Premier XE
UPLC-MS Method 6:
Column: Acquity UPLC HSS T3 1.8µm; 2.1 x 50mm
Flow: 0.7ml/min
Column temp: 30°C
Mobile phases: A: 10 mM Ammonium acetate + 0.1% formic acid
B: 100% Acetonitrile + 0.1% formic acid
UV: 240-400 nm
Injection volume: 1µl
Gradient: Time A% B%
0.0 99% A 1% B
0.5 94% A 6% B
1.0 94% A 6% B
2.6 5% A 95% B
3.8 5% A 95% B
3.81 99% A 1% B
4.8 99% A 1% B
UPLC (inlet method): XEV Metode 1 CM
MS – method: Pos_50_1000 or Neg_50_1000
Instruments: Waters Acquity UPLC, Waters XEVO G2-XS QTof
Basic preparative HPLC conditions:
Column: XBridge Prep C18 5 μm OBD, 19x150 mm
Eluents: Ammonium formate (50 mM)/acetonitrile, 10-100% acetonitrile
Flow: 30 mL/min
Acidic preparative HPLC conditions:
Column: XTerra RP-18 5 μm OBD, 19x150 mm
Eluents: 0.1% formic acid in water/acetonitrile, 10-100% acetonitrile
Flow: 30 mL/min
List of Abbreviations
AcOH acetic acid
CDI 1,1’-carbonyldiimidazole
CHCl3 chloroform
c.HNO concentrated nitric acid
c.H SO concentrated sulfuric acid
DAST (diethylamino)sulfur trifluoride
DCC dicyclohexylcarbodiimide
DCM dichloromethane
Deoxyfluor bis(2-methoxyethyl)aminosulfur trifluoride
DMAP N,N-dimethylpyridinamine
DMF dimethylformamide
DMSO dimethylsulfoxide
EtOAc ethyl acetate
EtOH ethanol
FA Formic acid
Fe iron
HATU N,N,N ′,N ′-tetramethyl-O-(1H-benzotriazol
yl)uronium hexafluorophosphate
HCl hydrogen chloride
HOAT 1-hydroxyazabenzotriazole
HOBT 1-hydroxybenzotriazole
Hunig’s base diisopropylethylamine
IPA propanol
K CO potassium carbonate
KI potassium iodide
LiAlH lithium aluminium hydride
LiOH lithium hydroxide
mcpba 3-chloroperbenzoic acid
MeCN acetonitrile
MeI iodomethane
MeOH methanol
NaBH sodium borohydride
NaBH(OAc) sodium triacetoxyborohydride
Na2CO3 sodium carbonate
NaH sodium hydride
NMM 4-methylmorpholine
Oxone potassium peroxymonosulfate
PCC pyridinium chlorochromate
Pd palladium
POCl phosphorous oxychloride
thionyl chloride
SOCl2
TEA triethylamine
THF tetrahydrofuran
Ti(OPr-i)4 titanium isopropoxide
TMSCHN2 trimethylsilyldiazomethane
TsCl tosyl chloride
WSCDI 3-(ethyliminomethyleneamino)-N,N-dimethyl-
propanamine hydrochloride
Zn zinc
O N O N O N
2 2 2
OH OH
Cl Cl
Cl Cl
O N H N
N O N O
Cl O Cl O
N N N
H N N
N O S N O
Cl O Cl O
Scheme 9.1
Preparation 1: 5-chloromethylnitrobenzoic acid
-Chloromethylbenzoic acid (75.0 g, 439 mmol) was added portion-wise to conc.
sulphuric acid (525 ml, 7 vol) at 0°C. After complete addition a solution of conc. nitric
acid (41.1 g, 978 mmol, 67%) in conc. sulphuric acid (82.5 ml) was added drop-wise
maintaining internal temperature at 0°C. On complete addition the reaction mixture was
stirred for an additional 30 mins at 0°C. The mixture was poured onto ice/water and the
precipitate was filtered, washed with water, dried and filtered to afford title compound as
an off-white solid. (80.0 g, 84.4 %, as a mixture of isomers)
H NMR (400MHz, CDCl3) δ = 8.18 (d, J = 2.4 Hz, 1H), 7.90 (d, J = 2.4 Hz, 1H), 2.66 (s,
3H). Peaks at 7.55 (d, J = 8.3 Hz, 1H), 7.39 (d, J = 8.3 Hz, 1H), 2.57 (s, 3H) relate to
regioisomer. LCMS Method 1: m/z 214.03 [M-H ]; RT = 2.49 min.
Preparation 2: (5-chloromethylnitro-phenyl)methanol
Borane tetrahydrofuran complex solution (1.11 L, 1.0 M in THF) was added to a solution
of the acid from Preparation 1 (80.0 g, 371 mmol) drop-wise at 0°C. On complete
addition the reaction mixture was warmed to room temperature then stirred at reflux for
3 h. The reaction mixture was cooled to room temperature. Methanol was added drop-
wise until evolution of gas subsided. The reaction mixture was stirred at reflux for 2 h.
The cooled reaction mixture was poured into water (500 mL) and extracted with ethyl
acetate (2 x 1000 mL). The combined ethyl acetate layers were dried over sodium
sulphate and evaporated under reduced pressure to afford title compound as a pale
brown solid. (75.0 g, 100%)
H NMR (400MHz, CDCl ) δ = 7.71 (br d, J=6.8 Hz, 2H), 7.34-7.40 (m, 0.24H), 7.27-
7.32 (m, 0.24H), 4.77 (s, 2H), 4.58 (s, 0.5H), 2.47 (s, 1H), 2.33 (s, 3H).
Preparation 3: 5-chloromethylnitro-benzaldehyde
Pyridinium chlorochromate (104 g, 483 mmol) was slowly added to a stirred solution of
alcohol from Preparation 2 (75.0 g, 372 mmol) in dichloromethane (200 mL). The
reaction mixture was stirred at room temperature for 3 h then filtered through Celite .
The solvent was removed under reduced pressure. The obtained residue was purified by
silica gel (100-200 mesh) column chromatography eluting with a gradient of 0-10%
ethyl acetate in petroleum ether. Clean fractions were evaporated under reduced
pressure to give the title compound as an off-white solid. (39.0 g, 52.5%)
H NMR (400MHz, CDCl ) δ = 10.34 (s, 1H), 8.02 (d, J=2.0 Hz, 1H), 7.97 (d, J=2.4 Hz,
1H), 2.75 (s, 3H). LCMS Method 1: m/z 198.08 [M-H ]; 82.8%; RT = 2.74 min.
Preparation 4: tert-butyl (2S)[(5-chloromethylnitro-phenyl)methyl]methyl-
piperazinecarboxylate
tert-Butyl (2S)methylpiperazinecarboxylate (43.1 g, 215 mmol) was added to a
solution of aldehyde from Preparation 3 (39.0 g, 195 mmol) in dichloromethane (780
mL). The reaction mixture was stirred at room temperature for 10 min then sodium
triacetoxyborohydride (83.1 g, 391 mmol) was added portion-wise. On complete
addition the reaction mixture was stirred at room temperature for 4 h. The reaction
mixture was carefully quenched with water (200 mL) and extracted with
dichloromethane (200 mL). The organic layer was dried over sodium sulphate and
concentrated under reduced pressure. Trituration of the crude product with n-pentane
afforded the title compound as an off-white solid. (43.0 g, 57.3%)
H NMR (300MHz, DMSO-d6) δ =7.92 (d, J=2.2 Hz, 1H), 7.68 (d, J=2.2 Hz, 1H), 4.09
(m, 1H), 3.67 (br d, J=13.1 Hz, 1H), 3.52 (s, 2H), 2.88-3.02 (m, 1H), 2.69 (br d,
J=11.1 Hz, 1H), 2.57 (br d, J=11.3 Hz, 1H), 2.35 (s, 3H), 2.15 (dd, J=11.3, 3.6 Hz, 1H),
1.98 (td, J=11.7, 3.4 Hz, 1H), 1.39 (s, 9H), 1.13 (d, J=6.7 Hz, 3H). LCMS Method 1:
m/z 384.66 [M+H ]; RT = 3.47 min.
Preparation 5: tert-butyl (2S)[(3-aminochloromethyl-phenyl)methyl]
methyl-piperazinecarboxylate
Cl O
Iron powder (7.29 g, 130 mmol) was added to a solution of nitro compound from
Preparation 4 (25.0 g, 65.3 mmol) in acetic acid (250 mL), portion-wise at room
temperature. The reaction mixture was stirred for 16 h and then concentrated to low
volume under reduced pressure. The crude product was diluted in dichloromethane (100
mL) and filtered through a pad of Celite . The filtrate was concentrated and pH adjusted
to pH 8 with saturated sodium hydrogen carbonate. The mixture was extracted with
dichloromethane (3 x 200 mL). The combined organic layer was dried over sodium
sulphate and evaporated under reduced pressure. The obtained residue was purified by
silica gel (100-200 mesh) column chromatography eluting with a gradient of 20-30%
ethyl acetate in petroleum ether. Clean fractions were evaporated under reduced
pressure to give the title compound as an off-white solid. (18.0 g, 78.1%)
H NMR (400MHz, DMSO-d6) δ = 6.59 (d, J=2.1 Hz, 1H), 6.47 (d, J=2.1 Hz, 1H), 5.10
(s, 2H), 4.07 (br s, 1H), 3.65 (br d, J=13.1 Hz, 1H), 3.21-3.31 (m, 2H), 2.91 (br t,
J=11.4 Hz, 1H), 2.67 (br d, J=11.0 Hz, 1H), 2.56 (br d, J=11.3 Hz, 1H), 2.12 (s, 3H),
1.94-2.12 (m, 1H), 1.86 (td, J=11.6, 3.4 Hz, 1H), 1.39 (s, 9H), 1.11 (d, , J=6.7 Hz,
3H). LCMS Method 1: m/z 354.27 [M+H ]; RT = 2.19 min.
Preparation 6: tert-butyl (2S)[(5-chloroisothiocyanatomethyl-phenyl)methyl]-
2-methyl-piperazinecarboxylate
Thiocarbonyl dichloride (0.17 mL, 2.12 mmol) was added drop-wise to a rapidly stirred
mixture of the product from Preparation 5 (750 mg, 2.12 mmol) in chloroform (70 mL)
and saturated sodium hydrogen carbonate (70 mL). The reaction mixture was stirred at
room temperature for 16 h. The reaction mixture was extracted with dichloromethane (2
x 50 mL). The combined organic layers were dried over magnesium sulphate and
evaporated under reduced pressure to afford title compound as off-white solid. (839 mg,
100%)
H NMR (300 MHz, CDCl3) δ = 7.20 (d, J = 2.2 Hz, 1H), 7.16 (d, J = 2.2 Hz, 1H), 4.21
(s, 1H), 3.80 (d, J = 13.1 Hz, 1H), 3.36 (s, 2H), 3.05 (td, J = 12.7, 3.4 Hz, 1H), 2.67 (d,
J = 11.0 Hz, 1H), 2.54 (d, J = 11.0 Hz, 1H), 2.34 (s, 3H), 2.20 (dd, J = 11.1, 3.9 Hz,
1H), 2.01 (d, J = 3.5 Hz, 1H), 1.46 (d, J = 0.6 Hz, 9H), 1.21 (d, J = 6.7 Hz, 3H). LCMS
Method 4: m/z 396.2 [M+H ]; RT = 1.15 min.
Preparation 7: tert-butyl (2S)[[3-(aminocarbamothioylamino)chloromethyl-
phenyl]methyl]methyl-piperazinecarboxylate
The thioisocyanate from Preparation 6 (839 mg, 2.12 mmol), in chloroform (4 mL),
was added to a solution of hydrazine hydrate (111 mg, 2.22 mmol) in chloroform (10
mL) over 10 min. The resulting mixture was stirred at room temperature for 16 h. The
reaction mixture was evaporated under reduced pressure to afford title compound as
pale yellow solid. (906 mg, 99%)
H NMR (300 MHz, CDCl3) δ = 8.97 (s, 1H), 7.59 (s, 1H), 7.26 (1H), 7.23 (s, 1H), 4.20
(s, 1H), 4.01 (s, 2H), 3.80 (d, J = 13.1 Hz, 1H), 3.40 (s, 2H), 3.05 (td, J = 12.7, 3.4 Hz,
1H), 2.71 (d, J = 11.1 Hz, 1H), 2.57 (d, J = 11.1 Hz, 1H), 2.25 (s, 3H), 2.18 (d, J = 3.9
Hz, 1H), 2.01 (td, J = 11.7, 3.5 Hz, 1H), 1.46 (s, 9H), 1.21 (d, J = 6.7 Hz, 3H). LCMS
Method 4: m/z 396.2 [M+H ]; RT = 0.74 min.
2HCl
Scheme 9.2
Preparation 8: 5-chloromethyl[[(3S)methylpiperazinyl]methyl]aniline
dihydrochloride
.2HCl
Hydrogen chloride (4M solution in 1,4-dioxane, 15 mL, 60 mmol) was added to a
solution of the piperazine compound from Preparation 5 (3.00 g, 8.48 mmol) in
dichloromethane (30 mL) and stirred at room temperature for 4 h. The reaction mixture
was concentrated under reduced pressure to afford title compound as a colourless solid
that was used without any purification. (2.77 g, 100%) LCMS Method 4: m/z 254.2
[M+H ]; RT = 0.42 min.
Preparation 9: [(2S)[(3-aminochloromethyl-phenyl)methyl]methyl-
piperazinyl]-phenyl-methanone
Cl O
Benzoic acid (561 mg, 4.59 mmol) was added to a solution of the amine from
Preparation 8 (1.50 g, 4.59 mmol) in ethyl acetate (25 mL). To this mixture was added
triethylamine (3.84 mL, 27.6 mmol) and N,N,N ′,N ′-tetramethyl-O-(1H-benzotriazol
yl)uronium hexafluorophosphate (1.83 g, 4.82 mmol). The resulting reaction mixture
was stirred at room temperature for 16 h and then quenched with water and extracted
with dichloromethane (2x 30 mL). The combined organic layers was dried over
magnesium sulphate and evaporated under reduced pressure. The obtained residue was
purified by silica gel (100-200 mesh) column chromatography eluting with a gradient of
0-60% ethyl acetate in heptane. Clean fractions were evaporated under reduced
pressure to give the title compound as a colourless solid. (1.36 g, 83.0%)
H NMR (300 MHz, DMSO-d6) δ = 7.42-7.45 (m, 3H), 7.32-7.35 (m, 2H), 6.59 (d, J =
2.2 Hz, 1H), 6.47 (d, J = 2.2 Hz, 1H), 5.10 (s, 2H), 3.10 (bs, 1H), 2.71 (d, J = 10.1 Hz,
1H), 2.61 (d, J = 7.3 Hz, 1H), 2.12 (dd, J = 11.3, 3.8 Hz, 1H), 2.01 (s, 3H), 1.95 (td, J
= 11.7, 3.5 Hz, 1H), 1.22 (d, J = 6.7 Hz, 3H). LCMS Method 4: m/z 358.3 [M+H ]; RT
= 0.42 min.
Preparation 10: [(2S)[(5-chloroisothiocyanatomethyl-phenyl)methyl]
methyl-piperazinyl]-phenyl-methanone
Using a procedure similar to that described for Preparation 6, but using the compound
described in Preparation 9 (675 mg, 1.89 mmol), the title compound was prepared as
a yellow oil. (750 mg, 99%)
H NMR (300 MHz, CDCl3) δ = 7.30 – 7.47 (m, 5H), 7.09 – 7.23 (m, 2H), 3.40 (s, 2H),
3.24 (s, 1H), 2.73 (s, 1H), 2.58 (s, 1H), 2.35 (s, 4H), 2.11 (d, J = 13.6 Hz, 1H), 1.33
(d, J = 6.8 Hz,, 3H). LCMS Method 4: m/z 400.3 [M+H ]; RT = 1.04 min.
Preparation 11: 1-amino[3-[[(3S)benzoylmethyl-piperazinyl]methyl]
chloromethyl-phenyl]thiourea
Using a procedure similar to that described for Preparation 7, but using the compound
described in Preparation 10 (550 mg, 1.37 mmol), the title compound was prepared as
an off-white solid. (490 mg, 82%)
H NMR (300 MHz, CDCl3) δ = 8.97 (s, 1H), 7.59 (s, 1H), 7.38 (tdd, J = 6.4, 2.8, 1.9 Hz,
5H), 7.20 (d, J = 2.2 Hz, 1H), 4.06 (d, J = 15.7 Hz, 2H), 3.43 (s, 2H), 3.23 (s, 1H), 2.76
(s, 1H), 2.63 (d, J = 11.4 Hz, 1H), 2.24 (s, 4H), 2.11 (d, J = 11.9 Hz, 1H), 1.32 (d, J =
6.7 Hz, 2H). LCMS Method 4: m/z 432.2 [M+H ]; RT = 0.64 min.
2HCl
Scheme 9.3
Preparation 12: (3S)[(5-chloromethylnitro-phenyl)methyl]methyl-
piperazine hydrochloride
.HCL
Hydrogen chloride (4M solution in 1,4-dioxane, 200 mL) was added to a solution of the
piperazine compound from Preparation 4 (15.0 g, 39.2 mmol) in 1,4-dioxane (45 mL)
at 0°C. The resulting mixture was stirred at room temperature for 16 h before being
concentrated under reduced pressure to afford title compound as a colourless solid.
(12.5 g, 100%)
H NMR (300MHz, DMSO-d6) δ = 7.86-8.17 (m, 2H), 5.46 (br s, 2H), 4.10 (br s, 2H),
3.57 (s, 3H), 3.25 (br s, 2H), 2.40 (s, 3H), 1.25 (br d, J=6.6 Hz, 3H).
LCMS Method 1: m/z 284, 17 [M+H ]; RT = 2.04 min.
Preparation 13: isopropyl (2S)[(5-chloromethylnitro-phenyl)methyl]
methyl-piperazinecarboxylate
Isopropyl chloroformate (2M solution in toluene, 3.66 mmol) was added drop-wise to a
solution of the amine from Preparation 12 (900 mg, 2.81 mmol) and
diisopropylethylamine (1.5 mL, 8.44 mmol) in dichloromethane (10 mL) at 0°C. The
reaction mixture was stirred to room temperature over 2 h. The mixture was diluted with
water (50 mL) and extracted with dichloromethane (2 x 50 mL). The combined organic
layer was dried over sodium sulphate and evaporated under reduced pressure. The
obtained residue was purified by silica gel (100-200 mesh) column chromatography
eluting with a gradient of 10-20% ethyl acetate in petroleum ether. Clean fractions were
evaporated under reduced pressure to give the title compound as a colourless oil. (600
mg, 57.7%)
H NMR (300MHz, CDCl3) δ = 7.69 (d, J=2.1 Hz, 1H), 7.53 (d, J=2.1 Hz, 1H), 4.92-4.96
(m, 1H), 4.28-4.31 (m, 1H), 3.85-3.88 (m, 1H), 3.46 (s, 2H), 3.10-3.14 (m, 1H), 2.70-
2.73 (m, 1H), 2.52-2.57 (m, 1H), 2.44 (s, 3H), 2.21 – 2.31 (m, 1H), 2.01 – 2.15 (m,
1H), 1.24 (m, 9H). LCMS Method 1: m/z 370.62 [M+H ]; RT = 3.18 min.
Preparation 14: isopropyl (2S)[(3-aminochloromethyl-phenyl)methyl]
methyl-piperazinecarboxylate
Cl O
Using a procedure similar to that described for Preparation 5 but using the nitro
compound from preparation 13 (3.30 g, 8.94 mmol), the title compound was prepared
as a brown gum (2.60 g, 85.8%).
H NMR (400MHz, DMSO-d6) δ = 6.59 (d, J=2.1 Hz, 1H), 6.47 (d, J=2.1 Hz, 1H), 5.10
(s, 2H), 4.75-4.79 (m, 1H), 4.11 (br s, 1H), 3.65-3.69 (m, 1H), 3.20-3.30 (m, 2H),
2.86-3.04 (m, 1H), 2.65-2.69 (m, 1H), 2.53-2.57 (m, 1H), 1.98-2.15 (m, 4H), 1.82-
1.89 (m, 1H), 1.17 (d, J=6.1 Hz, 6H), 1.13 (d, J=6.7 Hz, 3H). LCMS Method 1: m/z 384.
[M+H ]; 98.8%; RT = 2.05 min.
Preparation 15: isopropyl (2S)[(5-chloroisothiocyanatomethyl-
phenyl)methyl]methyl-piperazinecarboxylate
Using a procedure similar to that described for Preparation 6, but using the compound
described in Preparation 14 (1.00 g, 2.94 mmol), the title compound was prepared as
a yellow oil. (1.11 g, 98.8%)
H NMR (300 MHz, CDCl3) δ=7.20 (s, 1H), 7.17 (s, 1H), 4.92 (h, J = 6.2 Hz, 1H), 4.26
(s, 1H), 3.86 (d, J = 13.2 Hz, 1H), 3.37 (s, 2H), 3.08 (td, J = 12.7, 3.4 Hz, 1H), 2.68 (d,
J = 11.0 Hz, 1H), 2.55 (d, J = 11.1 Hz, 1H), 2.34 (s, 3H), 2.28 – 2.13 (m, 1H), 2.03 (td,
J = 11.6, 3.5 Hz, 1H), 1.24 (d, J = 4.6, Hz, 6H) overlapping 1.22 (d, J = 6.5, Hz, 3H).
LCMS Method 4: m/z 382.1 [M+H ]; RT = 1.08 min.
Preparation 16: isopropyl (2S)[[3-(aminocarbamothioylamino)chloromethyl-
phenyl]methyl]methyl-piperazinecarboxylate
Using a procedure similar to that described for Preparation 7, but using the compound
described in Preparation 15 (1.11 g, 2.91 mmol), the title compound was prepared as
a yellow oil. (869 mg, 72.2%)
H NMR (300 MHz, CDCl3) δ =7.59 (br s, 1H), 7.23 (s, 1H), 4.93 (p, J = 6.2 Hz, 1H),
4.25 (s, 1H), 4.04 (s, 2H), 3.85 (d, J = 13.2 Hz, 1H), 3.40 (s, 2H), 3.09 (td, J = 12.9,
3.4 Hz, 1H), 2.72 (d, J = 10.9 Hz, 1H), 2.58 (d, J = 11.1 Hz, 1H), 2.25 (s, 4H), 2.13 –
1.88 (m, 1H), 1.24 (d, J = 4.6, Hz, 6H) overlapping 1.22 (d, J = 6.5, Hz, 3H). LCMS
Method 4: m/z 414.1 [M+H ]; RT = 0.66 min.
O N O N O N
2 2 2
OH OH OH
O N H N
N O N O
2HCl
C H H
H N N
S N O
Scheme 9.4
Preparation 17: 2,5-dimethylnitro-benzoic acid
Using a procedure similar to that described for Preparation 1, but using 2,5-
dimethylbenzoic acid (40.0g, 266 mmol), the title compound was prepared as an off-
white solid (37.0 g, 71.1%, mixture of isomers).
H NMR (400MHz, acetone- d ) δ = 7.89 (s, 1H), 7.79 (s, 1H), 2.54(s, 3H), 2.42 (s, 3H).
Preparation 18: (2,5-dimethylnitro-phenyl)methanol
Using a procedure similar to that described for Preparation 2, but using the acid from
Preparation 17 (37.0 g, 189 mmol), the title compound was prepared as a pale brown
solid (15.9 g, 46.3%, mixture of isomers). Used directly without purification.
Preparation 19: 2,5-dimethylnitro-benzaldehyde
Using a procedure similar to that described for Preparation 3, but using the compound
described in Preparation 18 (12.0 g, 66.2 mmol), the title compound was prepared as
an off white solid (10.5 g, 88.4%).
H NMR (300 MHz, CDCl ) δ = 10.35 (s, 1H), 7.85 (s, 1H), 7.78 (s, 1H), 2.72 (s, 3H),
2.47 (s, 3H).
Preparation 20: tert-butyl (2S)[(2,5-dimethylnitro-phenyl)methyl]methyl-
piperazinecarboxylate
Using a procedure similar to that described for Preparation 4, but using the compound
from Preparation 19 (10.5 g, 56.6 mmol), the title compound was prepared as a
colourless gum (11.5 g, 54.0%).
H NMR (300 MHz, DMSO-d ) δ = 7.57 (s, 1H), 7.39 (s, 1H), 4.09 (br s, 1H), 3.64-3.67
(m, 1H), 3.40-3.53 (m, 2H), 2.86-2.99 (m, 1H), 2.67-2.69 (m, 1H), 2.57 (m, 1H), 2.25-
2.40 (m, 5H), 2.11-2.14 ( m, 1H), 1.86-2.00 (m, 1H), 1.39 (s, 9H), 1.12 (d, J=6.6 Hz,
3H). LCMS Method 1: m/z 364.91 [M+H ]; RT = 2.86 min.
Preparation 21: tert-butyl (2S)[(3-amino-2,5-dimethyl-phenyl)methyl]methyl-
piperazinecarboxylate
Using a procedure similar to that described for Preparation 5, but using the compound
described in Preparation 20 (11.5 g, 31.7 mmol), the title compound was prepared as
an off-white solid. (9.90 g, 93.8%).
H NMR (400 MHz, DMSO-d6) δ = 6.37 (s, 1H), 6.25 (s, 1H), 4.64 (br s, 2H), 4.06 (br s,
1H), 3.61-3.66 (m, 1H), 3.15-3.30 (m, 2H), 2.81-2.99 (m, 1H), 2.67 (br d, J=10.8 Hz,
1H), 2.57 (br d, J=11.2 Hz, 1H), 2.10 (s, 3H), 1.96-2.05 (m, 4H), 1.80 (td, J=11.6, 3.2
Hz, 1H), 1.38 (s, 9H), 1.10 (d, J=6.8 Hz, 3H). LCMS Method 1: m/z 334.15 [M+H ]; RT
= 1.93 min.
Preparation 22: 2,5-dimethyl[[(3S)methylpiperazinyl]methyl]aniline
dihydrochloride
2HCl
Using a procedure similar to that described for Preparation 12, but using the
compound described in Preparation 21 (400 mg, 1.2 mmol) and replacing 1,4-dioxane
with methanol as solvent, the title compound was prepared as an off-white solid taken
directly into next step. (366 mg, 100%)
LCMS Method 4: m/z 232.2 [M+H ]; RT = 0.31 min.
Preparation 23: isopropyl (2S)[(3-amino-2,5-dimethyl-phenyl)methyl]methyl-
piperazinecarboxylate
Using a procedure similar to that described for Preparation 13, but using the
compound described in Preparation 22 (10.0 g, 32.6 mmol), the title compound was
prepared as a brown oil. (5.60 g, 54.0%)
H NMR (500 MHz, DMSO-d ) δ = 6.37 (s, 1H), 6.25 (s, 1H), 4.76 (quin, J=6.2 Hz, 1H),
4.65 (s, 2H), 4.10 (br s, 1H), 3.68 (br d, J=12.8 Hz, 1H), 3.20-3.30 (m, 2H), 2.87-2.98
(m, 1H), 2.68 (br d, J=11.0 Hz, 1H), 2.58 (br d, J=11.3 Hz, 1H), 2.10 (s, 3H), 1.96-
2.05 (m, 4H), 1.82 (td, J=11.7, 3.4 Hz, 1H), 1.17 (d, J=6.3 Hz, 6H), 1.12 (d, J=6.7 Hz,
3H). LCMS Method 2: m/z 320.38 [M+H ]; RT = 1.24 min.
Preparation 24: isopropyl (2S)[(3-isothiocyanato-2,5-dimethyl-phenyl)methyl]
methyl-piperazinecarboxylate
Using a procedure similar to that described for Preparation 6, but using the compound
described in Preparation 23 (3.52 g, 11.0 mmol), the title compound was prepared as
a yellow oil and used directly in next step. (3.98 g, 100%) LCMS Method 4: m/z 362.2
[M+H ]; RT = 1.06 min.
Preparation 25: isopropyl (2S)[[3-(aminocarbamothioylamino)-2,5-dimethyl-
phenyl]methyl]methyl-piperazinecarboxylate
Using a procedure similar to that described for Preparation 7, but using the compound
described in Preparation 24 (3.98 g, 11.0 mmol), the title compound was prepared as
a yellow oil. (3.17 g, 73.2%)
H NMR (600 MHz, CDCl3) δ =8.95 (s, 1H), 6.92-7.10 (m, 1H), 4.92 (p, J = 6.2 Hz, 1H),
4.24 (s, 1H), 4.05 (s, 1H), 3.84 (d, J = 13.2 Hz, 1H), 3.39 (s, 2H), 3.07 (td, J = 12.8,
3.5 Hz, 1H), 2.72 (d, J = 10.9 Hz, 1H), 2.58 (d, J = 11.3 Hz, 1H), 2.32 (s, 3H), 2.25 (s,
3H), 2.22 – 2.10 (m, 1H), 2.00 (td, J = 11.7, 3.6 Hz, 1H), 1.24 (dd, J = 6.2, 1.6 Hz,
6H), 1.21 (d, J = 6.7 Hz, 3H). LCMS Method 4: m/z 294.2 [M+H ]; RT = 0.50 min.
Scheme 9.5
Preparation 26: tert-butyl (2S)[(3-isothiocyanato-2,5-dimethyl-phenyl)methyl]
methyl-piperazinecarboxylate
Using a procedure similar to that described for Preparation 6, but using the compound
described in Preparation 21 (1.15 g, 3.45 mmol), the title compound was prepared as
a yellow oil. (1.40 g, 100%)
H NMR (300 MHz, CDCl3) δ = 6.97 (m, 2H), 4.19 (s, 1H), 3.78 (d, J = 13.0 Hz, 1H),
3.44 – 3.24 (m, 2H), 3.03 (td, J = 12.7, 3.4 Hz, 1H), 2.66 (d, J = 11.2 Hz, 1H), 2.54 (d,
J = 11.1 Hz, 1H), 2.35 (s, 3H), 2.28 (d, J = 0.8 Hz, 3H), 2.21 – 2.09 (m, 1H), 2.03 –
1.90 (m, 1H), 1.45 (s, 9H), 1.19 (d, J = 6.7 Hz, 3H). LCMS Method 4: m/z 376.2
[M+H ]; RT = 1.12 min.
Preparation 27: tert-butyl (2S)[[3-(aminocarbamothioylamino)-2,5-dimethyl-
phenyl]methyl]methyl-piperazinecarboxylate
Using a procedure similar to that described for Preparation 7, but using the compound
described in Preparation 26 (1.40 g, 3.45 mmol), the title compound was prepared as
a yellow oil. (1.50 g, 98.7%)
H NMR (300 MHz, DMSO-d6) δ = 8.95 (s, 1H), 7.20 (s, 1H), 6.91 (s, 1H), 4.73 (s, 1H),
4.08 (s, 1H), 3.66 (d, J = 13.0 Hz, 1H), 2.92 (t, J = 12.1 Hz, 1H), 2.70 (d, J = 11.5 Hz,
1H), 2.59 (d, J = 11.4 Hz, 1H), 2.24 (s, 3H), 2.14 (s, 3H), 2.06 (dd, J = 11.1, 4.0 Hz,
1H), 1.95 – 1.81 (m, 1H), 1.39 (s, 9H), 1.12 (d, J = 6.7 Hz, 3H). LCMS Method 4: m/z
408.2 [M+H ]; RT = 0.54 min.
Scheme 9.6
Preparation 28: cyclobutyl-[(2S)[(3-isothiocyanato-2,5-dimethyl-phenyl)methyl]
methyl-piperazinyl]methanone
N,N,N ′,N ′-tetramethyl-O-(1H-benzotriazolyl)uronium hexafluorophosphate (478 mg,
1.26 mmol) was added to a solution of the product from Preparation 22 (280 mg, 0.91
mmol), cyclobutane carboxylic acid (105 mg, 1.05 mmol) and triethylamine (0.73 mL,
5.24 mmol) in dichloromethane (3.0 mL) and the reaction mixture was stirred at room
temperature for 16 h. The reaction mixture was quenched with water and extracted with
dichloromethane (2 x 50 mL). The combined organic layers were dried over magnesium
sulphate, filtered and evaporated under reduced pressure. The obtained residue (270
mg) was dissolved in chloroform (10 mL) and saturated sodium hydrogen carbonate (10
mL) added. The resulting mixture was rapidly stirred while thiocarbonyl dichloride (0.069
mL, 0.89 mmol) was added drop-wise. The reaction mixture was stirred at room
temperature for 16 h before being extracted with dichloromethane (2 x 50 mL). The
combined organic layers were dried over magnesium sulphate and evaporated under
reduced pressure to afford title compound as off-white solid. (260 mg, 80%)
H NMR (600 MHz, CDCl ) δ = 6.99 (s, 1H), 6.95 (s, 1H), 4.71 (s, 0.5H), 4.34-4.47 (m,
0.5H), 3.81-3.86 (m, 0.5H), 3.31-3.39 (m, 2.5H), 3.16-3.26 (m, 1.5H), 2.90 (td, J =
12.9, 3.5 Hz, 0.5H), 2.70 (dd, J = 32.9, 11.1 Hz, 1H), 2.59 (t, J = 12.1 Hz, 1H), 2.46 –
2.26 (m, 2H) covering 2.35 (s, 3H), 2.28 (s, 3H), 2.12 (qq, J = 12.4, 6.8, 5.2 Hz, 3H),
2.02 – 1.90 (m, 2H), 1.86 (tt, J = 12.4, 6.1 Hz, 1H), 1.31 – 1.14 (m, 3H). LCMS Method
4: m/z 358.2 [M+H ]; RT = 1.00 min.
Preparation 29: 1-amino[3-[[(3S)(cyclobutanecarbonyl)methyl-piperazin
yl]methyl]-2,5-dimethyl-phenyl]thiourea
Using a procedure similar to that described for Preparation 7, but using the compound
described in Preparation 28 (260 mg, 0.72 mmol), the title compound was prepared as
a colourless solid. (240 mg, 84.7%)
LCMS Method 4: m/z 390.2 [M+H ]; RT = 0.46 min.
2 O N
OH OH
OH O
O N O N
OH OH
F F F F
O N H N
O N S
N O N O
F F F F
H N N
S N O
Scheme 9.7
Preparation 30: 5-formylmethyl-benzoic acid
n-Butyllithium (139 mL, 348 mmol, 2,5M solution in tetrahydrofuran) was added drop-
wise to a solution of 5-bromomethylbenzoic acid (30.0 g, 139mmol) in
tetrahydrofuran (300 mL) at -78°C. The resulting mixture was stirred for 1 h and then
dimethylformamide (54.0 mL, 697 mmol) was added drop-wise and stirring continue for
a further 1 h at -78°C. The reaction mixture was then poured onto aqueous hydrogen
chloride solution (500 mL, 1M) and extracted with ethyl acetate (2 x 1000 mL). The
combined organic layer was dried over sodium sulphate and evaporated under reduced
pressure to afford title compound as yellow solid that was used in the next step without
purification. (12.0 g, 52.4%)
H NMR (500 MHz, DMSO-d ): δ =13.16 (br s, 1H), 10.02 (s, 1H), 8.34 (d, J=1.8 Hz,
1H), 7.96 (dd, J=1.8, 7.9 Hz, 1H), 7.55 (d, J=7.9 Hz, 1H), 2.62 (s, 3H). LCMS Method 2:
m/z 164.80 [M+H ]; RT = 1.43 min.
Preparation 31:5-formylmethylnitro-benzoic acid
Using a procedure similar to that described for Preparation 1, but using the compound
described in Preparation 30 (42.0 g, 256 mmol), the title compound was prepared as
an off-white solid. (32.0 g, 59.8%)
H NMR (300 MHz, DMSO-d6): δ = 13.80 (br s, 1H), 10.07 (s, 1H), 8.49 (d, J=2.2 Hz,
2H), 2.61 (s, 3H). LCMS Method 1: m/z 208.32 [M-H ]; RT = 1.81 min.
Preparation 32: methyl 5-formylmethylnitro-benzoate
Potassium carbonate (63.0 g, 459 mmol) was added portion-wise to a solution of
product from Preparation 31 (32.0 g, 153 mmol) in dimethylformamide (200 mL) at
0°C. The reaction mixture was stirred for 10 min before methyl iodide (33.9 mL, 306.2
mmol) was added drop-wise maintaining temperature around 0°C. The reaction was
stirred for 3 h and allowed to reach to room temperature before being poured onto
ice/water (500 mL) and extracted with ethyl acetate (2 x 1000 mL). The combined
organic layer was dried over sodium sulphate and evaporated under reduced pressure to
afford title compound as a brown oil that was used in the next step without purification.
(30.0 g, 87.8%)
H NMR (300 MHz, CDCl ): δ = 10.05 (s, 1H), 8.50 (s, 1H), 8.32 (s, 1H), 3.99 (s, 3H),
2.73 (s, 3H). LCMS Method 2: m/z 222.19 [M-H ]; RT = 2.33 min.
Preparation 33: methyl 5-(difluoromethyl)methylnitro-benzoate
N,N-Diethylaminosuflur trifluoride (35.0 mL, 269 mmol) was added to a solution of
product from Preparation 32 (30.0g, 134 mmol) in dichloromethane at -10°C. The
resulting reaction mixture was stirred at room temperature for 16 h. The reaction
mixture was quenched with saturated sodium hydrogen carbonate solution (500 mL) and
extracted with dichloromethane (2 x 1000 mL). The combined organic layers were
washed with saturated brine (500 mL) then dried over sodium sulphate and evaporated
under reduced pressure. The obtained residue was purified by silica gel (100-200 mesh)
column chromatography eluting with a gradient of 0-10% ethyl acetate in petroleum
ether. Clean fractions were evaporated under reduced pressure to give the title
compound as an off-white solid. (20.0 g, 60.7%)
H NMR (400MHz, CDCl3): δ = 8.15 (s, 1H), 8.00 (s, 1H), 6.87 - 6.52 (m, 1H), 3.97 (s,
3H), 2.68 (s, 3H).
Preparation 34: 5-(difluoromethyl)methylnitro-benzoic acid
Lithium hydroxide hydrate (22.7 g, 542 mmol) was added to a solution of product from
Preparation 33 (19.0 g, 77.5 mmol) in tetrahydrofuran (200 mL) and water (100 mL)
portion-wise at room temperature. The reaction mixture was stirred for 5 h then
neutralised with aqueous hydrogen chloride solution (1M). The precipitated solid was
collected, washed with water and dried under reduced pressure to afford title compound
as a colourless solid. (17.0 g, 94.9%)
H NMR (300MHz, CDCl3): δ = 8.30 (s, 1H), 8.04 (s, 1H), 6.95 - 6.50 (m, 1H), 2.74 (s,
3H).LCMS Method 2: m/z 230.10 [M-H ]; RT = 1.76 min.
Preparation 35: [5-(difluoromethyl)methylnitro-phenyl]methanol
Using a procedure similar to that described for Preparation 2, but using the compound
described in Preparation 34 (17.0 g, 73.6 mmol), the title compound was prepared as
an off-white solid. (16.0 g, 100%)
H NMR (500MHz, DMSO-d6): δ = 7.97 (s, 1H), 7.92 (s, 1H), 7.31 - 6.99 (m, 1H), 5.58
(t, J=5.4 Hz, 1H), 4.64 (d, J=5.3 Hz, 2H), 2.33 (s, 3H). LCMS Method 2: m/z 215.71 [M-
H ]; RT = 1.81 min.
Preparation 36: [5-(difluoromethyl)methylnitro-phenyl]methyl methanesulfonate
Triethylamine (27.0 mL, 193 mmol) was added drop-wise to a solution of the product
from Preparation 35 (14.0 g, 64.5 mmol) in dichloromethane (10 mL) at 0°C. After 10
min, methanesulfonyl chloride (10.0 mL, 129 mmol) was added drop-wise maintaining
temperature at 0°C. The reaction mixture was stirred for 2 h then diluted with water
(200 mL) and extracted with dichloromethane (2 x 200 mL). The combined organic layer
was dried over sodium sulphate and evaporated under reduced pressure to afford title
compound as a brown oil. Used without further purification. (18.0 g, 94.5%)
H NMR (400 MHz, CDCl3): δ = 7.92 (s, 1H), 7.72 (s, 1H), 6.86 - 6.52 (m, 1H), 4.68 (s,
2H), 3.14 (s, 3H), 2.58 (s, 3H).
Preparation 37: isopropyl (2S)[[5-(difluoromethyl)methylnitro-
phenyl]methyl]methyl-piperazinecarboxylate
Potassium carbonate (10.8 g, 79.3 mmol) was added portion-wise to a solution of
product from Preparation 36 (7.80 g, 26.4 mmol) in acetonitrile (100 mL) at 0°C.
Isopropyl (2S)methylpiperazinecarboxylate hydrochloride from Preparation 49
(5.04 g, 26.4 mmol) was added portion-wise at 0°C. The reaction mixture was warmed
to 75°C and stirred for 16 h. The reaction mixture was quenched with water (200 mL)
and extracted with ethyl acetate (2 x 300 mL). The combined organic layers were dried
over sodium sulphate and evaporated under reduced pressure. The obtained residue was
purified by silica gel (100-200 mesh) column chromatography eluting with a gradient of
0-15% ethyl acetate in petroleum ether. Clean fractions were evaporated under reduced
pressure to give the title compound as a brown gum. (8.0 g, 79.2%)
H NMR (500 MHz, CDCl ): δ = 7.83 (s, 1H), 7.69 (s, 1H), 6.85 - 6.44 (m, 1H), 4.94-
4.92 (m, 1H), 4.28 (br s, 1H), 3.88 (m, 1H), 3.53 (s, 2H), 3.12-3.10 (m, 1H), 2.70 (m,
1H), 2.56 (m, 1H), 2.52 (s, 3H), 2.27 (m, 1H), 2.12-2.10 (m, 1H), 1.27 - 1.22 (m, 9H).
LCMS Method 2: m/z 386.37. [M+H ]; RT = 2.93 min.
Preparation 38: isopropyl (2S)[[3-amino(difluoromethyl)methyl-
phenyl]methyl]methyl-piperazinecarboxylate
Using a procedure similar to that described for Preparation 5, but using the compound
described in Preparation 37 (8.0 g, 20.7 mmol), the title compound was prepared as a
yellow gum. (6.40 g, 86.0%)
H NMR (400 MHz , DMSO-d ): δ = 6.98 - 6.57 (m, 3H), 5.09 (s, 2H), 4.77 (m, 1H),
4.11 (br s, 1H), 3.69 (m, 1H), 3.34 (m, 2H), 3.02 - 2.88 (m, 1H), 2.68 (m, 1H), 2.57
(m, 1H), 2.12 - 2.02 (m, 4H), 1.9-1.86 (m, 1H), 1.19 - 1.08 (m, 9H).LCMS Method 3:
m/z 356.2 [M+H ]; RT = 6.0 min.
Preparation 39: isopropyl (2S)[[5-(difluoromethyl)isothiocyanatomethyl-
phenyl]methyl]methyl-piperazinecarboxylate
Using a procedure similar to that described for Preparation 6, but using the compound
described in Preparation 38 (430 mg, 1.21 mmol), the title compound was prepared as
a yellow oil. (447 mg, 92.9%)
H NMR (300 MHz, CDCl ): δ = 7.33 (s, 1H), 7.31 (s, 1H), 6.58 (t, J = 56.3 Hz, 1H),
4.92 (h, J = 6.2 Hz, 1H), 4.26 (s, 1H), 3.86 (d, J = 13.3 Hz, 1H), 3.44 (s, 2H), 3.09 (td,
J = 12.7, 3.5 Hz, 1H), 2.68 (d, J = 11.0 Hz, 1H), 2.54 (d, J = 11.1 Hz, 1H), 2.43 (s,
3H), 2.22 (dd, J = 11.1, 3.9 Hz, 1H), 2.05 (td, J = 11.6, 3.5 Hz, 1H), 1.24 (d, J = 6.1
Hz, 6H) overlapping with 1.22 (d, J = 6.1 Hz, 3H). LCMS Method 4: m/z 398.2 [M+H ];
RT = 1.01 min.
Preparation 40: isopropyl (2S)[[3-(aminocarbamothioylamino)(difluoromethyl)-
2-methyl-phenyl]methyl]methyl-piperazinecarboxylate
Using a procedure similar to that described for Preparation 7, but using the compound
described in Preparation 39 (447 mg, 1.12 mmol), the title compound was prepared as
a yellow oil. (357 mg, 73.9%)
H NMR (300 MHz, , CDCl3) δ = 7.65 (br s, 1H), 7.39 (s, 1H), 6.63 (t, J = 56.6 Hz, 1H),
4.93 (hept, J = 6.2 Hz, 1H), 4.25 (s, 1H), 4.05 (s, 2H), 3.86 (d, J = 13.1 Hz, 1H), 3.48
(s, 2H), 3.09 (td, J = 12.8, 3.4 Hz, 1H), 2.72 (d, J = 11.1 Hz, 1H), 2.58 (d, J = 11.2 Hz,
1H), 2.33 (d, J = 1.4 Hz, 3H), 2.21 (dd, J = 11.2, 3.9 Hz, 1H), 2.13 – 1.94 (m, 1H),
Method 4: m/z
1.24 (d, J = 6.1 Hz, 6H) overlapping with 1.22 (d, J = 6.1 Hz, 3H). LCMS
430.2 [M+H ]; RT = 0.62 min
2HCl
Scheme 9.8
Preparation 41: 5-(difluoromethyl)methylnitro-benzaldehyde
Using a procedure similar to that described for Preparation 3, but using the compound
described in Preparation 35 (1.0 g, 4.60 mmol), the title compound was prepared as
an off white solid (500 mg, 50.5%).
H NMR (300 MHz, CDCl ) δ = 10.42 (s, 1H), 8.19 (s, 1H), 8.13 (s, 1H), 6.52-6.98 (m,
1H), 2.83 (s, 3H). LCMS Method 1: m/z 356.2 [M+H ]; RT = 2.51 min.
Preparation 42: tert-butyl (2S)[[5-(difluoromethyl)methylnitro-
phenyl]methyl]methyl-piperazinecarboxylate
Using a procedure similar to that described for Preparation 4, but using the compound
described in Preparation 41 (600 mg, 2.79 mmol), the title compound was prepared as
an off white solid (700 mg, 62.8%).
H NMR (400 MHz, DMSO-d6): δ = 7.99 (s, 1H), 7.81 (s, 1H), 6.95-7.27 (m, 1H), 4.08 -
4.10 (m, 1H), 3.67 - 3.70 (m, 1H), 3.58 (s, 2H), 2.91-3.02 (m, 1H), 2.69 - 2.71 (m,
1H), 2.55 - 2.58 (m, 1H), 2.43 (s, 3H), 2.14 - 2.18 (m, 1H), 1.98-2.04 (m, 1H), 1.39 (s,
9H), 1.14 (d, J = 6.4 Hz, 3H); LCMS Method 1: m/z 356.2 [M+H ]; RT = 3.11 min.
Preparation 43: tert-butyl (2S)[[3-amino(difluoromethyl)methyl-
phenyl]methyl]methyl-piperazinecarboxylate
Using a procedure similar to that described for Preparation 5, but using the compound
described in Preparation 42 (7.0 g, 17.5 mmol), the title compound was prepared as a
tacky yellow solid (5.1 g, 79%).
H NMR (300 MHz, CDCl3) δ = 6.80 (s, 1H), 6.77 (s 1H), 6.40-6.64 (m, 1H), 4.18-4.20
(m, 1H), 3.76-3.80 (m, 3H), 3.36-3.45 (m, 2H), 3.00-3.06 (m, 1H), 2.68-2.70 (m, 1H),
2.55-2.58 (m, 1H), 2.20 (s, 3H) 2.14-2.17 (m, 1H), 1.95-2.00 (m, 1H), 1.45 (s, 9H),
1.19 (d, J = 6.7 Hz, 3H). LCMS Method 2: m/z 270.2 [M+H ]; RT = 1.57 min.
Preparation 44: 5-(difluoromethyl)methyl[[(3S)methylpiperazin
yl]methyl]aniline dihydrochloride
2HCl
Using a procedure similar to that described for Preparation 8, but using the compound
described in Preparation 43 (1.10 g, 2.98 mmol), the title compound was prepared as
a colourless foam. (1.0 g, 100%) LCMS Method 4: m/z 270.2 [M+H ]; RT = 0.37 min.
Preparation 45: [(2S)[[3-amino(difluoromethyl)methyl-phenyl]methyl]
methyl-piperazinyl]-cyclobutyl-methanone
Using a procedure similar to that described for Preparation 9, but using the compound
described in Preparation 44 (1.10 g, 2.98 mmol) and cyclobutane carboxylic acid, the
title compound was prepared as a yellow oil. (1.03 g, 98%)
H NMR (600 MHz, CDCl3) δ = 6.79 (s, 1H), 6.77 (d, J = 1.4 Hz, 1H), 6.52 (t, J = 56.8
Hz, 1H), 4.71 (s, 0.5H), 4.36 (d, J = 13.4 Hz, 0.5H), 3.83 (s, 0.5H), 3.46 (dd, J = 12.9,
9.7 Hz, 1H), 3.35 (dd, J = 15.1, 11.3 Hz, 1.5H), 3.17-3.25 (m, 1.5H), 2.87-2.93 (m,
0.5H). 2.76 (s, 0.5H), 2.67-2.72 (m, 0.5H), 2.61 (dd, J = 27.1, 11.2 Hz, 1H), 2.38 –
2.43 (m, 0.5H), 2.25 – 2.35 (m, 1.5H), 2.19 (s, 3H), 2.05 – 2.17 (m, 3H), 1.90 – 2.01
(m, 2H), 1.81 – 1.89 (m, 1H), 1.19-1.27 (m, 3H). LCMS Method 4: m/z 352.2 [M+H ];
RT = 0.58 min.
Preparation 46: cyclobutyl-[(2S)[[5-(difluoromethyl)isothiocyanatomethyl-
phenyl]methyl]methyl-piperazinyl]methanone
Using a procedure similar to that described for Preparation 6, but using the compound
described in Preparation 45 (550 mg, 1.56 mmol), the title compound was prepared as
a yellow oil. (588 mg, 95%)
H NMR (600 MHz, CDCl3) δ = 7.33 (s, 1H) overlapping with 7.31 (s, 1H), 6.58 (s, 1H),
4.74 (d, J = 5.8 Hz, 1H), 4.36-4.41 (m, 0.5H), 3.85 (s, 0.5H), 3.38-3.48 (m, 2.5H),
3.16-3.28 (m, 1.5H), 2.89-2.95 (m, 0.5H), 2.75 (d, 0.5H), 2.68 (d, 0.5H), 2.58 (dd, J =
21.4, 11.2 Hz, 1H), 2.43 (s, 3H) overlapping with 2.38-2.43 (m, 0.5H), 2.27 – 2.37 (m,
1.5H), 2.06 – 2.33 (m, 3H), 1.92-2.03 (m, 2H), 1.86 (d, J = 10.1 Hz, 1H), 1.25 (dd, J =
37.8, 6.8 Hz, 3H). LCMS Method 4: m/z 394.2 [M+H ]; RT = 0.95 min.
Preparation 47: 1-amino[3-[[(3S)(cyclobutanecarbonyl)methyl-piperazin
yl]methyl](difluoromethyl)methyl-phenyl]thiourea
Using a procedure similar to that described for Preparation 7, but using the compound
described in Preparation 46 (588 mg, 1.19 mmol), the title compound was prepared as
a yellow oil. (617 mg, 97%)
H NMR (600 MHz, CDCl ) δ = 9.05 (s, 1H), 7.72 (s, 1H), 7.50 (s, 1H), 7.38 (s, 1H),
6.64 (t, J = 56.6 Hz, 1H), 4.72 (s, 0.5H), 4.38 (d, J = 13.4 Hz, 0.5H), 4.03 (s, 2H), 3.84
(s, 0.5H), 3.52 (dd, J = 13.4, 8.5 Hz, 1H), 3.36 – 3.44 (m, 1.5H), 3.17 – 3.28 (m,
1.5H), 2.93 (td, J = 12.9, 3.5 Hz, 0.5H), 2.71 – 2.80 (m, 1H), 2.62 (dd, J = 25.7, 11.2
Hz, 1H), 2.38 – 2.45 (m, 0.5H), 2.27 – 2.35 (m, 1.5H) overlapping 2.33 (s, 3H), 1.92 –
2.22 (m, 5H), 1.86 (t, J = 10.0 Hz, 1H), 1.17-1.30 (m, 3H). LCMS Method 4: m/z 426.3
[M+H ]; RT = 0.56 min.
Scheme 9.9
Preparation 48: O4-tert-butyl O1-isopropyl (2S)methylpiperazine-1,4-dicarboxylate
Isopropyl chloroformate (39.0 mL, 78.0 mmol, 2M solution in toluene,) was added drop-
wise to a solution of diisopropylethylamine (34.0 mL, 195 mmol) and tert-butyl (3S)
methylpiperazinecarboxylate (13.0 g, 65.0 mmol) in dichloromethane (130 mL) at
0°C. The reaction mixture was allowed to warm to room temperature over 2 h. The
mixture was diluted with water (200 mL) and extracted with dichloromethane (2 x 200
mL). The combined organic layer was dried over sodium sulphate and evaporated under
reduced pressure. The obtained residue was purified by silica gel (100-200 mesh)
column chromatography eluting with a gradient of 20-50% ethyl acetate in petroleum
ether. Clean fractions were evaporated under reduced pressure to give the title
compound as a colourless oil. (12.0 g, 64.5%)
H NMR (400 MHz, CDCl ): δ = 4.96 – 4.93 (m, 1H), 4.28 (m, 1H), 4.15 - 3.67 (m, 3H),
3.16 - 2.94 (m, 2H), 2.81 (m, 1H), 1.47 (s, 9H), 1.25 (d, J=6.2 Hz, 6H), 1.14 (d, J=6.7
Hz, 3H).
Preparation 49: isopropyl (2S)methylpiperazinecarboxylate
Using a procedure similar to that described for Preparation 8, but using the compound
described in Preparation 48 (12.0 g, 41.9 mmol), the title compound was prepared as
a colourless solid. (9.0 g, 96.4%)
H NMR (300 MHz, DMSO-d6): δ = 9.52 (br s, 2H), 4.85 - 4.73 (m, 1H), 4.38 - 4.24 (m,
1H), 3.91 (m, 1H), 3.26 - 3.12 (m, 2H), 3.10 (s, 1H), 3.08 - 2.98 (m, 1H), 2.92 - 2.75
(m, 1H), 1.27 (d, J=7.0 Hz, 3H), 1.20 (d, J=6.2 Hz, 6H).
Scheme 9.10
Preparation 50: ethyl 2-[3-[[(3S)tert-butoxycarbonylmethyl-piperazin
yl]methyl]chloromethyl-anilino]oxazolecarboxylate
Ethyl 2-chlorooxazolecarboxylate (372 mg, 2.12 mmol) was added to a solution of
tert-butyl (2S)[(3-aminochloromethyl-phenyl)methyl]methyl-piperazine
carboxylate from Preparation 5 (500 mg, 1.41 mmol) in propanol (5.0 mL) and
stirred under microwave irradiation at 160°C for 30 min. The solvent was removed under
reduced pressure and the obtained residue was purified by silica gel (100-200 mesh)
column chromatography eluting with a gradient of 10-70% ethyl acetate in heptane.
Clean fractions were evaporated under reduced pressure to give title compound as
colourless oil. (130 mg, 18.7%)
LCMS Method 4: m/z 493.3 [M+H ]; RT = 0.94 min.
Preparation 51: 5-[3-[[(3S)benzoylmethyl-piperazinyl]methyl]chloro
methyl-anilino]-1,3,4-oxadiazolecarboxamide
Oxamic acid (7.42 mg, 0.083 mmol) was added to a solution of product from
Preparation 11 (30.0 mg, 0.069 mmol) in dichloromethane (0.6 mL) followed by 3-
(ethyliminomethyleneamino)-N,N-dimethyl-propanamine hydrochloride (53.3 mg,
0.278 mmol). The reaction was stirred at room temperature for 1 h until complete. The
reaction mixture was concentrated under reduced pressure then dissolved in
dimethylformamide (0.7 mL) and purified by basic preparative HPLC. Clean fractions
were evaporated under reduced pressure to give title compound (6.0 mg, 18.4%). LCMS
Method 4: m/z 469.2 [M+H ]; RT = 0.63 min.
Preparation 52: (1R)[5-[2,5-dimethyl[[(3S)methylpiperazin
yl]methyl]anilino]-1,3,4-oxadiazolyl]ethanol dihydrochloride
2HCl
3-(Ethyliminomethyleneamino)-N,N-dimethyl-propanamine hydrochloride (423 mg,
2.21 mmol) was added to a solution of tert-butyl (2S)[[3-
(aminocarbamothioylamino)-2,5-dimethyl-phenyl]methyl]methyl-piperazine
carboxylate from Preparation 27 (300 mg, 0.74 mmol) and (2R)hydroxypropanoic
acid (66.3 mg, 0.74 mmol) in dichloromethane (10.0 mL) at room temperature and
stirred for 2 h. The mixture was concentrated under reduced pressure and the obtained
residue was purified by silica gel (100-200 mesh) column chromatography eluting with a
gradient of 30-100% ethyl acetate in heptane. Clean fractions were evaporated under
reduced pressure to give the tert-butyl carbamate intermediate as a colourless solid.
Hydrogen chloride (4M in 1,4-dioxane, 1.0 mL) was added to a solution of the tert-butyl
carbamate intermediate (75 mg, 0.17 mmol) in dichloromethane (3.0 mL) and stirred at
room temperature for 2 hrs. Toluene (5 mL) was added and then the solvent was
removed under reduced pressure to give title compound as colourless solid. (72 mg,
23%)
LCMS Method 4: m/z 346.2 [M+H ]; RT = 0.36 min.
Preparation 53: (1S)[5-[2,5-dimethyl[[(3S)methylpiperazin
yl]methyl]anilino]-1,3,4-oxadiazolyl]ethanol dihydrochloride
2HCl
3-(Ethyliminomethyleneamino)-N,N-dimethyl-propanamine hydrochloride (715 mg,
3.75 mmol) was added to a solution of tert-butyl (2S)[[3-
(aminocarbamothioylamino)-2,5-dimethyl-phenyl]methyl]methyl-piperazine
carboxylate from Preparation 27 (545 mg, 1.34 mmol) and (2S)hydroxypropanoic
acid (120 mg, 1.34 mmol) in dichloromethane (10.0 mL) at room temperature and
stirred for 16 h. The mixture was diluted with water (5 mL) and extracted with
dichloromethane (2 x 10 mL). The combined organic layer was dried over sodium
sulphate and evaporated under reduced pressure. The obtained residue was purified by
silica gel (100-200 mesh) column chromatography eluting with a gradient of 0-80%
ethyl acetate in heptane. Clean fractions were evaporated under reduced pressure to
give the tert-butyl carbamate intermediate as a colourless solid. Hydrogen chloride (4M
in 1,4-dioxane, 8.0 mL) was added to a solution of this intermediate material (280 mg,
0.63mmol) in 1,4-dioxane (4.0 mL) and stirred at room temperature for 4 hrs. The
solvent was removed under reduced pressure to give title compound as colourless solid.
(263 mg, 47%)
LCMS Method 4: m/z 346.2 [M+H ]; RT = 0.37 min.
Preparation 54: 2-[5-[5-chloromethyl[[(3S)methylpiperazin
yl]methyl]anilino]-1,3,4-oxadiazolyl]acetonitrile dihydrochloride
N NH
2HCl
Using a procedure similar to that described for Preparation 52, but using 2-cyanoacetic
acid instead of (2R)hydroxypropanoic acid and the thiosemicarbazide from
Preparation 7 the title compound was prepared as a colourless solid. (112 mg, 61%)
LCMS Method 4: m/z 341.2 [M+H ]; RT = 0.36 min.
Preparation 55: 3-[5-[2,5-dimethyl[[(3S)methylpiperazinyl]methyl]anilino]-
1,3,4-oxadiazolyl]cyclobutanol dihydrochloride
2HCl
Using a procedure similar to that described for Preparation 52, but using Cis
hydroxycyclobutanecarboxylic acid instead of (2R)hydroxypropanoic acid the title
compound was prepared as a colourless solid. (146 mg, 61%)
LCMS Method 4: m/z 372.2 [M+H ]; RT = 0.36 min.
Scheme 9.11
Preparation 56: (1S)[5-[2,5-dimethyl[[(3S)methylpiperazin
yl]methyl]anilino]-1,3,4-oxadiazolyl]ethane-1,2-diol hydrochloride
3-(Ethyliminomethyleneamino)-N,N-dimethyl-propanamine hydrochloride (846 mg,
4.42 mmol) was added to a solution of product from Preparation 27 (600 mg, 1.47
mmol) and (4S)-2,2-dimethyl-1,3-dioxolanecarboxylic acid (323 mg, 2.21
mmol) dissolved in dry dichloromethane (30 mL) and stirred at room temperature for 12
h. The reaction mixture was quenched with water (30 mL) and extracted with
dichloromethane (30 mL). The organic layer was collected and concentrated under
reduced pressure. The obtained residue was purified by silica gel (100-200 mesh)
column chromatography eluting with a gradient of 0-40% ethyl acetate in heptane.
Clean fractions were evaporated under reduced pressure to give the intermediate
product as a colourless oil. (600 mg, 81.2 %) LCMS Method 4: m/z 502.4 [M+H ]; RT =
0.77 min. Hydrogen chloride (4M solution in 1,4-dioxane, 2.99 mL, 12 mmol) was added
to a solution of the intermediate in methanol (5 mL) and stirred at room temperature for
3 h. The reaction mixture was concentrated under reduced pressure to afford title
compound as a colourless foam that was used without any purification. (476 mg, 100%)
LCMS Method 4: m/z 362.3 [M+H ]; RT = 0.33 min.
Scheme 9.12
Preparation 57: isopropyl (2S)[[3-[[5-[(2S)tert-butoxycarbonylpyrrolidinyl]-
1,3,4-oxadiazolyl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazine
carboxylate
3-(Ethyliminomethyleneamino)-N,N-dimethyl-propanamine hydrochloride (450 mg,
2.34 mmol) was added to a solution of product from Preparation 25 (264 mg, 0.67
mmol) and (2S)tert-butoxycarbonylpyrrolidinecarboxylic acid (159 mg, 0.74
mmol) in dichloromethane (15 mL) and stirred at room temperature for 4.5 h. The
mixture was concentrated to low volume and purified by silica gel (100-200 mesh)
column chromatography eluting with a gradient of 0-80% ethyl acetate in heptanes.
Clean fractions were combined and evaporated under reduced pressure to give the title
compound as a colourless solid. (292 mg, 78 %) LCMS Method 5: m/z 557.3 [M+H ]; RT
= 2.23 min.
Preparation 58: isopropyl (2S)[[2,5-dimethyl[[5-[(2S)-pyrrolidinyl]-1,3,4-
oxadiazolyl]amino]phenyl]methyl]methyl-piperazinecarboxylate
Hydrogen chloride (4M solution in 1,4-dioxane, 2.60 mL, 10.4 mmol) was added to a
solution of the product from Preparation 57 (290 mg, 0.52 mmol) in methanol (4 mL)
and stirred at room temperature for 2 h. The reaction mixture was concentrated under
reduced pressure then partitioned between dichloromethane and saturated aqueous
NaHCO3. The organic layer was washed with brine, then dried over Na2SO4, filtered and
concentrated to dryness. The residue was taken up in DMSO and purified by basic
preparative HPLC. Clean fractions were combined and evaporated under reduced
pressure to give the title compound as a colourless solid. (224 mg, 94 %)
H NMR (600 MHz, DMSO-d ) δ : 9.26 (s, 1H), 7.39 (d, J = 1.7 Hz, 1H), 6.83 (d, J = 1.7
Hz, 1H), 4.77 (hept, J = 6.2 Hz, 1H), 4.26 (dd, J = 8.1, 5.9 Hz, 1H), 4.12 (t, J = 5.7 Hz,
1H), 3.70 (dt, J = 13.1, 2.6 Hz, 1H), 3.38 (m, 2H), 2.95 (td, J 12.9, 3.4 Hz, 1H), 2.88
(ddd, J = 10.0, 7.6, 5.7 Hz, 1H), 2.83 (dt, J = 9.9, 6.9 Hz, 1H), 2.71 (ddt, J = 11.2, 3.6,
1.9 Hz, 1H), 2.60 (dt, J = 11.2, 1.9 Hz, 1H), 2.25 (s, 3H), 2.21 (s, 3H), 2.06 (m, 2H),
1.96 (m, 1H), 1.90 (td, J = 11.7, 3.5 Hz, 1H), 1.81 (dddd, J = 13.9, 12.0, 7.7, 5.9 Hz,
1H), 1.71 (m, 1H), 1.17 (dd, J = 6.3, 0.9 Hz, 6H), 1.13 (d, J = 6.7 Hz, 3H). LCMS
]; RT = 0.45 min.
Method 4: m/z 457.4 [M+H
Scheme 9.13
Preparation 59: cyclopentyl-[(2S)methylpiperazinyl]methanone hydrochloride
Cyclopentanecarbonyl chloride (12.3 mL, 101 mmol) was added dropwise to a solution of
tert-butyl (3S)methylpiperazinecarboxylate (18.4 g, 92 mmol) and triethylamine
(46.1 mL, 243 mmol) in dichloromethane (270 mL) at 0 C. On complete addition the
reaction mixture was stirred to room temperature over 2 h. The mixture was
concentrated to dryness and the residue dissolved in ethyl acetate (150 ml) and washed
successively with 10% citric acid (aq), saturated NaHCO (aq). The organic layer was
filtered through a small plug of silica then concentrated in vacuo to leave crude
intermediate material. This intermediate material (27.0 g) was dissolved in
dichloromethane and using a procedure similar to that described for Preparation 8, the
title compound was prepared as an off white solid (21.0 g, 95%). LCMS Method 4: m/z
197.2 [M+H ]; RT = 0.35 min.
Scheme 9.14
Preparation 60: 1-(chloromethyl)-2,5-dimethylnitro-benzene
Methanesulfonyl chloride (3.3 mL, 42 mmol) was added to a solution of product from
Preparation 18 (5.1 g, 28 mmol) and triethylamine (7.9 mL, 56 mmol) in
dichloromethane (25 mL) at room temperature and stirred for 72 h. The mixture was
diluted with dichloromethane (25 mL) and washed successively with HCl (0.5 M aq, 5
mL), saturated NaHCO3 (aq, 5 mL), water and brine. The organic layer was dried over
Na2SO4, filtered and concentrated in vacuo to afford the title compound as an off white
solid. (5.6 g, 100% ).
H NMR (600 MHz, CDCl ) δ : 7.57 (d, J = 1.8 Hz, 1H), 7.37 (d, J = 1.8 Hz, 1H), 4.61 (s,
2H), 2.49 (s, 3H), 2.39 (s, 3H).
Preparation 61: cyclopentyl-[(2S)[(2,5-dimethylnitro-phenyl)methyl]methyl-
2piperazinyl]methanone
Potassium carbonate (12 g, 84 mmol) was added to a solution of product from
Preparation 60 (5.6 g, 28 mmol), product from Preparation 59 (7.2 g, 31 mmol) and
potassium iodide (0.23 g, 1.4 mmol) in dimethylformamide (20 mL) and stirred at room
temperature for 18 h. The mixture was concentrated to dryness in vacuo. The residue
was partitioned between dichloromethane (50 mL) and water (10 mL). The organic layer
was collected, dried over Na SO , filtered and concentrated to dryness. The obtained
residue was purified by silica gel (100-200 mesh) column chromatography eluting with a
gradient of 0-40% ethyl acetate in heptane. Clean fractions were evaporated under
reduced pressure to give the title compound as a yellow oil (8.43 g, 84%). LCMS Method
4: m/z 360.3 [M+H ]; RT = 0.90 min.
Preparation 62: [(2S)[(3-amino-2,5-dimethyl-phenyl)methyl]methyl-piperazin-
1-yl]-cyclopentyl-methanone
Iron powder (19.6 g, 352 mmol) was added to a solution of product from Preparation
61 (8.43 g, 23.4 mmol) in acetic acid (210 mL) and stirred at room temperature for 18
h. The mixture was filtered through a Celite pad, washing the pad with methanol. The
combined filtrate and methanol washings were concentrated to dryness. The crude
residue was dissolved in water (20 mL) and basified to pH 12 with 4N NaOH (aq). The
aqueous phase was extracted with dichloromethane (3 x 100 mL). The combined
extracts were washed successively with saturated NaHCO3 (aq) and brine, then dried
over Na SO , filtered and concentrated in vacuo to leave the product as pale yellow oil
(7.66 g, 99%). LCMS Method 4: m/z 330.3 [M+H ]; RT = 0.57 min.
Preparation 63: cyclopentyl-[(2S)[(3-isothiocyanato-2,5-dimethyl-phenyl)methyl]-
2-methyl-piperazinyl]methanone
Using a procedure similar to that described for Preparation 6, but using the compound
described in Preparation 62 (6.00, 18.2 mmol), the title compound was prepared as a
yellow oil (6.76 g, 99%). LCMS Method 4: m/z 330.3 [M+H ]; RT = 1.05 min.
Preparation 64: 1-amino[3-[[(3S)(cyclopentanecarbonyl)methyl-piperazin
yl]methyl]-2,5-dimethyl-phenyl]thiourea
Using a procedure similar to that described for Preparation 7, but using the compound
described in Preparation 63 (6.00, 18.2 mmol), the title compound was prepared as a
yellow oil (6.06 g, 82%). LCMS Method 4: m/z 330.3 [M+H ]; RT = 0.54 min.
Scheme 9.15
Preparation 65: tert-butyl (2S)[[3-[[5-[(2S,3R)benzyloxycarbonylhydroxy-
pyrrolidinyl]-1,3,4-oxadiazolyl]amino]-2,5-dimethyl-phenyl]methyl]methyl-
piperazinecarboxylate
Using a similar procedure to that described in Example 31, but using (2S,3R)
benzyloxycarbonylhydroxy-pyrrolidinecarboxylic acid (0.89 g, 3.36 mmol) and
product from Preparation 27 (1.14 g, 2.80 mmol). The obtained residue was purified
by silica gel (100-200 mesh) column chromatography eluting with a gradient of 0-100%
ethyl acetate in heptane. Clean fractions were evaporated under reduced pressure to
give the title compound as a colourless oil (0.85 g, 49%). LCMS Method 4: m/z 621.5
[M+H ]; RT = 0.74 min.
Preparation 66: benzyl (2S,3R)[5-[2,5-dimethyl[[(3S)methylpiperazin
yl]methyl]anilino]-1,3,4-oxadiazolyl]hydroxy-pyrrolidinecarboxylate
N N NH
Hydrogen chloride (4M solution in 1,4-dioxane, 6.85 mL, 27.3 mmol) was added to a
solution of product from Preparation 65 (0.85 g, 1.37 mmol) in methanol (5 mL) and
stirred at room temperature for 2 h. The reaction mixture was concentrated under
reduced pressure then azeotroped with toluene. The residue was purified by basic HPLC.
Clean fractions were evaporated under reduced pressure to afford the title compound as
a colourless solid. (443 mg, 62 %) LCMS Method 4: m/z 521.3 [M+H ]; RT = 0.56 min.
General routes to exemplified compounds:
All exemplified oxadiazole compounds can be accessed through either of the two general
routes described in Scheme 10.1.
Route 1:
Route 2:
H N R H N R
2 4 4
N O NH
R O R
2HCl
H N R
4 N R
N R
2 R O
H N N
S N R
Scheme 10.1
Those skilled in the art would recognize that R1 and R5 may carry protected functional
groups that require additional, standard methodology, to deprotect said functionality.
Such methodology for the removal of these protecting groups can for example be found
in “Greene’s Protective Groups in Organic Synthesis” Fifth edition, Wiley, Ed. P. G. M.
Wuts.
Exemplified compounds are shown in Table 1 below.
Specific preparation of selected compounds is described in Examples below.
Table 1
Mass
Example Structure Name Rt
-[3-[[(3S)benzoyl
methyl-piperazin
1 yl]methyl]chloro 450.16 2.44
methyl-anilino]-1,3,4-
oxadiazolecarbonitrile
[(2S)[[5-chloro[[5-
(methoxymethyl)-1,3,4-
oxadiazolyl]amino]
2 methyl-phenyl]methyl] 469.19 2.21
methyl-piperazinyl]-
phenyl-methanone
[(2S)[[5-chloro
methyl[(5-
tetrahydrofuranyl-
1,3,4-oxadiazol
3 495.20 2.19
yl)amino]phenyl]methyl]-
Cl O
2-methyl-piperazinyl]-
phenyl-methanone
[(2S)[[5-chloro
methyl[(5-
tetrahydrofuranyl-
1,3,4-oxadiazol
4 495.20 2.29
yl)amino]phenyl]methyl]-
2-methyl-piperazinyl]-
phenyl-methanone
[(2S)[[5-chloro[(5-
cyclopropyl-1,3,4-
oxadiazolyl)amino]
methyl-phenyl]methyl] 465.19 2.31
methyl-piperazinyl]-
phenyl-methanone
[(2S)[[5-chloro[[5-
(1-hydroxycyclopropyl)-
1,3,4-oxadiazol
yl]amino]methyl-
6 481.19 2.10
phenyl]methyl]methyl-
piperazinyl]-phenyl-
methanone
3-[5-[3-[[(3S)benzoyl-
3-methyl-piperazin
yl]methyl]chloro
O N O
7 methyl-anilino]-1,3,4- 478.19 2.17
oxadiazol
yl]propanenitrile
1-[(2S)[[5-chloro
[[5-(methoxymethyl)-
1,3,4-oxadiazol
yl]amino]methyl-
8 471.18 2.44
phenyl]methyl]methyl-
piperazinyl]-2,2-
difluoro-butanone
[(2S)[[5-chloro[[5-
(methoxymethyl)-1,3,4-
oxadiazolyl]amino]
9 methyl-phenyl]methyl] 487.18 2.27
methyl-piperazinyl]-(2-
fluorophenyl)methanone
[(2S)[[5-chloro[[5-
(methoxymethyl)-1,3,4-
oxadiazolyl]amino]
methyl-phenyl]methyl]
methyl-piperazinyl]- 497.20 2.24
(3,3-
difluorocyclopentyl)methan
(2S)[(2S)[[5-chloro-
3-[[5-(methoxymethyl)-
1,3,4-oxadiazol
N NO
N yl]amino]methyl-
11 449.22 2.17
phenyl]methyl]methyl-
piperazinyl]methyl-
butanone
[(2S)[[5-chloro[[5-
H (methoxymethyl)-1,3,4-
oxadiazolyl]amino]
N NO
12 methyl-phenyl]methyl] 447.20 2.11
methyl-piperazinyl]-
cyclobutyl-methanone
[(2S)[[5-chloro[[5-
(methoxymethyl)-1,3,4-
oxadiazolyl]amino]
13 methyl-phenyl]methyl] 461.22 2.23
methyl-piperazinyl]-
cyclopentyl-methanone
cyclobutyl-[(2S)[[2,5-
dimethyl[(5-methyl-
1,3,4-oxadiazol
14 398.25 1.80
yl)amino]phenyl]methyl]-
2-methyl-piperazin
yl]methanone
2-[5-[3-[[(3S)
(cyclobutanecarbonyl)
methyl-piperazin
yl]methyl]-2,5-dimethyl- 422.24 1.82
anilino]-1,3,4-oxadiazol
yl]acetonitrile
2-[5-[3-[[(3S)
(cyclopropanecarbonyl)
methyl-piperazin
16 yl]methyl]-2,5-dimethyl- 408.22 1.72
anilino]-1,3,4-oxadiazol
yl]acetonitrile
2-[5-[3-[[(3S)(3,3-
difluorocyclopentanecarbon
yl)methyl-piperazin
17 yl]methyl]-2,5-dimethyl- 472.24 1.94
anilino]-1,3,4-oxadiazol
yl]acetonitrile
2-[5-[5-chloro[[4-
(cyclopentanecarbonyl)
methyl-piperazin
18 yl]methyl]methyl- 456.20 2.22
anilino]-1,3,4-oxadiazol
yl]acetonitrile
cyclobutyl-[(2S)[[3-[[5-
[(1R)hydroxyethyl]-
1,3,4-oxadiazol
19 yl]amino]-2,5-dimethyl- 428.26 1.75
phenyl]methyl]methyl-
piperazinyl]methanone
cyclobutyl-[(2S)[[3-[[5-
[(1S)hydroxyethyl]-
1,3,4-oxadiazol
yl]amino]-2,5-dimethyl- 428.26 1.75
phenyl]methyl]methyl-
piperazinyl]methanone
2,2-difluoro[(2S)[[3-
[[5-[(1R)hydroxyethyl]-
1,3,4-oxadiazol
N N O
21 yl]amino]-2,5-dimethyl- 451.24 1.99
phenyl]methyl]methyl-
piperazinyl]butanone
cyclopropyl-[(2S)[[3-
[[5-[(1R)hydroxyethyl]-
1,3,4-oxadiazol
22 yl]amino]-2,5-dimethyl- 413.24 1.66
phenyl]methyl]methyl-
piperazinyl]methanone
[(2S)[[3-[[5-[(1R)
hydroxyethyl]-1,3,4-
oxadiazolyl]amino]-2,5-
dimethyl-phenyl]methyl]-
23 2-methyl-piperazinyl]- 428.27 1.74
methylcyclopropyl)methan
cyclopentyl-[(2S)[[3-
[[5-[(1R)hydroxyethyl]-
1,3,4-oxadiazol
24 442.28 1.82
yl]amino]-2,5-dimethyl-
phenyl]methyl]methyl-
piperazinyl]methanone
(3,3-difluorocyclopentyl)-
[(2S)[[3-[[5-[(1R)
hydroxyethyl]-1,3,4-
oxadiazolyl]amino]-2,5- 478.25 1.85
dimethyl-phenyl]methyl]-
2-methyl-piperazin
yl]methanone
2-cyclobutyl[(2S)
[[3-[[5-[(1R)
hydroxyethyl]-1,3,4-
26 oxadiazolyl]amino]-2,5- 442.28 1.83
dimethyl-phenyl]methyl]-
2-methyl-piperazin
yl]ethanone
cyclobutyl-[(2S)[[5-
(difluoromethyl)[[5-
[(1S)hydroxyethyl]-
27 1,3,4-oxadiazol 464.25 1.90
yl]amino]methyl-
phenyl]methyl]methyl-
piperazinyl]methanone
tert-butyl (2S)[[3-[[5-
[(1S)hydroxyethyl]-
1,3,4-oxadiazol
28 446.26 1.90
yl]amino]-2,5-dimethyl-
phenyl]methyl]methyl-
piperazinecarboxylate
tert-butyl (2S)[[3-[[5-
(3-hydroxycyclobutyl)-
1,3,4-oxadiazol
29 471.28 1.91
yl]amino]-2,5-dimethyl-
phenyl]methyl]methyl-
piperazinecarboxylate
tert-butyl (2S)[[2,5-
N dimethyl[[5-(3-
O N O
483.27 2.06
methyltriazolyl)-1,3,4-
oxadiazol
yl]amino]phenyl]methyl]-
2-methyl-piperazine
carboxylate
tert-butyl (2S)[[2,5-
dimethyl[[5-(2-
methylpyrazolyl)-1,3,4-
31 oxadiazol 482.28 2.13
yl]amino]phenyl]methyl]-
2-methyl-piperazine
carboxylate
tert-butyl (2S)[[3-[(5-
isoxazolyl-1,3,4-
O N O
oxadiazolyl)amino]-2,5-
32 469.25 2.14
O dimethyl-phenyl]methyl]-
2-methyl-piperazine
carboxylate
tert-butyl (2S)[[2,5-
dimethyl[[5-(1,2,5-
thiadiazolyl)-1,3,4-
O N O
33 oxadiazol 486.22 2.21
yl]amino]phenyl]methyl]-
2-methyl-piperazine
carboxylate
tert-butyl (2S)[[2,5-
dimethyl[[5-(4-methyl-
1,2,5-oxadiazolyl)-
34 1,3,4-oxadiazol 484.26 2.38
yl]amino]phenyl]methyl]-
2-methyl-piperazine
carboxylate
isopropyl (2S)[[2,5-
dimethyl[(5-methyl-
1,3,4-oxadiazol
402.24 1.89
yl)amino]phenyl]methyl]-
2-methyl-piperazine
carboxylate
isopropyl (2S)[[3-[[5-
[(1S)aminohydroxy-
ethyl]-1,3,4-oxadiazol
36 446.26 1.65
yl]amino]-2,5-dimethyl-
phenyl]methyl]methyl-
piperazinecarboxylate
isopropyl (2S)[[3-[[5-
(3-hydroxycyclobutyl)-
1,3,4-oxadiazol
37 457.27 1.84
yl]amino]-2,5-dimethyl-
phenyl]methyl]methyl-
piperazinecarboxylate
isopropyl (2S)[[3-[[5-
[(1S)aminopropyl]-
1,3,4-oxadiazol
38 yl]amino]chloro 465.23 1.91
methyl-phenyl]methyl]
methyl-piperazine
carboxylate
isopropyl (2S)[[5-
chloro[[5-[(1R)
hydroxyethyl]-1,3,4-
39 oxadiazolyl]amino] 452.21 2.06
methyl-phenyl]methyl]
methyl-piperazine
carboxylate
isopropyl (2S)[[5-
chloromethyl[[5-
(oxetanyl)-1,3,4-
O N O
40 oxadiazol 463.20 2.17
Cl O
yl]amino]phenyl]methyl]-
2-methyl-piperazine
carboxylate
isopropyl (2S)[[3-[[5-
[(1S,2R)amino
41 461.29 1.68
hydroxy-propyl]-1,3,4-
oxadiazolyl]amino]-2,5-
dimethyl-phenyl]methyl]-
2-methyl-piperazine
carboxylate
isopropyl (2S)[[3-[[5-
(cyanomethyl)-1,3,4-
oxadiazolyl]amino]-2,5-
42 426.24 1.93
dimethyl-phenyl]methyl]-
2-methyl-piperazine
carboxylate
isopropyl (2S)[[5-
(difluoromethyl)[[5-
[(1S)hydroxyethyl]-
43 1,3,4-oxadiazol 468.23 2.00
yl]amino]methyl-
phenyl]methyl]methyl-
piperazinecarboxylate
isopropyl (2S)[[5-
chloromethyl[(5-
tetrahydropyranyl-
44 1,3,4-oxadiazol 491.23 2.35
yl)amino]phenyl]methyl]-
2-methyl-piperazine
carboxylate
isopropyl (2S)[[5-
chloro[[5-(1-
hydroxycyclopropyl)-1,3,4-
45 oxadiazolyl]amino] 463.20 2.11
methyl-phenyl]methyl]
methyl-piperazine
carboxylate
isopropyl (2S)[[5-
chloro[[5-[1-
(hydroxymethyl)cycloprop
46 yl]-1,3,4-oxadiazol 477.21 2.13
yl]amino]methyl-
phenyl]methyl]methyl-
piperazinecarboxylate
isopropyl (2S)[[5-
chloromethyl[[5-
(2,2,2-trifluorohydroxy-
47 ethyl)-1,3,4-oxadiazol 505.17 2.35
yl]amino]phenyl]methyl]-
2-methyl-piperazine
carboxylate
isopropyl (2S)[[5-
chloromethyl[[5-(2-
oxopyrrolidinyl)-1,3,4-
48 oxadiazol 490.21 2.01
yl]amino]phenyl]methyl]-
2-methyl-piperazine
carboxylate
isopropyl (2S)[[3-[[5-
[(1S)aminoethyl]-1,3,4-
N N O
oxadiazolyl]amino]-2,5-
H N N
49 431.27 1.68
dimethyl-phenyl]methyl]-
2-methyl-piperazine
carboxylate
isopropyl (2S)[[5-
(difluoromethyl)[[5-
[(1R)hydroxyethyl]-
50 1,3,4-oxadiazol 468.23 2.00
yl]amino]methyl-
phenyl]methyl]methyl-
piperazinecarboxylate
isopropyl (2S)[[2,5-
dimethyl[[5-(5-
oxopyrrolidinyl)-1,3,4-
O N O
471.27 1.78
51 oxadiazol
yl]amino]phenyl]methyl]-
2-methyl-piperazine
carboxylate
isopropyl (2S)[[2,5-
dimethyl[[5-[(5S)
oxooxazolidinyl]-1,3,4-
52 oxadiazol 473.25 1.82
yl]amino]phenyl]methyl]-
2-methyl-piperazine
carboxylate
isopropyl (2S)[[5-
chloromethyl[[5-
[(2S)oxoazetidinyl]-
53 1,3,4-oxadiazol 476.19 2.04
yl]amino]phenyl]methyl]-
2-methyl-piperazine
carboxylate
isopropyl (2S)[[2,5-
dimethyl[[5-(4-methyl-
1,2,5-oxadiazolyl)-
54 1,3,4-oxadiazol 470.25 2.29
yl]amino]phenyl]methyl]-
2-methyl-piperazine
carboxylate
isopropyl (2S)[[2,5-
dimethyl[[5-[(3S)-
morpholinyl]-1,3,4-
oxadiazol
55 473.28 1.72
2HCl yl]amino]phenyl]methyl]-
2-methyl-piperazine
carboxylate
dihydrochloride
isopropyl (2S)[[3-[[5-
[(1R)hydroxyethyl]-
1,3,4-oxadiazol
56 432.26 1.83
yl]amino]-2,5-dimethyl-
phenyl]methyl]methyl-
piperazinecarboxylate
isopropyl (2S)[[2,5-
dimethyl[[5-[(2R)-
3,3,3-trifluorohydroxy-
57 propyl]-1,3,4-oxadiazol 500.25 2.00
yl]amino]phenyl]methyl]-
2-methyl-piperazine
carboxylate
isopropyl (2S)[[2,5-
dimethyl[[5-(2-oxo
piperidyl)-1,3,4-oxadiazol-
O N O
58 2- 485.29 1.79
yl]amino]phenyl]methyl]-
2-methyl-piperazine
carboxylate
isopropyl (2S)[[2,5-
dimethyl[[5-(2-
methylpyrazolyl)-1,3,4-
59 oxadiazol 468.27 2.05
yl]amino]phenyl]methyl]-
2-methyl-piperazine
carboxylate
isopropyl (2S)[[3-[[5-
[(2S)hydroxypropyl]-
1,3,4-oxadiazol
60 446.28 1.83
yl]amino]-2,5-dimethyl-
phenyl]methyl]methyl-
piperazinecarboxylate
isopropyl (2S)[[3-[[5-
[(2R)hydroxypropyl]-
O N O
1,3,4-oxadiazol
61 446.28 1.83
yl]amino]-2,5-dimethyl-
phenyl]methyl]methyl-
piperazinecarboxylate
isopropyl (2S)[[3-[[5-
[(1S)hydroxypropyl]-
62 446.28 1.89
1,3,4-oxadiazol
yl]amino]-2,5-dimethyl-
phenyl]methyl]methyl-
piperazinecarboxylate
isopropyl (2S)[[5-
chloro[[5-[(1S)
hydroxyethyl]-1,3,4-
63 oxadiazolyl]amino] 451.20 2.08
methyl-phenyl]methyl]
methyl-piperazine
carboxylate
isopropyl (2S)[[5-
chloro[[5-(3-
hydroxycyclobutyl)-1,3,4-
64 oxadiazolyl]amino] 477.21 2.07
methyl-phenyl]methyl]
methyl-piperazine
carboxylate
isopropyl (2S)[[2,5-
dimethyl[[5-[(2S)
methylsulfonylpyrrolidin
65 yl]-1,3,4-oxadiazol 534.26 1.95
yl]amino]phenyl]methyl]-
2-methyl-piperazine
carboxylate
isopropyl (2S)[[3-[[5-
[(1S)hydroxyethyl]-
1,3,4-oxadiazol
66 432.26 1.83
yl]amino]-2,5-dimethyl-
phenyl]methyl]methyl-
piperazinecarboxylate
isopropyl (2S)[[5-
chloromethyl[[5-(5-
oxopyrrolidinyl)-1,3,4-
O N O
oxadiazol
67 490.21 1.99
Cl O
yl]amino]phenyl]methyl]-
2-methyl-piperazine
carboxylate
isopropyl (2S)[[3-[[5-
H [(1R)aminoethyl]-
1,3,4-oxadiazol
N N O
H N N
68 yl]amino]-2,5-dimethyl- 431.27 1.68
phenyl]methyl]methyl-
piperazinecarboxylate
2,2,2-trifluoroethyl (2S)
[[5-chloro[[5-
(cyanomethyl)-1,3,4-
oxadiazolyl]amino]
69 486.14 2.39
methyl-phenyl]methyl]
methyl-piperazine
carboxylate
2,2,2-trifluoroethyl (2S)
[[3-[[5-(3-
HO N hydroxycyclobutyl)-1,3,4-
N N O
oxadiazolyl]amino]-2,5-
70 O 497.22 1.96
dimethyl-phenyl]methyl]-
2-methyl-piperazine
carboxylate
ethyl (2S)[[3-[[5-[(1R)-
1-hydroxyethyl]-1,3,4-
oxadiazolyl]amino]-2,5-
71 dimethyl-phenyl]methyl]- 417.24 1.73
2-methyl-piperazine
carboxylate
isopropyl (2S)[[3-[[5-
[(1S)-1,2-dihydroxyethyl]-
1,3,4-oxadiazol
72 yl]amino]-2,5-dimethyl- 448.25 1.74
phenyl]methyl]methyl-
piperazinecarboxylate
isopropyl (2S)[[5-
chloromethyl[(5-
morpholinyl-1,3,4-
73 oxadiazol 492.22 1.90
yl)amino]phenyl]methyl]-
2-methyl-piperazine
carboxylate
tert-butyl (2S)[[5-
chloro[[5-
(hydroxymethyl)oxazol
74 2.21
yl]amino]methyl-
phenyl]methyl]methyl-
piperazinecarboxylate
[(1R)-2,2,2-trifluoro
methyl-ethyl] (2S)[[3-
[[5-[(1S)-1,2-
dihydroxyethyl]-1,3,4- 1.88
75 502.2
oxadiazolyl]amino]-2,5-
dimethyl-phenyl]methyl]-
2-methyl-piperazine
carboxylate
isopropyl (2S)[[2,5-
dimethyl[[5-[(3S)-
tetrahydrofuranyl]-
76 1,3,4-oxadiazol 458.2 1.92
yl]amino]phenyl]methyl]-
2-methyl-piperazine
carboxylate
isopropyl (2S)[[3-[[5-
[(2S,3R)
hydroxypyrrolidinyl]-
77 1,3,4-oxadiazol 473.2 1.67
yl]amino]-2,5-dimethyl-
phenyl]methyl]methyl-
piperazinecarboxylate
cyclopentyl-[(2S)[[3-
[[5-[(2S,3R)
hydroxypyrrolidinyl]-
1,3,4-oxadiazol 1.63
78 483.3
yl]amino]-2,5-dimethyl-
phenyl]methyl]methyl-
piperazinyl]methanone
(3,3-difluorocyclopentyl)-
[(2S)[[3-[[5-[(2S,3R)-
3-hydroxypyrrolidinyl]-
1,3,4-oxadiazol 0.55
79 519.3
yl]amino]-2,5-dimethyl-
phenyl]methyl]methyl-
piperazinyl]methanone
[(1R)-2,2,2-trifluoro
methyl-ethyl] (2S)[[3-
[[5-[(2S,3R)
hydroxypyrrolidinyl]-
0.71
80 1,3,4-oxadiazol 527.4
yl]amino]-2,5-dimethyl-
phenyl]methyl]methyl-
piperazinecarboxylate
2,2,2-trifluoroethyl (2S)
[[3-[[5-[(2S,3R)
hydroxypyrrolidinyl]-
1,3,4-oxadiazol 0.68
81 513.2
yl]amino]-2,5-dimethyl-
phenyl]methyl]methyl-
piperazinecarboxylate
[(1R)methylpropyl]
(2S)[[3-[[5-[(2S,3R)
hydroxypyrrolidinyl]-
1,3,4-oxadiazol 0.71
82 487.4
yl]amino]-2,5-dimethyl-
phenyl]methyl]methyl-
piperazinecarboxylate
isopropyl (2S)[[2,5-
dimethyl[[5-[(3S)
oxopyrrolidinyl]-1,3,4-
oxadiazol
83 471.1 1.79
yl]amino]phenyl]methyl]-
2-methyl-piperazine
carboxylate
• RT quoted for UPLC-MS Method 5 unless a) UPLC-MS method 6 or b) UPLC-MS Method 4
Example 1: 5-[3-[[(3S)benzoylmethyl-piperazinyl]methyl]chloromethyl-
anilino]-1,3,4-oxadiazolecarbonitrile
2,2,2-Trifluoracetic anhydride (0.006 mL, 0.043mmol) was added to a solution of 5-[3-
[[(3S)benzoylmethyl-piperazinyl]methyl]chloromethyl-anilino]-1,3,4-
oxadiazolecarboxamide from Preparation 51 (4.0 mg, 0.008 mmol) and pyridine
(0.014 mL, 0.17 mmol) in 1,4-dioxane (0.2 mL). After 2 h of stirring at room
temperature a further aliquot of 2,2,2-trifluoracetic anhydride (0.006 mL, 0.043mmol)
was added. The reaction mixture was stirred for 4 h and then was concentrated under
reduced pressure. The crude material was then dissolved in dimethylformamide (0.7 mL)
and purified by basic preparative HPLC. Clean fractions were evaporated under reduced
pressure to give title compound (1.7 mg, 39%).
H NMR (600 MHz, DMSO-d6) δ 7.70 (d, J = 2.3 Hz, 1H), 7.49 – 7.40 (m, 3H), 7.40 –
7.30 (m, 2H), 7.03 (d, J = 2.3 Hz, 1H), 3.42 (s, 2H), 2.74 (s, 1H), 2.23 (s, 3H), 2.21 –
2.14 (m, 1H), 2.02 (td, J = 11.6, 3.4 Hz, 1H), 1.23 (d, J = 6.6 Hz, 3H). UPLC-MS
Method 5: m/z 450.2 [M+H ]; RT = 2.44 min.
Example 2: [(2S)[[5-chloro[[5-(methoxymethyl)-1,3,4-oxadiazolyl]amino]
methyl-phenyl]methyl]methyl-piperazinyl]-phenyl-methanone
2-Methoxyacetyl chloride (7.91 mg, 0.073 mmol) was added to a solution of product
from Preparation 11 (30.0 mg, 0.069 mmol) and triethylamine (7.73 mg, 0.076 mmol)
in tetrahydrofuran (2.0 mL) at 0°C. After 16 h at room temperature a further aliquot of
both triethylamine (7.73 mg, 0.076 mmol) and 2-methoxyacetyl chloride (7.91 mg,
0.073 mmol) were added. On completion the reaction mixture was filtered and
concentrated under reduced pressure. The crude intermediate was dissolved in
dichloromethane (3.0 mL) and to this added 3-(ethyliminomethyleneamino)-N,N-
dimethyl-propanamine hydrochloride (26.6mg, 0.139 mmol). The reaction mixture
was stirred at room temperature for 16 h. The solvent was removed under reduced
pressure. The obtained residue was purified by silica gel (100-200 mesh) column
chromatography eluting with a gradient of 35-100% ethyl acetate in heptane. Clean
fractions were evaporated under reduced pressure to give the title compound as a
colourless solid. (7.0 mg, 21%)
H NMR (300 MHz, DMSO-d6) δ 9.72 (s, 1H), 7.82 (d,2.2 Hz, 1H), 7.44 (q, J = 2.8, 2.3
Hz, 3H), 7.35 (dd, J = 6.5, 3.2 Hz, 2H), 7.11 (d, J = 2.3 Hz, 1H), 4.53 (s, 2H), 3.45 (s,
2H), 3.33 (s, 3H), 3.14 (s, 3H), 2.73 (br s, 1H), 2.62 (d, J = 11.0 Hz, 1H), 2.25 (s, 3H),
2.18 (dd, J = 11.2, 3.8 Hz, 1H), 2.09 – 2.01 (m, 1H), 1.23 (d, J = 6.3 Hz, 3H).
UPLC-MS Method 5: m/z [M+H ]; RT = 2.2 min
Example 3: [(2S)[[5-chloromethyl[(5-tetrahydrofuranyl-1,3,4-oxadiazol
yl)amino]phenyl]methyl]methyl-piperazinyl]-phenyl-methanone
3-(Ethyliminomethyleneamino)-N,N-dimethyl-propanamine hydrochloride (14.2mg, 4
eq) was added to a solution of the product from Preparation 11 (8.0 mg, ) and
tetrahydrofurancarboxylic acid (2.58 mg, 1.2 eq) in dichloromethane (0.3 mL) and
stirred at room temperature for 2 h. The reaction mixture was concentrated under
reduced pressure then re-dissolved in dimethylformamide (0.3 mL) and purified by basic
preparative HPLC. Clean fractions were evaporated under reduced pressure to give title
compound (0.8 mg, 9%).
H NMR (600 MHz, DMSO-d6) δ = 9.59 (s, 1H), 7.84 (d, J = 2.3 Hz, 1H), 7.43 – 7.45
(m, 3H), 7.35 (ddd, J = 4.9, 3.7, 1.8 Hz, 2H), 7.09 (d, J = 2.3 Hz, 1H), 3.99 (dd, J =
8.6, 7.7 Hz, 1H), 3.83 – 3.89 (m, 2H), 3.77 (td, J = 8.0, 6.6 Hz, 1H), 3.65 (ddt, J = 8.8,
7.5, 5.7 Hz, 1H), 3.44 (s, 2H), 3.04-3.24 (br s, 1H), 2.73 (d, J = 14.6 Hz, 1H), 2.59 –
2.64 (m, 1H), 2.26-2.33 (m, 1H), 2.25 (s, 3H), 2.08-2.21 (m, 3H), 2.02 (td, J = 11.6,
3.3 Hz, 1H), 1.23 (d, J = 6.7 Hz, 3H).
UPLC-MS Method 5: m/z 496.2 [M+H ]; RT = 2.19 min.
Example 19: cyclobutyl-[(2S)[[3-[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazol
yl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinyl]methanone
3-(ethyliminomethyleneamino)-N,N-dimethyl-propanamine hydrochloride (216 mg,
1.13 mmol) was added to a solution of 1-amino[3-[[(3S)(cyclobutanecarbonyl)
methyl-piperazinyl]methyl]-2,5-dimethyl-phenyl]thiourea from Preparation 29 (220
mg, 0.56 mmol) and (2R)hydroxypropanoic acid (61.0 mg, 0.68 mmol) in
dichloromethane (8.0 mL) at room temperature. The reaction was stirred for 1.5 h and
then purified by automated silica gel chromatography. Clean fractions were evaporated
under reduced pressure to give the title compound as an off-white solid (21.0 mg,
8.7%).
H NMR (600 MHz, DMSO-d6) δ = 9.34 (s, 1H), 7.38 (s, 1H), 6.84 (s, 1H), 5.78 (d, J =
5.5 Hz, 1H), 4.79 (qd, J = 6.6, 5.3 Hz, 1H), 4.50 (s, 1H), 3.46 – 3.32 (m, 3H), 3.27 (dq,
J = 16.9, 8.2 Hz, 1H), 3.08 (t, J = 12.0 Hz, 1H), 2.71 (dd, J = 24.2, 11.7 Hz, 2H), 2.60
(s, 1H), 2.25 (s, 3H), 2.21 (s, 3H), 2.20 – 1.96 (m, 5H), 1.95 – 1.76 (m, 2H), 1.72 (d, J
= 9.6 Hz, 1H), 1.44 (d, J = 6.6 Hz, 3H), 1.18 (d, J = 6.5 Hz, 1H), 1.08 (d, J = 6.7 Hz,
2H). UPLC-MS Method 5: RT = 1.75 min.
Example 20: cyclobutyl-[(2S)[[3-[[5-[(1S)hydroxyethyl]-1,3,4-oxadiazol
yl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinyl]methanone
N,N,N ′,N ′-tetramethyl-O-(1H-benzotriazolyl)uronium hexafluorophosphate (136 mg,
0.36 mmol) was added to a solution of (1S)[5-[2,5-dimethyl[[(3S)
methylpiperazinyl]methyl]anilino]-1,3,4-oxadiazolyl]ethanol hydrochloride from
Preparation 53 (100 mg, 0.24 mmol), cyclobutanecarboxylic acid (28.7 mg, 0.29
mmol) and diisopropylethylamine (0.21 mL, 1.20 mmol) in dimethylformamide (4.0 mL)
and the resulting mixture was stirred at room temperature for 13 h. The reaction
mixture was quenched with water and extracted with dichloromethane (2x 50 mL). The
combined extracted organic layers were dried over sodium sulphate and then evaporated
under reduced pressure. The obtained residue was purified by silica gel (100-200 mesh)
column chromatography eluting with a gradient of 0-100% ethyl acetate in heptane.
Clean fractions were evaporated under reduced pressure to give the title compound as a
colourless solid (25.0 mg, 24.5%).
H NMR (600 MHz, DMSO-d6) δ = 9.34 (s, 1H), 7.38 (d, J = 1.7 Hz, 1H), 6.85 (d, J =
1.7 Hz, 1H), 5.79 (d, J = 5.5 Hz, 1H), 4.85 – 4.70 (m, 1H), 4.09 (q, J = 5.9 Hz, 1H),
3.66 (dt, J = 13.1, 2.6 Hz, 1H), 3.39 (d, J = 13.0 Hz, 1H), 2.97 – 2.85 (m, 1H), 2.69
(ddt, J = 11.1, 3.5, 1.9 Hz, 1H), 2.59 (dt, J = 11.3, 1.9 Hz, 1H), 2.25 (s, 3H), 2.21 (s,
3H), 2.07 (dd, J = 11.3, 3.9 Hz, 1H), 1.88 (td, J = 11.7, 3.5 Hz, 1H), 1.44 (d, J = 6.6
Hz, 3H), 1.12 (d, J = 6.8 Hz, 3H). UPLC-MS Method 5: RT = 1.75 min.
Example 21: 2,2-difluoro[(2S)[[3-[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazol
yl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinyl]butanone
N N O
N,N,N ′,N ′-tetramethyl-O-(1H-benzotriazolyl)uronium hexafluorophosphate (8.7 mg,
0.023 mmol) was added to a solution of (1R)[5-[2,5-dimethyl[[(3S)
methylpiperazinyl]methyl]anilino]-1,3,4-oxadiazolyl]ethanol hydrochloride from
Preparation 52 (8.0 mg, 0.019 mmol), 2,2-difluorobutanoic acid (2.37 mg, 0.019
mmol) and triethylamine (11.6 mg, 0.11 mmol) in dimethylformamide (0.5 mL) After 3
h stirring the reaction mixture was purified by basic preparative HPLC. Clean fractions
were evaporated under reduced pressure to give title compound as a colourless solid
(0.8 mg, 9%).
H NMR (600 MHz, DMSO-d6) δ = 9.35 (s, 1H), 7.40 (s, 1H), 6.85 (s, 1H), 5.79 (d, J =
.5 Hz, 1H), 4.74 – 4.84 (m, 1H), 4.52 (s, 0.5H), 4.33 (s, 0.5H), 4.14 (d, J = 13.5 Hz,
0.5H), 3.88 (d, J = 13.7 Hz, 0.5H), 3.28-3.43 (m, 3H), 2.97 (t, J = 12.7 Hz, 0.5H), 2.80
(t, J = 15.3 Hz, 1H), 2.68 (d, J = 11.4 Hz, 1H), 2.25 (s, 3H), 2.22 (s, 3H), 2.03-2.18
(m, 3.5H), 1.94 (dt, J = 28.0, 11.9 Hz, 1H), 1.44 (d, J = 6.6 Hz, 3H), 1.23 (dd, J =
65.2, 6.6 Hz, 3H), 0.97 (q, J = 7.5 Hz, 3H). UPLC-MS Method 5: RT = 1.99 min.
Example 22: cyclopropyl-[(2S)[[3-[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazol
yl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinyl]methanone
Using a procedure similar to that described for Example 21, but using
cyclopropanecarboxylic acid (1.65 mg, 0.19 mmol) the title compound was prepared.
After 3 h stirring the reaction mixture was purified by basic preparative HPLC. Clean
fractions were evaporated under reduced pressure to give title compound as a colourless
solid (0.8 mg, 10%).
H NMR (600 MHz, DMSO-d6) δ = 9.35 (s, 1H), 7.39 (s, 1H), 6.86 (m, 1H), 5.79 (d, J =
.5 Hz, 1H), 4.74-4.82 (m, 1H), 4.49 (br s, 1H), 4.07 (br d, J = 39.4 Hz, 1H), 3.39 (q, J
= 13.0 Hz, 2H), 2.76 (d, J = 10.8 Hz, 1H), 2.62 – 2.57 (m, 4H), 2.26 (s, 3H), 2.23 (s,
3H), 2.01-2.18 (m, 1H), 1.84-1.97 (m, 2H), 1.44 (d, J = 6.6 Hz, 3H), 1.05-1.30 (m,
3H), 0.68 (br d, J = 9.5 Hz, 4H). UPLC-MS Method 5: RT = 1.66 min.
Example 23: [(2S)[[3-[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5-
dimethyl-phenyl]methyl]methyl-piperazinyl]-(2-methylcyclopropyl)methanone
Using a procedure similar to that described for Example 21, but using 2-
methylcyclopropanecarboxylic acid the title compound was prepared. After 3 h stirring
the reaction mixture was purified by basic preparative HPLC. Clean fractions were
evaporated under reduced pressure to give title compound as a colourless solid (4.5 mg,
54%).
H NMR (600 MHz, DMSO-d6) δ = 9.35 (s, 1H), 7.39 (s, 1H), 6.86 (s, 1H), 5.79 (d, J =
.5 Hz, 1H), 4.78 (qd, J = 6.6, 5.3 Hz, 1H), 4.40-4.50 (m, 1H), 4.04 (d, J = 47.1 Hz,
1H), 3.39 (ddd, J = 28.7, 13.0, 4.9 Hz, 2H), 2.75 (d, J = 10.7 Hz, 1H), 2.58-2.69 (s,
1H), 2.26 (s, 3H), 2.22 (s, 3H), 1.80 – 2.20 (m, 2H), 1.65 (s, 1H), 1.44 (d, J = 6.6 Hz,
3H), 1.07-1.28 (m, 4H), 1.06 (d, J = 3.5 Hz, 3H), 0.52 (s, 1H). UPLC-MS Method 5: RT
= 1.74 min.
Example 25: (3,3-difluorocyclopentyl)-[(2S)[[3-[[5-[(1R)hydroxyethyl]-1,3,4-
oxadiazolyl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinyl]methanone
Using a procedure similar to that described for Example 21, but using 3,3-
difluorocyclopentanecarboxylic acid the title compound was prepared. After 3 h stirring
the reaction mixture was purified by basic preparative HPLC. Clean fractions were
evaporated under reduced pressure to give title compound as a colourless solid (5.7 mg,
63%).
H NMR (600 MHz, DMSO-d6) δ = 9.35 (s, 1H), 7.39(s, 1H), 6.85 (s, 1H), 5.79 (d, J =
.5 Hz, 1H), 4.79 (qd, J = 6.6, 5.4 Hz, 1H), 4.53 (s, 0.5H), 4.14-4.21 (m, 1H), 3.71 (t, J
= 15.5 Hz, 0.5H), 3.34-3.42 (m, 2H), 3.14-3.31 (m, 1.5H), 2.71-2.81 (m, 1.5H), 2.62
(d, J = 6.6 Hz 1H), 2.28 – 2.44 (m, 0.5H), 2.25 (s, 3H), 2.22 (s, 3H), 1.98-2.15 (m,
4H), 1.89 – 1.99 (m, 1H), 1.77-1.85 (m, 1H), 1.63 – 1.75 (m, 0.5H), 1.44 (d, J = 6.6
Hz, 3H), 1.09 – 1.25 (m, 3H). UPLC-MS Method 5: RT = 1.75 min.
Example 26: 2-cyclobutyl[(2S)[[3-[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazol
yl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinyl]ethanone
Using a procedure similar to that described for Example 21, but using 2-
cyclobutylacetic acid the title compound was prepared. After 3 h stirring the reaction
mixture was purified by basic preparative HPLC. Clean fractions were evaporated under
reduced pressure to give title compound as a colourless solid (3.5 mg, 42%).
H NMR (600 MHz, DMSO-d6) δ= 9.35 (s, 1H), 7.39 (d, J = 1.8 Hz, 1H), 6.85 (d, J = 1.8
Hz, 1H), 5.79 (d, J = 5.5 Hz, 1H), 4.79 (qd, J = 6.6, 5.5 Hz, 1H), 4.50 (s, 0.5H), 4.13
(d, J = 13.3 Hz, 0.5H), 4.06 (s, 0.5H), 3.62 (d, J = 13.2 Hz, 0.5H), 3.37 (q, 2H), 3.16
(t, J = 12.6 Hz, 1H), 2.72 (d, J = 11.2 Hz, 1.5H), 2.54 – 2.64 (m, 1.5H), 2.37-2.46 (m,
1H), 2.32 (dt, J = 22.9, 7.9 Hz, 1H), 2.25 (s, 3H), 2.21 (s, 3H), 2.06-2.12 (m, 0.5H),
2.01 (s, 2.5H), 1.88-1.94 (m, 0.5H), 1.74-1.85 (m, 2.5H), 1.62 (dq, J = 12.0, 8.5 Hz,
2H), 1.44 (d, J = 6.6 Hz, 3H), 1.13 (dd, J = 78.2, 6.6 Hz, 3H). UPLC-MS Method 5: RT =
1.83 min.
Example 27: cyclobutyl-[(2S)[[5-(difluoromethyl)[[5-[(1S)hydroxyethyl]-
1,3,4-oxadiazolyl]amino]methyl-phenyl]methyl]methyl-piperazin
yl]methanone
Using a procedure similar to that described for Example 19, but using 1-amino[3-
[[(3S)(cyclobutanecarbonyl)methyl-piperazinyl]methyl](difluoromethyl)
methyl-phenyl]thiourea from Preparation 47 (300 mg, 0.2390 mmol) and (2S)
hydroxypropanoic acid the title compound was prepared as a colourless solid (40.0 mg,
15.3%).
H NMR (600 MHz, DMSO-d6) δ = 9.61 (s, 1H), 7.91 (s, 1H), 7.23 (s, 1H), 7.00 (t, J =
56.0 Hz, 1H), 5.83 (d, J = 5.4 Hz, 1H), 4.81 (td, J = 6.6, 5.5 Hz, 1H), 4.51 (s, 0.5H),
4.16 (d, J = 13.0 Hz, 0.5H), 3.90 (s, 0.5H), 3.42-3.49 (m, 2.5H), 3.25-3.34 (m, 1H),
3.10 (m, 0.5H), 2.68-2.80 (m, 1.5H), 2.60 (m, 1H), 2.31 (s, 3H), 1.99-2.22 (m, 5H),
1.89 (qq, J = 17.9, 9.5 Hz, 2H), 1.73 (dd, J = 12.1, 7.4 Hz, 1H), 1.45 (d, J = 6.6 Hz,
3H), 1.15 (dd, J = 55.9, 6.6 Hz, 3H). UPLC-MS Method 5: RT = 1.90 min.
Example 31: tert-butyl (2S)[[2,5-dimethyl[[5-(2-methylpyrazolyl)-1,3,4-
oxadiazolyl]amino]phenyl]methyl]methyl-piperazinecarboxylate
3-(ethyliminomethyleneamino)-N,N-dimethyl-propanamine hydrochloride
was added to a solution of tert-butyl (2S)[[3-(aminocarbamothioylamino)-2,5-
dimethyl-phenyl]methyl]methyl-piperazinecarboxylate from Preparation 27
(8.55 mg, 0.021 mmol) and 2-methylpyrazolecarboxylic acid (3.17 mg, 0.025 mmol)
in dichloromethane (1.0 mL). After 3 h the reaction mixture was quenched with water
(0.5 mL) and extracted with dichloromethane (2.0 mL). The organic layer was collected
and concentrated under reduced pressure. The residue was dissolved in
dimethylformamide (0.4 mL) and purified basic preparative HPLC. Clean fractions were
evaporated under reduced pressure to give title compound as a colourless solid (1.0 mg,
10%).
H NMR (600 MHz, DMSO-d6) δ = 9.68 (s, 1H), 7.60 (d, J = 2.0 Hz, 1H), 7.44 (s, 1H),
6.89 (s, 1H), 6.74 (d, J = 2.0 Hz, 1H), 4.15 (s, 3H), 4.09 (s, 1H), 3.67 (d, J = 13.2 Hz,
2H), 3.36-3.47 (m, 2H), 2.91 (t, J = 13.4 Hz, 1H), 2.70 (d, J = 11.2 Hz, 1H), 2.60 (dd, J
= 11.5, 2.2 Hz, 1H), 2.27 (s, 3H), 2.24 (s, 3H), 2.08 (dd, J = 11.4, 3.8 Hz, 1H), 1.89
(td, J = 11.7, 3.5 Hz, 1H), 1.39 (s, 9H), 1.12 (d, J = 6.6 Hz, 3H). UPLC-MS Method 5:
RT = 2.13 min.
Example 33: tert-butyl (2S)[[2,5-dimethyl[[5-(1,2,5-thiadiazolyl)-1,3,4-
oxadiazolyl]amino]phenyl]methyl]methyl-piperazinecarboxylate
3-(Ethyliminomethyleneamino)-N,N-dimethyl-propanamine hydrochloride was added
to a solution of tert-butyl (2S)[[3-(aminocarbamothioylamino)-2,5-dimethyl-
phenyl]methyl]methyl-piperazinecarboxylate from Preparation 27 (8.55 mg,
0.021 mmol) and 1,2,5-thiadiazolecarboxylic acid (3.25 mg, 0.025 mmol) in
dichloromethane (1.0 mL). After 3 h the reaction mixture was quenched with water (0.5
mL) and extracted with dichloromethane (2.0 mL). The organic layer was collected and
concentrated under reduced pressure. The residue was dissolved in dimethylformamide
(0.4 mL) and purified basic preparative HPLC. Clean fractions were evaporated under
reduced pressure to give title compound as a colourless solid (1.94 mg, 19%).
H NMR (600 MHz, DMSO-d6) δ = 9.95 (s, 1H), 9.37 (s, 1H), 7.41 (s, 1H), 6.93 (s, 1H),
4.09 (s, 1H), 3.62 – 3.72 (m, 1H), 3.39 (q, J = 19.7 Hz, 2H), 2.93 (t, J = 12.6 Hz, 1H),
2.71 (d, J = 11.7 Hz, 1H), 2.60 (dt, J = 11.3, 1.9 Hz, 1H), 2.28 (s, 3H), 2.25 (s, 3H),
2.22 (d, J = 17.0 Hz, 1H), 2.09 (dd, J = 11.4, 4.0 Hz, 2H), 1.90 (td, J = 11.7, 3.5 Hz,
1H), 1.39 (s, 9H), 1.13 (d, J = 6.7 Hz, 3H). UPLC-MS Method 5: RT = 2.21 min.
Example 34: tert-butyl (2S)[[2,5-dimethyl[[5-(4-methyl-1,2,5-oxadiazolyl)-
1,3,4-oxadiazolyl]amino]phenyl]methyl]methyl-piperazinecarboxylate
3-(Ethyliminomethyleneamino)-N,N-dimethyl-propanamine hydrochloride
was added to a solution of tert-butyl (2S)[[3-(aminocarbamothioylamino)-2,5-
dimethyl-phenyl]methyl]methyl-piperazinecarboxylate from Preparation 27 (8.55
mg, 0.021 mmol) and 4-methyl-1,2,5-oxadiazolecarboxylic acid (3.20 mg, 0.025
mmol) in dichloromethane (1.0 mL). After 3 h the reaction mixture was quenched with
water (0.5 mL) and extracted with dichloromethane (2.0 mL). The organic layer was
collected and concentrated under reduced pressure. The residue was dissolved in
dimethylformamide (0.4 mL) and purified basic preparative HPLC. Clean fractions were
evaporated under reduced pressure to give title compound as a colourless solid (1.4 mg,
13%).
H NMR (600 MHz, DMSO-d6) δ = 10.07 (s, 1H), 7.39 (s, 1H), 6.94 (s, 1H), 4.09 (s,
1H), 3.67 (d, J = 12.8 Hz, 1H), 3.36-3.44 (m, 2H), 2.91 (t, J = 13.1 Hz, 1H), 2.70 (d, J
= 11.2 Hz, 1H), 2.64 (s, 3H), 2.60 (dt, J = 11.5, 2.0 Hz, 1H), 2.28 (s, 3H), 2.25 (s, 3H),
2.09 (dd, J = 11.3, 3.9 Hz, 1H), 1.90 (td, J = 11.7, 3.5 Hz, 1H), 1.39 (s, 9H), 1.12 (d, J
= 6.7 Hz, 3H). UPLC-MS Method 5: RT = 2.38 min.
Example 36: isopropyl (2S)[[3-[[5-[(1S)aminohydroxy-ethyl]-1,3,4-oxadiazol-
2-yl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinecarboxylate
3-(Ethyliminomethyleneamino)-N,N-dimethyl-propanamine hydrochloride (73.1 mg,
0.38 mmol) was added to a solution of isopropyl (2S)[[3-
(aminocarbamothioylamino)-2,5-dimethyl-phenyl]methyl]methyl-piperazine
carboxylate from Preparation 25 (50.0 mg, 0.127 mmol) and (2S)(tert-
butoxycarbonylamino)hydroxy-propanoic acid (28.7 mg, 0.14 mmol) in
dichloromethane (3.0 mL) and stirred for 12 h. The reaction mixture was quenched with
water (2.0 mL) and extracted with dichloromethane (5.0 mL). The organic layer was
collected and concentrated under reduced pressure. The obtained residue was purified
by silica gel (100-200 mesh) column chromatography eluting with a gradient of 0-90%
ethyl acetate in heptane. Clean fractions were evaporated under reduced pressure to
give intermediate compound, isopropyl-(2S)[[3-[[5-[(1S)(tert-
butoxycarbonylamino)hydroxy-ethyl]-1,3,4-oxadiazolyl]amino]-2,5-dimethyl-
phenyl]methyl]methyl-piperazinecarboxylate (33.0 mg, 0.60 mmol, 47.5%).
Hydrogen chloride (0.6 mL, 4M in dioxane) was added to a solution of intermediate
isopropyl-(2S)[[3-[[5-[(1S)(tert-butoxycarbonylamino)hydroxy-ethyl]-1,3,4-
oxadiazolyl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinecarboxylate
in dichloromethane (5.0 mL) and stirred for 1 h. The suspension was diluted with
methanol and purified on 1g SCX column, eluting with methanol, then methanolic
ammonia (2N). Clean fractions were evaporated under reduced pressure to give title
compound as colourless solid (25.0 mg, 0.056 mmol, 44% overall).
H NMR (600 MHz, DMSO-d6) δ = 9.30 (s, 1H), 7.39 (d, J = 1.6 Hz, 1H), 6.83 (d, J =
1.7 Hz, 1H), 5.01 (s, 1H), 4.77 (hept, J = 6.3 Hz, 1H), 4.12 (s, 1H), 4.01 (t, J = 5.9 Hz,
1H), 3.70 (dt, J = 12.9, 2.6 Hz, 1H), 3.63 (dd, J = 5.9, 2.4 Hz, 2H), 3.32-3.41 (m, 3H),
2,91-3.00 (m, 1H), 2.71 (ddt, J = 11.0, 3.3, 1.8 Hz, 1H), 2.60 (dt, J = 11.3, 1.9 Hz,
1H), 2.25 (s, 3H), 2.21 (s, 3H), 2.08 (dd, J = 11.4, 3.9 Hz, 1H), 1.90 (td, J = 11.7, 3.6
Hz, 1H), 1.17 (dd, J = 6.2, 1.1 Hz, 6H), 1.13 (d, J = 6.8 Hz, 3H). UPLC-MS Method 5:
RT = 1.68 min.
Example 38: isopropyl (2S)[[3-[[5-[(1S)aminopropyl]-1,3,4-oxadiazol
yl]amino]chloromethyl-phenyl]methyl]methyl-piperazinecarboxylate
Cl O
3-(Ethyliminomethyleneamino)-N,N-dimethyl-propanamine hydrochloride (27.8 mg,
0.15 mmol) was added to a solution isopropyl (2S)[[3-(aminocarbamothioylamino)
chloromethyl-phenyl]methyl]methyl-piperazinecarboxylate from Preparation
16 (15.0 mg, 0.036 mmol) and (2R)(tert-butoxycarbonylamino)butanoic acid (7.73
mg, 0.038 mmol) in dichloromethane (1.0 mL) and stirred for 12 h. The reaction mixture
was purified by silica gel (100-200 mesh) column chromatography eluting with of 33%
ethyl acetate in heptane. Clean fractions were evaporated under reduced pressure to
give intermediate compound, isopropyl (2S)[[3-[[5-[(1S)(tert-
butoxycarbonylamino)propyl]-1,3,4-oxadiazolyl]amino]chloromethyl-
phenyl]methyl]methyl-piperazinecarboxylate. (15 mg, 73%)
Hydrogen chloride (0.6 mL, 4M in dioxane) was added to a solution of intermediate
isopropyl (2S)[[3-[[5-[(1S)(tert-butoxycarbonylamino)propyl]-1,3,4-oxadiazol
yl]amino]chloromethyl-phenyl]methyl]methyl-piperazinecarboxylate (15mg,
0.026mmol) in dichloromethane (1.0 mL) and stirred for 5 h. The reaction was
evaporated under reduced pressure and the residue obtained was purified by silica gel
(100-200 mesh) column chromatography eluting with dichloromethane/methanol/
ammonia (95/5/0.5). Clean fractions were evaporated under reduced pressure to give
title compound as colourless solid (7.0 mg, 57% overall).
H NMR (300 MHz, DMSO-d6) δ = 9.56 (s, 1H), 7.83 (d, J = 2.2 Hz, 1H), 7.08 (d, J =
2.3 Hz, 1H), 4.77 (hept, J = 6.1 Hz, 1H), 4.12 (s, 1H), 3.86 (t, J = 6.8 Hz, 1H), 3.71 (d,
J = 12.8 Hz, 1H), 3.42 (s, 2H), 2.98 (dd, J = 13.0, 9.8 Hz, 1H), 2.71 (d, J = 11.3 Hz,
1H), 2.58 (d, J = 11.3 Hz, 1H), 2.24 (s, 3H), 2.11 (dd, J = 11.3, 3.8 Hz, 1H), 1.95 (td, J
= 11.4, 3.2 Hz, 1H), 1.59-1.85 (m, 2H), 1.17 (d, J = 6.2 Hz, 6H), 1.14 (d, J = 6.7 Hz,
3H), 0.90 (t, J = 7.4 Hz, 3H). UPLC-MS Method 5: RT = 1.91 min.
Example 41: isopropyl (2S)[[3-[[5-[(1S,2R)aminohydroxy-propyl]-1,3,4-
oxadiazolyl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinecarboxylate
3-(Ethyliminomethyleneamino)-N,N-dimethyl-propanamine hydrochloride (73.1 mg,
0.38 mmol) was added to a solution of isopropyl (2S)[[3-
(aminocarbamothioylamino)-2,5-dimethyl-phenyl]methyl]methyl-piperazine
carboxylate from Preparation 25 (50.0 mg, 0.127 mmol) and (2S,3R)(tert-
butoxycarbonylamino)hydroxy-butanoic acid (30.6 mg, 0.14 mmol) in
dichloromethane (5.0 mL) and stirred for 12 h. h The reaction mixture was quenched
with water (2.0 mL) and extracted with dichloromethane (5.0 mL). The organic layer
was collected and concentrated under reduced pressure. The obtained residue was
purified by silica gel (100-200 mesh) column chromatography eluting with a gradient of
0-90% ethyl acetate in heptane. Clean fractions were evaporated under reduced
pressure to give intermediate compound, isopropyl-(2S)[[3-[[5-[(1S,2R)(tert-
butoxycarbonylamino)hydroxy-propyl]-1,3,4-oxadiazolyl]amino]-2,5-dimethyl-
phenyl]methyl]methyl-piperazinecarboxylate (33.0 mg, 0.058 mmol, 46.3%).
Hydrogen chloride (0.6 mL, 4M in dioxane) was added to a solution of the intermediate
isopropyl-(2S)[[3-[[5-[(1S,2R)(tert-butoxycarbonylamino)hydroxy-propyl]-
1,3,4-oxadiazolyl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazine
carboxylate in dichloromethane and stirred for 12 h. The suspension was diluted with
methanol and purified on 1g SCX column, eluting with methanol, then methanolic
ammonia (2N). Clean fractions were evaporated under reduced pressure to give title
compound as colourless solid (23.0 mg, 40% overall).
H NMR (600 MHz, DMSO-d6) δ= 9.28 (s, 1H), 7.39 (d, J = 1.7 Hz, 1H), 6.83 (d, J = 1.7
Hz, 1H), 4.93 (s, 1H), 4.77 (hept, J = 6.2 Hz, 1H), 4.10-4.14 (m, 1H), 3.82 (q, J = 6.1
Hz, 1H), 3.79 (d, J = 5.5 Hz, 1H), 3.70 (dt, J = 13.0, 2.7 Hz, 1H), 3.36 (q, J = 15.7 Hz,
2H), 2.93-2.98 (m, 1H), 2.70 (ddt, J = 11.1, 3.4, 1.8 Hz, 1H), 2.59 (dt, J = 11.4, 1.8
Hz, 1H), 2.25 (s, 3H), 2.21 (s, 3H), 2.08 (dd, J = 11.4, 3.8 Hz, 1H), 1.89 (td, J = 11.6,
3.5 Hz, 1H), 1.17 (dd, J = 6.3, 1.0 Hz, 6H), 1.13 (d, J = 6.7 Hz, 3H), 1.09 (d, J = 6.2
Hz, 3H). UPLC-MS Method 5: RT = 1.68 min.
Example 43: isopropyl (2S)[[5-(difluoromethyl)[[5-[(1S)hydroxyethyl]-1,3,4-
oxadiazolyl]amino]methyl-phenyl]methyl]methyl-piperazinecarboxylate
3-(Ethyliminomethyleneamino)-N,N-dimethyl-propanamine hydrochloride (78.1 mg,
0.41 mmol) was added to a solution of isopropyl (2S)[[3(aminocarbamothioylamino)-
-(difluoromethyl)methyl-phenyl]methyl]methyl-piperazinecarboxylate
Preparation 40 (50.0 mg, 0.116 mmol) and (2S)hydroxypropanoic acid (12.6 mg,
0.14mmol). After 5 h stirring the reaction mixture was purified by basic preparative
HPLC. Clean fractions were evaporated under reduced pressure to give title compound as
a colourless solid (16.0 mg, 29.4%).
H NMR (600 MHz, DMSO-d6) δ = 9.63 (s, 1H), 7.90 (s, 1H), 7.24 (s, 1H), 7.00 (t, J =
56.0 Hz, 1H), 5.83 (d, J = 5.4 Hz, 1H) 4.72-4.88 (m, 2H), 4.12 (q, J = 6.5, 6.0 Hz, 1H),
3.72 (dt, J = 13.1, 2.7 Hz, 1H), 3.47 (s, 2H), 2.92-3.06 (m, 1H), 2.71 (ddt, J = 11.2,
3.5, 1.8 Hz, 1H), 2.59 (dt, J = 11.4, 2.0 Hz, 1H), 2.31 (d, J = 1.5 Hz, 3H), 2.12 (dd, J =
11.3, 3.9 Hz, 1H), 1.97 (td, J = 11.7, 3.5 Hz, 1H), 1.45 (d, J = 6.6 Hz, 3H), 1.17 (d, J =
6.2 Hz, 6H), 1.14 (d, J = 6.7 Hz, 3H). UPLC-MS Method 5: RT = 2.00 min.
Example 48: isopropyl (2S)[[5-chloromethyl[[5-(2-oxopyrrolidinyl)-1,3,4-
oxadiazolyl]amino]phenyl]methyl]methyl-piperazinecarboxylate
3-(ethyliminomethyleneamino)-N,N-dimethyl-propanamine hydrochloride (14.8 mg,
0.077 mmol) was added to a solution of isopropyl (2S)[[3-
(aminocarbamothioylamino)chloromethyl-phenyl]methyl]methyl-piperazine
carboxylate from Preparation 16 (8.0 mg, 0.019 mmol) and 2-oxopyrrolidine
carboxylic acid (3.0 mg, 0.023 mmol) in dichloromethane (0.8 mL). After 5 h stirring the
reaction mixture was purified by basic preparative HPLC. Clean fractions were
evaporated under reduced pressure to give title compound as a colourless solid (4.8 mg,
46%).
H NMR (600 MHz, DMSO-d6) δ =9.67 (s, 1H), 8.10 (s, 1H), 7.83 (d, J = 2.3 Hz, 1H),
7.09 (d, J = 2.3 Hz, 1H), 4.77 (hept, J = 6.3 Hz, 1H), 4.12 (s, 1H), 3.97 (t, J = 9.3 Hz,
1H), 3.59 – 3.77 (m, 1H), 3.42 (s, 2H), 2.98 (t, J = 12.5 Hz, 1H), 2.74 – 2.68 (m, 1H),
2.61 – 2.55 (m, 2H), 2.54 (s, 29H), 2.51 (s, 6H), 2.47 (ddd, J = 12.5, 7.8, 3.1 Hz, 1H),
2.41 – 2.32 (m, 1H), 2.11 (dd, J = 11.3, 3.9 Hz, 1H), 1.95 (td, J = 11.6, 3.5 Hz, 1H),
1.26 – 1.06 (m, 9H). UPLC-MS Method 5: RT = 2.01 min.
Example 52: isopropyl (2S)[[2,5-dimethyl[[5-[(5S)oxooxazolidinyl]-1,3,4-
oxadiazolyl]amino]phenyl]methyl]methyl-piperazinecarboxylate
3-(Ethyliminomethyleneamino)-N,N-dimethyl-propanamine hydrochloride (195 mg,
1.02 mmol) was added to a solution of (2S)[[3-(aminocarbamothioylamino)-2,5-
dimethyl-phenyl]methyl]methyl-piperazinecarboxylate (100 mg, 0.25 mmol) and
(5S)oxooxazolidinecarboxylic acid from Preparation 25 (48.1 mg, 0.33 mmol) in
dichloromethane (10 mL) and stirred at room temperature for 48 h. The reaction
mixture was quenched with water (2.0 mL) and extracted with dichloromethane (5.0
mL). The organic layer was collected and concentrated under reduced pressure. The
obtained residue was purified by silica gel (100-200 mesh) column chromatography
eluting with a gradient of 0-90% ethyl acetate in heptane, then by acidic preparative
HPLC to afford title compound as colourless solid (20.0 mg, 16.6%).
H NMR (600 MHz, DMSO-d6) δ = 9.61 (s, 1H), 7.99 (s, 1H), 7.37 (d, J = 1.7 Hz, 1H),
6.88 (d, J = 1.8 Hz, 1H), 5.78 (dd, J = 9.2, 5.7 Hz, 1H), 4.77 (hept, J = 6.2 Hz, 1H),
4.12 (s, 1H), 3.88 (t, J = 9.3 Hz, 1H), 3.81 (dd, J = 9.3, 5.8 Hz, 1H), 3.70 (dt, J = 13.0,
2.7 Hz, 1H), 3.34-3.41 (m, 2H), 2.96 (td, J = 12.9, 3.3 Hz, 1H), 2.71 (ddt, J = 11.2,
3.7, 1.9 Hz, 1H), 2.59 (dt, J = 11.4, 1.8 Hz, 1H), 2.26 (s, 3H), 2.22 (s, 3H), 2.03-2.13
(m, 1H), 1.90 (td, J = 11.6, 3.5 Hz, 1H), 1.17 (dd, J = 6.3, 1.0 Hz, 6H), 1.13 (d, J = 6.7
Hz, 3H). UPLC-MS Method 5: RT = 1.82 min.
Example 53: isopropyl (2S)[[5-chloromethyl[[5-[(2S)oxoazetidinyl]-
1,3,4-oxadiazolyl]amino]phenyl]methyl]methyl-piperazinecarboxylate
3-(Ethyliminomethyleneamino)-N,N-dimethyl-propanamine hydrochloride (18.5 mg,
0.097 mmol) was added to a solution of isopropyl (2S)[[3-
(aminocarbamothioylamino)chloromethyl-phenyl]methyl]methyl-piperazine
carboxylate from Preparation16 (10.0 mg, 0.024 mmol) and 4-oxoazetidine
carboxylic acid (3.6 mg, 0.031 mmol) in dichloromethane (0.6 mL). After 2 h stirring the
reaction mixture was purified by basic preparative HPLC. Clean fractions were
evaporated under reduced pressure to give title compound as a colourless solid (4.9 mg,
42%).
H NMR (300 MHz, DMSO-d6) δ = 8.56 (s, 1H), 7.83 (d, J = 2.2 Hz, 1H), 7.07 (d, J =
2.3 Hz, 1H), 6.70 (br s, 1H), 4.74-4.82 (m, 2H), 4.13 (s, 1H), 3.71 (d, J = 12.8 Hz, 1H),
3.36-3.44 (m, 3H), 3.15 (dd, J = 14.8, 2.5 Hz, 1H), 2.91-3.07 (m, 1H), 2.71 (d, J =
11.1 Hz, 1H), 2.58 (d, J = 11.4 Hz, 1H), 2.24 (s, 3H), 2.02-2.17 (m, 1H), 1.95 (td, J =
11.5, 3.3 Hz, 1H), 1.17 (d, J = 6.2 Hz, 6H), 1.14 (d, J = 6.6 Hz, 3H). UPLC-MS Method
: RT = 2.04 min.
Example 55: isopropyl (2S)[[2,5-dimethyl[[5-[(3S)-morpholinyl]-1,3,4-
oxadiazolyl]amino]phenyl]methyl]methyl-piperazinecarboxylate dihydrochloride
2HCl
3-(Ethyliminomethyleneamino)-N,N-dimethyl-propanamine hydrochloride (97.4 mg,
0.51 mmol) was added to a solution of (2S)[[3-(aminocarbamothioylamino)-2,5-
dimethyl-phenyl]methyl]methyl-piperazinecarboxylate from Preparation 25 (50.0
mg, 0.127 mmol) and (3S)tert-butoxycarboylmorpholinecarboxylic acid (38.2 mg,
0.16 mmol) in dichloromethane (3.0 mL) and stirred for 2.5 h. The mixture was
concentrated under reduced pressure and the obtained residue was purified by silica gel
(100-200 mesh) column chromatography eluting with a gradient of 10-100% ethyl
acetate in heptane. Clean fractions were evaporated under reduced pressure to give
intermediate compound tert-butyl 3-[5-[3-[[(3S)isopropoxycarbonylmethyl-
piperazinyl]methyl]-2,5-dimethyl-anilino]-1,3,4-oxadiazolyl]morpholine
carboxylate (56.0 mg, 0.098 mmol, 77%). Hydrogen chloride (1.5 mL, 4M in dioxane)
was added to a solution of intermediate tert-butyl 3-[5-[3-[[(3S)isopropoxycarbonyl-
3-methyl-piperazinyl]methyl]-2,5-dimethyl-anilino]-1,3,4-oxadiazolyl]morpholine-
4-carboxylate (52.0 mg, 0.091 mmol) in dichloromethane (5.0 mL) and stirred for 3 h.
Toluene (3.0 mL) was added and the solid was collected and dried under reduced
pressure to give title compound as colourless salt. (52.0 mg, 0,091 mmol, 77% overall).
H NMR (600 MHz, DMSO-d6) δ = 10.59 (s, 1H), 10.42 (s, 1H), 10.22 (s, 1H), 9.86 (s,
1H), 7.51 (s, 1H), 7.45 (s, 1H), 4.88 (d, J = 7.7 Hz, 1H), 4.80 (hept, J = 6.3 Hz, 1H),
4.30-4.45 (m, 2H), 4.23 (dd, J = 12.4, 3.6 Hz, 1H), 3.89-4.02 (m, 3H), 3.84 (ddd, J =
12.3, 9.2, 2.8 Hz, 2H), 3.66-3.72 (m, 0.5H), 3.45-3.51 (m, 0.5H), 3.36 (s, 2H), 3.23 (d,
J = 12.0 Hz, 2H), 3.13 (dd, J = 31.5, 12.5 Hz, 2H), 2.30 (s, 3H), 2.28 (s, 3H), 1.32 (d, J
= 7.2 Hz, 3H), 1.20 (d, J = 6.3 Hz, 6H). UPLC-MS Method 5: RT = 1.72 min.
Example 56: isopropyl (2S)[[3-[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazol
yl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinecarboxylate
3-(Ethyliminomethyleneamino)-N,N-dimethyl-propanamine hydrochloride (219 mg,
1.14 mmol) was added to a solution of (2S)[[3-(aminocarbamothioylamino)-2,5-
dimethyl-phenyl]methyl]methyl-piperazinecarboxylate from Preparation 25 (150
mg, 0.38 mmol) and (2R)hydroxypropanoic acid (41.2 mg, 0.46 mmol) in
dichloromethane.(15 mL). After 1 h stirring the reaction mixture was purified by basic
preparative HPLC. Clean fractions were evaporated under reduced pressure to give title
compound as a colourless solid (16.0 mg, 29.4%).
H NMR (600 MHz, DMSO-d6) δ = 9.34 (s, 1H), 7.38 (s, 1H), 6.84 (s, 1H), 5.78 (d, J =
.5 Hz, 1H), 4.74-4.82 (m, 2H), 4.12 (s, 1H), 3.70 (d, J = 12.9 Hz, 1H), 3.37 (q, J =
.4 Hz, 2H), 2.95 (t, J = 12.2 Hz, 1H), 2.69-2.72 (m, 1H), 2.58-2.62 (m, 1H), 2.25 (s,
3H), 2.21 (s, 3H), 2.08 (d, J = 8.2 Hz, 1H), 1.90 (td, J = 11.7, 3.5 Hz, 1H), 1.44 (d, J =
6.6 Hz, 3H), 1.17 (dd, J = 6.2, 1.0 Hz, 6H), 1.13 (d, J = 6.7 Hz, 3H). UPLC-MS Method
: RT = 1.83 min.
Example 63: isopropyl (2S)[[5-chloro[[5-[(1S)hydroxyethyl]-1,3,4-oxadiazol-
2-yl]amino]methyl-phenyl]methyl]methyl-piperazinecarboxylate
3-(Ethyliminomethyleneamino)-N,N-dimethyl-propanamine hydrochloride (14.8 mg,
0.077 mmol) was added to a solution of isopropyl (2S)[[3-
(aminocarbamothioylamino)chloromethyl-phenyl]methyl]methyl-piperazine
carboxylate from Preparation 16 (8.0 mg, 0.019 mmol) and (2S)hydroxypropanoic
acid (3.0 mg, 0.023 mmol) in dichloromethane (0.8 mL). After 5 h stirring the reaction
mixture was purified by basic preparative HPLC. Clean fractions were evaporated under
reduced pressure to give title compound as a colourless solid (2.6 mg, 12%).
H NMR (600 MHz, DMSO-d6) δ = 9.66 (s, 1H), 7.83 (d, J = 2.2 Hz, 1H), 7.10 (d, J =
2.3 Hz, 1H), 5.84 (d, J = 5.5 Hz, 1H), 4.80 – 4.85 (m, 1H), 4.77 (h, J = 6.3 Hz, 1H),
4.13 (s, 1H), 3.70 – 3.73 (m, 1H), 3.42 (s, 2H), 2.98 (t, J = 12.4 Hz, 1H), 2.71 (d, J =
11.3 Hz, 1H), 2.59 (dt, J = 13.1, 2.7 Hz, 1H), 2.24 (s, 3H), 2.11 (dd, J = 11.4, 3.9 Hz,
1H), 1.95 (td, J = 11.7, 3.6 Hz, 1H), 1.46 (d, J = 6.6 Hz, 3H), 1.17 (dd, J = 6.2, 0.8 Hz,
6H), 1.14 (d, J = 6.7 Hz, 3H). UPLC-MS Method 5: RT = 2.08 min.
Example 65: isopropyl (2S)[[2,5-dimethyl[[5-[(2S)methylsulfonylpyrrolidin
yl]-1,3,4-oxadiazolyl]amino]phenyl]methyl]methyl-piperazinecarboxylate
Methanesulfonyl chloride (4.57 mg, 0.04 mmol) was added to a solution of pyrrolidine
compound from Preparation 58 (19.0 mg, 0.04 mmol) and diisopropylethylamine (0.04
mL, 0.21 mmol) in dimethylformamide (0.8 mL) and stirred at room temperature for 0.5
h. The mixture was purified directly by acidic preparative HPLC. Clean fractions were
evaporated under reduced pressure to give title compound. (4.3 mg, 24 %).
H NMR (600 MHz, DMSO-d6) δ = 9.40 (s, 1H), 7.39 (d, J = 1.7 Hz, 1H), 6.84 (d, J = 1.7
Hz, 1H), 5.03 (dd, J = 8.2, 4.0 Hz, 1H), 4.77 (hept, J = 6.2 Hz, 1H), 4.12 (dq, J = 10.7,
6.2 Hz, 1H), 3.70 (dt, J = 13.1, 2.7 Hz, 1H), 3.40 (m, 4H), 3.02 (s, 3H), 2.96 (td, J =
12.9, 3.4 Hz, 1H), 2.71 (ddt, J = 11.1,3.6, 1.9 Hz, 1H), 2.60 (dt, J = 11.2, 1.8 Hz, 1H),
2.29 (m, 1H), 2.25 (s, 3H), 2.22 (s, 3H), 2.11 (m, 2H), 2.01 (m, 2H), 1.90 (td, J =
11.7, 3.5 Hz, 1H), 1.17 (dd, J = 6.2, 1.0 Hz, 6H), 1.13 (d, J = 6.7 Hz, 3H). UPLC-MS
Method 5: m/z 535.3 [M+H ]; RT = 1.95 min.
Example 66: isopropyl (2S)[[3-[[5-[(1S)hydroxyethyl]-1,3,4-oxadiazol
yl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinecarboxylate
3-(Ethyliminomethyleneamino)-N,N-dimethyl-propanamine hydrochloride (292 mg,
1.52 mmol) was added to a solution of (2S)[[3-(aminocarbamothioylamino)-2,5-
dimethyl-phenyl]methyl]methyl-piperazinecarboxylate from Preparation 25 (200
mg, 0.51 mmol) and (2S)hydroxypropanoic acid (50.0 mg, 0.56 mmol) in
dichloromethane.(5 mL). After 3 h the reaction mixture was quenched with water (2.0
mL) and extracted with dichloromethane (5.0 mL). The organic layer was collected and
concentrated under reduced pressure. The obtained residue was purified by silica gel
(100-200 mesh) column chromatography eluting with a gradient of 0-85% ethyl acetate
in heptanes. Clean fractions were evaporated under reduced pressure to give title
compound as a colourless solid. (124 mg, 56.6%) NMR and MS data as shown below.
Alternative preparation
3-(Ethyliminomethyleneamino)-N,N-dimethyl-propanamine hydrochloride (11.7 g,
60.9 mmol) was added to a solution of (2S)[[3-(aminocarbamothioylamino)-2,5-
dimethyl-phenyl]methyl]methyl-piperazinecarboxylate from Preparation 25 (6.00
g, 15.2 mmol) and (2S)hydroxypropanoic acid (2.20 g, 24.1 mmol) in acetonitrile (15
mL) at 0°C. The reaction mixture was stirred at room temperature for 48 h. Lithium
hydroxide solution (91.5 mL, 1.0 M) was added to the reaction mixture and stirred for
min. To the reaction mixture was added water (100 mL) followed by acetic acid (5.23
mL, 91.5 mmol). The mixture was reduced to low volume in vacuo. The aqueous residue
was neutralised with saturated NaHCO (aq) and extracted with ethyl acetate (3 x 250
mL). The combined organic layers were washed with saturated brine, dried over MgSO ,
filtered and concentrated in vacuo. The obtained residue was purified by silica gel (100-
200 mesh) column chromatography eluting with a gradient of 20-100% ethyl acetate in
heptanes. Clean fractions were evaporated under reduced pressure to give title
compound as a colourless non-crystalline solid. (3.05 g, 46.4%) This obtained material
(2.58 g, 5.98 mmol) was dissolved in diethyl ether (25.8 mL, 10 mL/g). The mixture was
left to crystallize over 12 h. The crystals were collected and dried in vacuo to give the
title material as a crystalline solid. (2.31 g, melting point 120-121 °C, 89.5%).
H NMR (600 MHz, DMSO-d6) δ = 9.34 (s, 1H), 7.38 (d, J = 1.7 Hz, 1H), 6.85 (d, J =
1.7 Hz, 1H), 5.79 (d, J = 5.5 Hz, 1H), 4.69-4.78 (m, 2H), 4.12 (s, 1H), 3.70 (dt, J =
13.0, 2.7 Hz, 1H), 3.33 – 3.43 (m, 2H), 2.90-3.02 (m, 1H), 2.71 (ddt, J = 11.1, 3.6, 1.9
Hz, 1H), 2.60 (dt, J = 11.2, 2.0 Hz, 1H), 2.25 (s, 3H), 2.21 (s, 3H), 2.08 (dd, J = 11.3,
3.8 Hz, 1H), 1.90 (td, J = 11.7, 3.5 Hz, 1H), 1.44 (d, J = 6.6 Hz, 3H), 1.17 (dd, J = 6.2,
1.0 Hz, 6H), 1.13 (d, J = 6.7 Hz, 3H). UPLC-MS Method 5: RT = 1.83 min.
Example 67: isopropyl (2S)[[5-chloromethyl[[5-(5-oxopyrrolidinyl)-1,3,4-
oxadiazolyl]amino]phenyl]methyl]methyl-piperazinecarboxylate
O N O
Cl O
3-(ethyliminomethyleneamino)-N,N-dimethyl-propanamine hydrochloride (14.8 mg,
0.077 mmol) was added to a solution of isopropyl (2S)[[3-
(aminocarbamothioylamino)chloromethyl-phenyl]methyl]methyl-piperazine
carboxylate from Preparation 16 (8.0 mg, 0.019 mmol) and 2-oxopyrrolidine
carboxylic acid (3.0 mg, 0.023 mmol) in dichloromethane (0.8 mL). After 5 h stirring the
reaction mixture was purified by basic preparative HPLC. Clean fractions were
evaporated under reduced pressure to give title compound as a colourless solid (2.6 mg,
27%).
H NMR (600 MHz, DMSO-d6) δ = 9.62 (s, 1H), 7.81-7.85 (m, 2H), 7.09 (d, J = 2.3 Hz,
1H), 4.77 (hept, J = 6.3 Hz, 1H), 4.13 (s, 1H), 3.88 (dddd, J = 9.5, 8.3, 6.8, 5.7 Hz,
1H), 3.69-3.73 (m, 1H), 3.63 – 3.67 (m, 1H), 3.46 – 3.54 (m, 1H), 3.42 (s, 2H), 2.98
(t, J = 12.4 Hz, 1H), 2.71 (d, J = 11.4 Hz, 1H), 2.56 – 2.66 (m, 3H), 2.24 (s, 3H), 2.11
(dd, J = 11.4, 3.9 Hz, 1H), 1.95 (td, J = 11.6, 3.5 Hz, 1H), 1.17 (dd, J = 6.2, 0.9 Hz,
6H), 1.14 (d, J = 6.8 Hz, 3H). UPLC-MS Method 5: RT = 1.99 min.
Example 68: isopropyl (2S)[[3-[[5-[(1R)aminoethyl]-1,3,4-oxadiazol
yl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinecarboxylate
3-(Ethyliminomethyleneamino)-N,N-dimethyl-propanamine hydrochloride (46.4 mg,
0.24 mmol) was added to a solution of (2S)[[3-(aminocarbamothioylamino)-2,5-
dimethyl-phenyl]methyl]methyl-piperazinecarboxylate from Preparation 25 (32.0
mg, 0.08 mmol) and (2R)(tert-butoxycarbonylamino)propanoic acid (16.9 mg, 0.09
mmol) in dichloromethane (3.0 mL) and stirred for 2.5 h. The reaction mixture was
quenched with water (2.0 mL) and extracted with dichloromethane (5.0 mL). The
organic layer was collected and concentrated under reduced pressure. The obtained
residue was purified by silica gel (100-200 mesh) column chromatography eluting with a
gradient of 0-70% ethyl acetate in heptane. Clean fractions were evaporated under
reduced pressure to give intermediate compound isopropyl (2S)[[3-[[5-[(1R)(tert-
butoxycarbonylamino)ethyl]-1,3,4-oxadiazolyl]amino]-2,5-dimethyl-phenyl]methyl]-
2-methyl-piperazinecarboxylate (21.0 mg, 0.04 mmol, 48.7%). Hydrogen chloride
(0.6 mL, 4M in dioxane) was added to a solution of the intermediate isopropyl (2S)
[[3-[[5-[(1R)(tert-butoxycarbonylamino)ethyl]-1,3,4-oxadiazolyl]amino]-2,5-
dimethyl-phenyl]methyl]methyl-piperazinecarboxylate (21.0 mg, 0.04 mmol) in
dichloromethane (5.0 mL) and stirred for 2 h. The resulting suspension was diluted with
methanol and purified on 1g SCX column, eluting with methanol followed by methanolic
ammonia (2N). Clean fractions were evaporated under reduced pressure to give title
compound as a colourless solid (16.0 mg, 0.037 mmol, 93.9%).
H NMR (300 MHz, CDCl ) δ = 7.53 (d, J = 1.7 Hz, 1H), 6.97-7.04 (m, 1H), 6.75 (d, J =
1.7 Hz, 1H), 5.04 (d, J = 8.6 Hz, 1H), 4.77 – 4.97 (m, 2H), 4.17 (s, 1H), 3.76 (d, J =
13.1 Hz, 1H), 3.32 (s, 2H), 2.98 (td, J = 12.7, 3.4 Hz, 1H), 2.64 (d, J = 11.3 Hz, 1H),
2.50 (dt, J = 11.0, 1.8 Hz, 1H), 2.25 (s, 3H), 2.22 (s, 3H), 2.09 (dd, J = 11.2, 3.9 Hz,
1H), 1.85 – 1.96 (m, 1H), 1.50 (d, J = 6.9 Hz, 3H), 1.16 (d, J = 6.2 Hz, 6H), 1.12 (d, J
= 6.7 Hz, 3H). UPLC-MS Method 5: RT = 1.68 min.
Example 69: 2,2,2-trifluoroethyl (2S)[[5-chloro[[5-(cyanomethyl)-1,3,4-
oxadiazolyl]amino]methyl-phenyl]methyl]methyl-piperazinecarboxylate
2,2,2-trifluoroethyl carbonochloridate (4.12 mg, 0.025 mmol) was added to a solution of
2-[5-[5-chloromethyl[[(3S)methylpiperazinyl]methyl]anilino]-1,3,4-
oxadiazolyl]acetonitrile dihydrochloride from Preparation 54 (10.0 mg, 0.023 mmol)
and triethylamine (0.016 mL, 0.115 mmol) in dichloromethane (0.7 mL). The reaction
was complete after 1h. The reaction mixture was evaporated under reduced pressure
then diluted with dimethylformamide (0.4 mL). To this was added lithium hydroxide
solution (0.03mL, 1N) and the reaction was stirred for 1 h. The reaction was purified by
basic HPLC. Clean fractions were evaporated under reduced pressure to give title
compound as a colourless solid (0.8 mg, 8%).
H NMR (600 MHz, DMSO-d6) δ = 9.81 (s, 1H), 7.77 (d, J = 2.2 Hz, 1H), 7.14 (d, J =
2.2 Hz, 1H), 4.65-4.76 (m, 2H), 4.50 (s, 2H), 4.15 (s, 1H), 3.73 (d, J = 13.1 Hz, 1H),
3.44 (s, 2H), 3.09 (s, 1H), 2.75 (d, J = 11.4 Hz, 1H), 2.61-2.64 (m, 1H), 2.25 (s, 3H),
2.16 (dd, J = 11.5, 3.9 Hz, 1H), 2.00 (td, J = 11.8, 3.5 Hz, 1H), 1.18 (d, J = 6.8 Hz,
3H). UPLC-MS Method 5: RT = 2.39 min.
Example 70: 2,2,2-trifluoroethyl (2S)[[3-[[5-(3-hydroxycyclobutyl)-1,3,4-oxadiazol-
2-yl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinecarboxylate
HO N
N N O
A solution of 2,2,2-trifluoroethyl carbonochloridate in dichloromethane (0.15 mL, 0.18 M,
0.027 mmol) was added to a solution of 3-[5-[2,5-dimethyl[[(3S)methylpiperazin-
1-yl]methyl]anilino]-1,3,4-oxadiazolyl]cyclobutanol dihydrochloride from
Preparation 55 (12.0 mg, 0.027 mmol) and triethylamine (0.03 mL, 0.22 mmol) in
dichloromethane (0.8 mL). The resulting mixture was stirred for 30 min, a further
aliquot of 2,2,2-trifluoroethyl carbonochloridate in dichloromethane (0.15 mL, 0.18 M,
0.027 mmol) was added and stirring continued. After 1 h the reaction mixture was
evaporated under reduced pressure then diluted with dimethylformamide (0.6 mL) and
purified by basic HPLC. Clean fractions were evaporated under reduced pressure to give
title compound as a colourless solid (1.0 mg, 11%).
H NMR (600 MHz, DMSO-d6) δ = 9.23 (s, 1H), 7.41 (s, 1H), 6.83 (s, 1H), 5.31 (d, J =
6.5 Hz, 1H), 4.64-4.77 (m, 2H), 4.06-4.15 (m, 2H), 3.72 (d, J = 13.1 Hz, 1H), 3.38 (q, J
= 12.8 Hz, 2H), 3.04 (td, J = 10.8, 10.1, 5.7 Hz, 2H), 2.73-2.76 (m, 1H), 2.63 (dt, J =
11.1, 1.7 Hz, 1H), 2.54-2.61(m, 2H), 2.25 (s, 3H), 2.21 (s, 3H), 2.06-2.13 (m, 3H),
1.94 (td, J = 11.7, 3.6 Hz, 1H), 1.17 (d, J = 6.7 Hz, 3H). UPLC-MS Method 5: RT = 1.96
min.
Example 71: ethyl (2S)[[3-[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazolyl]amino]-
2,5-dimethyl-phenyl]methyl]methyl-piperazinecarboxylate
Ethyl carbonochloridate in dichloromethane (0.024 mL, 0.024 mmol) was added to a
solution of (1R)[5-[2,5-dimethyl[[(3S)methylpiperazinyl]methyl]anilino]-
1,3,4-oxadiazolyl]ethanol dihydrochloride from Preparation 52 (10.0 mg, 0.024
mmol) and triethylamine (14.5 mg, 0.143 mmol) in dichloromethane (0.7 mL). After 2h
the reaction mixture was evaporated under reduced pressure and then diluted with
dimethylformamide (0.6 mL) and purified by basic HPLC. Clean fractions were
evaporated under reduced pressure to give title compound as a colourless solid (0.5 mg,
%).
H NMR (600 MHz, DMSO-d6) δ = 7.38 (d, J = 1.7 Hz, 1H), 6.84 (d, J = 1.6 Hz, 1H),
5.84 (s, 1H), 4.78 (q, J = 6.6 Hz, 1H), 4.10-4.15 (m, 1H), 4.03 (qq, J = 10.8, 7.1 Hz,
2H), 3.71 (d, J = 13.0 Hz, 1H), 2.93-3.02 (m, 1H), 2.71 (d, J = 12.0 Hz, 1H), 2.56 –
2.66 (m, 1H), 2.25 (s, 3H), 2.21 (s, 3H), 2.08 (dd, J = 11.3, 3.9 Hz, 1H), 1.99 (dt, J =
18.9, 7.0 Hz, 1H), 1.90 (td, J = 11.7, 3.5 Hz, 1H), 1.44 (d, J = 6.6 Hz, 3H), 1.17 (t, J =
7.1 Hz, 3H), 1.13 (d, J = 6.7 Hz, 3H). UPLC-MS Method 5: RT = 1.73 min.
Example 72: isopropyl (2S)[[3-[[5-[(1S)-1,2-dihydroxyethyl]-1,3,4-oxadiazol
yl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinecarboxylate
3-(Ethyliminomethyleneamino)-N,N-dimethyl-propanamine hydrochloride (29.2 mg,
0.15 mmol) was added to a solution of isopropyl(2S)[[3(aminocarbamothioylamino)-
2,5-dimethyl-phenyl]methyl]methyl-piperazinecarboxylate (20.0 mg, 0.051 mmol)
and 4S)-2,2-dimethyl-1,3-dioxolanecarboxylic acid Preparation 25 (8.17mg, 0.056
mmol) dissolved in dry dichloromethane (5 mL) and stirred at room temperature for 12
h. The reaction mixture was quenched with water (2.0 mL) and extracted with
dichloromethane (5.0 mL). The organic layer was collected and concentrated under
reduced pressure. The obtained residue was purified by silica gel (100-200 mesh)
column chromatography eluting with a gradient of 10-100% ethyl acetate in heptane.
Clean fractions were evaporated under reduced pressure to give intermediate compound
isopropyl
(2S)[[3-[[5-[(4S)-2,2-dimethyl-1,3-dioxolanyl]-1,3,4-oxadiazolyl]amino]-2,5-
dimethyl-phenyl]methyl]methyl-piperazinecarboxylate (22.0 mg, 0.045 mmol,
88.8%). Hydrogen chloride (0.6 mL, 4M in dioxane) was added to a solution of the
intermediate isopropyl-(2S)[[3-[[5-[(4S)-2,2-dimethyl-1,3-dioxolanyl]-1,3,4-
oxadiazolyl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinecarboxylate
(22.0 mg, 0.045 mmol, 88.8%) in dichloromethane (5.0 mL). After 1 h the solvent was
removed under reduced pressure and the residue was dissolved in toluene and
evaporated under reduced pressure (2 x 20 mL). The crude product was purified by
basic HPLC. Clean fractions were evaporated under reduced pressure to give title
compound as a colourless solid (9.0 mg, 39.5%).
H NMR (600 MHz, DMSO-d6) δ = 7.39 (d, J = 1.7 Hz, 1H), 6.84 (d, J = 1.7 Hz, 1H),
.92 (s, 1H), 4.98 (s, 1H), 4.77 (h, J = 6.3 Hz, 1H), 4.61 (t, J = 6.7 Hz, 1H), 4.12 (dt, J
= 11.5, 4.6 Hz, 1H), 3.70 (dt, J = 13.1, 2.6 Hz, 1H), 3.65 (d, J = 6.6 Hz, 2H), 3.39 (m,
2H), 2.93-2.98 (m, 1H), 2.65 – 2.75 (m, 1H), 2.60 (dt, J = 11.2, 1.9 Hz, 1H), 2.25 (s,
3H), 2.21 (s, 3H), 2.02-2.12 (m, 1H), 1.90 (td, J = 11.7, 3.5 Hz, 1H), 1.17 (d, J = 6.2
Hz, 6H), 1.13 (d, J = 6.7 Hz, 3H). UPLC-MS Method 5: RT = 1.74 min.
Example 74: tert-butyl (2S)[[5-chloro[[5-(hydroxymethyl)oxazolyl]amino]
methyl-phenyl]methyl]methyl-piperazinecarboxylate
Lithium aluminium hydride (2.3 M in THF, 0.026 mL, 0.061 mmol) was added to a
solution of ethyl 2-[3-[[(3S)tert-butoxycarbonylmethyl-piperazinyl]methyl]
chloromethyl-anilino]oxazolecarboxylate Preparation 50 (130 mg, 0.26 mmol) in
tetrahydrofuran at 0 C. After 1h of stirring the mixture was quenched with water and
extracted with ethyl acetate (3x 10 mL). The organic phase was washed with brine and
water, dried over magnesium sulphate and evaporated under reduced pressure. The
residue was purified by basic HPLC. Clean fractions were evaporated under reduced
pressure to give title compound (4.0 mg, 21.8%).
H NMR (600 MHz, DMSO-d6) δ = 9.22 (s, 1H), 7.97 (d, J = 2.2 Hz, 1H), 7.01 (d, J =
2.2 Hz, 1H), 6.78 (s, 1H), 5.19 (t, J = 5.4 Hz, 1H), 4.37 (d, J = 4.7 Hz, 2H), 4.09 (m,
1H), 3.67 (dt, J = 13.1, 2.7 Hz, 1H), 3.44 – 3.36 (m, 2H), 2.93 (t, J = 12.2, 1H), 2.69
(dp, J = 11.2, 1.9 Hz, 1H), 2.58 (dt, J = 11.3, 1.9 Hz, 1H), 2.22 (s, 3H), 2.09 (dd, J =
11.3, 3.9 Hz, 1H), 1.92 (td, J = 11.6, 3.5 Hz, 1H), 1.39 (s, 9H), 1.13 (d, J = 6.7 Hz,
3H). UPLC-MS Method 5: RT = 2.21 min.
Example 75: [(1R)-2,2,2-trifluoromethyl-ethyl] (2S)[[3-[[5-[(1S)-1,2-
dihydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5-dimethyl-phenyl]methyl]methyl-
piperazinecarboxylate
Bis(trichloromethyl) carbonate (150 mg, 0.49 mmol) was added to a solution of (2R)-
1,1,1-trifluoropropanol (160 mg, 1.40mmol) and triethylamine (0.17 mL, 1.20 mmol)
in dichloromethane (6.0 mL) at 0 C. On complete addition the reaction mixture was
warmed to room temperature over 4 hr, whereupon the complete reaction mixture was
added to a solution of product from Preparation 56 (476 mg, 1.20 mmol) and
triethylamine (1.67 mL, 12.0 mmol) in dimethylformamide (20 mL) at room
temperature. The reaction was stirred for 18 h then the solvent was removed in vacuo.
The residue was dissolved in water (40 mL) and extracted with ethyl acetate (2 x 40
mL).The combined organic layers were dried over Na2SO4, filtered and concentrated in
vacuo. The obtained residue was purified by silica gel (100-200 mesh) column
chromatography eluting with a gradient of 0-100% ethyl acetate in heptane. Clean
fractions were evaporated under reduced pressure to give the title compound as a
colourless non-crystalline solid (140 mg, 23.3%).
H NMR (600 MHz, DMSO-d6) δ = 9.35 (s, 1H), 7.40 (s, 1H), 6.85 (s, 1H), 5.91 (d, J =
.2 Hz, 1H), 5.33 (p, J = 6.7 Hz, 1H), 4.96 (t, J = 6.0 Hz, 1H), 4.61 (td, J = 6.6, 5.2 Hz,
1H), 4.15 (s, 1H), 3.70 (d, J = 13.2 Hz, 1H), 3.65 (t, J = 6.3 Hz, 2H), 3.33-3.45 (m,
2H), 3.05 (bs, 1H), 2.72-2.77 (m, 1H), 2.64 (d, J = 11.4 Hz, 1H), 2.25 (s, 3H), 2.21 (s,
3H), 2.13 (d, J = 11.5 Hz, 1H), 1.89-1.97 (m, 1H), 1.35 (d, J = 6.6 Hz, 3H), 1.16 (d, J
= 6.7 Hz, 3H). UPLC-MS Method 6: m/z 502.2 [M+H ]; RT = 1.88 min.
Example 76: isopropyl (2S)[[2,5-dimethyl[[5-[(3R)-tetrahydrofuranyl]-1,3,4-
oxadiazolyl]amino]phenyl]methyl]methyl-piperazinecarboxylate
3-(Ethyliminomethyleneamino)-N,N-dimethyl-propanamine hydrochloride (29.2 mg,
0.15 mmol) was added to a solution of product from Preparation 25 (15.0 mg, 0.04
mmol) and (3R)-tetrahydrofurancarboxylic acid (6.20 mg, 0.05 mmol) in
dichloromethane at room temperature. The mixture was stirred for 1 h then
concentrated to dryness in vacuo. The residue was re-dissolved in 1,4-dioxan (0.5 mL)
and lithium hydroxide solution added (0.2 mL, 1.0 M). The mixture was stirred for 0.5 h.
The reaction mixture was purified by basic preparative HPLC. Clean fractions were
evaporated under reduced pressure to give title compound as a colourless oil (16 mg,
91%).
H NMR (600 MHz, DMSO-d6) δ : 7.39 (s, 1H), 6.83 (s, 1H), 4.77 (hept, J = 6.2 Hz, 1H),
4.11 (hept, J = 8.9, 6.6 Hz, 1H), 3.97 (dd, J = 8.6, 7.6 Hz, 1H), 3.84 (ddd, J = 10.8,
8.3, 5.8 Hz, 2H), 3.77 (td, J = 7.9, 6.6 Hz, 1H), 3.70 (dt, J = 12.9, 2.6 Hz, 1H), 3.62
(ddt, J = 8.9, 7.6, 5.8 Hz, 1H), 3.34-3.41 (m, 2H), 2.95 (m, 1H), 2.70 (ddt, J = 11.1,
3.4, 1.8 Hz, 1H), 2.59 (dt, J = 11.2, 1.8 Hz, 1H), 2.25-2.31 (m, 1H), 2.24 (s, 3H), 2.20
(s, 3H), 2.15 (ddt, J = 12.4, 7.7, 6.2 Hz, 1H), 2.06- 2.10 (m, 1H), 1.89 (td, J = 11.7,
3.5 Hz, 1H), 1.17 (dd, J = 6.2, 1.1 Hz, 6H), 1.13 (d, J = 6.7 Hz, 3H). UPLC-MS Method
: m/z 458.2 [M+H ]; RT = 1.92 min.
Example 77: isopropyl (2S)[[3-[[5-[(2S,3R)hydroxypyrrolidinyl]-1,3,4-
oxadiazolyl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinecarboxylate
3-(Ethyliminomethyleneamino)-N,N-dimethyl-propanamine hydrochloride (1.0 g,
.0 mmol) was added to a solution of product from Preparation 25 (500 mg, 1.0
mmol) and (2S,3R)tert-butoxycarbonylhydroxy-pyrrolidinecarboxylic acid (300
mg, 1.0 mmol) in dichloromethane (40 mL) and stirred at room temperature for 1.5h.
The mixture was concentrated to dryness in vacuo. The obtained residue was purified by
silica gel (100-200 mesh) column chromatography eluting with a gradient of 0-100%
ethyl acetate in heptanes. Clean fractions were combined and concentrated in vacuo to
leave intermediate product as colourless oil. LCMS Method 4: m/z 473.4 [M+H ]; RT =
0.68 min.
Hydrogen chloride (4M solution in 1,4-dioxane, 2.27 mL, 9.08 mmol) was added to a
solution of this piperazine intermediate (520 mg, 0.91 mmol) in methanol (2 mL) and
stirred at room temperature for 2 h. The reaction mixture was concentrated under
reduced pressure and was purified by silica gel (100-200 mesh) column chromatography
eluting with a gradient of 0-100% ethyl acetate in heptanes. Fractions were pooled and
concentrated in vacuo and the residue obtained was re-purified by basic HPLC (10-100%
MeCN). Clean fractions were combined and evaporated under reduced pressure to give
the title compound as a colourless non-crystalline solid. (208 mg, 48.4 %)
H NMR (600 MHz, DMSO-d6) δ : 9.23 (s, 1H), 7.41 (s, 1H), 6.82 (s, 1H), 4.98 (d, J =
4.9 Hz, 1H), 4.77 (hept, J = 6.3 Hz, 1H), 4.35 (p, J = 5.4 Hz, 1H), 4.17 (d, J = 5.7 Hz,
1H), 4.12 (d, J = 6.4 Hz, 1H), 3.69 (m, 1H), 3.32-3.42 (m, 2H), 3.09 (ddd, J = 9.9, 8.1,
5.8 Hz, 1H), 2.95 (m, 1H), 2.82 (ddd, J = 9.9, 8.1, 6.3 Hz, 1H), 2.71 (d, J = 10.6 Hz,
1H), 2.60 (dt, J = 11.2, 1.7 Hz, 1H), 2.24 (s, 3H), 2.21 (s, 3H), 2.08 (dd, J = 11.4, 3.9
Hz, 1H), 1.96 (ddt, J = 12.2, 8.0, 6.0 Hz, 1H), 1.89 (td, J = 11.7, 3.5 Hz, 1H), 1.77
(dddd, J = 12.6, 8.0, 6.3, 4.9 Hz, 1H), 1.17 (d, J = 6.2 Hz, 6H), 1.13 (d, J = 6.7 Hz,
3H). LCMS Method 5: m/z 473.2 [M+H ]; RT = 1.67 min.
Example 78: cyclopentyl-[(2S)[[3-[[5-[(2S,3R)hydroxypyrrolidinyl]-1,3,4-
oxadiazolyl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinyl]methanone
3-(Ethyliminomethyleneamino)-N,N-dimethyl-propanamine hydrochloride (1.21 g,
6.30 mmol) was added to a solution of product from Preparation 64 (635 mg, 1.58
mmol) and (2S,3R)tert-butoxycarbonylhydroxy-pyrrolidinecarboxylic acid (437
mg, 1.89 mmol) in dichloromethane (10 mL) and stirred at room temperature for 2h.
The reaction mixture was quenched with aqueous brine (10 mL) and extracted with
dichloromethane (40 mL). The organic layer was dried over Na2SO4, filtered and
concentrated in vacuo. The residue was dissolved in 2M AcOH/MeOH and loaded onto
10g SCX cartridge. Washed with methanol then eluted with 2N NH3/MeOH. Relevant
fractions were combined and concentrated in vacuo. The residue was re-purified by silica
gel (100-200 mesh) column chromatography eluting with a gradient of 0-20% of a 4%
methanolic ammonia solution in ethyl acetate. Relevant fractions were combined and
concentrated in vacuo to leave the intermediate material as a colourless oil (724 mg,
1.24 mmol, 78%). LCMS Method 4: m/z 473.4 [M+H ]; RT = 0.67 min.
Trifluoroacetic acid (4.0 mL, 52.2 mmol) was added to a solution of this intermediate
(724 mg, 1.24 mmol) in acetonitrile (4.0 mL) and stirred for 1 h, then concentrated to
dryness. The residue was dissolved in 2M AcOH/MeOH and loaded onto 10g SCX
cartridge. Washed with methanol then eluted with 2N ammonia in methanol. Relevant
fractions were combined and concentrated in vacuo. The residue was dissolved in
acetonitrile and purified by basic preparative HPLC. Clean fractions were evaporated
under reduced pressure to give the title compound (349 mg, 58.2 %).
H NMR (600 MHz, DMSO-d6) δ : 9.23 (s, 1H), 7.41 (s, 1H), 6.82 (s, 1H), 4.99 (d, J =
4.9 Hz, 1H), 4.54 (d, J = 7.4 Hz, 0.5H), 4.35 (p, J = 5.3 Hz, 1H), 4.20 (m, 0.5H)
overlapping 4.17 (d, J = 5.7 Hz, 1H), 3.73 (d, J = 13.3 Hz, 0.5H), 3.16 (t, J = 12.6 Hz,
0.5H), 3.09 (ddd, J = 10.0, 8.1, 5.7 Hz, 1H), 2.91 (q, J = 7.1 Hz, 1H), 2.83 (ddd, J =
.0, 8.2, 6.3 Hz, 1H), 2.77 (m, 0.5H) overlapping 2.73 (d, J = 11.0 Hz, 1H), 2.63 (m,
1H), 2.25 (s, 3H), 2.23 (s, 3H), 2.04 (m, 1H), 1.96 (ddt, J = 12.3, 8.2, 6.0 Hz, 1H),
1.86 (m, 0.5H), 1.77 (dddd, J = 12.8, 8.1, 6.3, 4.9 Hz, 1H), 1.70 (m, 2H), 1.57 (m,
3H), 1.50 (m, 2H), 1.15 (dd, J = 82.7, 6.6 Hz, 3H). ). LCMS Method 6: m/z 483.3
[M+H ]; RT = 1.63 min.
Example 80: [(1R)-2,2,2-trifluoromethyl-ethyl] (2S)[[3-[[5-[(2S,3R)
hydroxypyrrolidinyl]-1,3,4-oxadiazolyl]amino]-2,5-dimethyl-phenyl]methyl]
methyl-piperazinecarboxylate
Using a procedure similar to that described in Example 75, but using the product from
Preparation 66 (30.0 mg, 0.06 mmol) and (2R)-1,1,1-trifluoropropanol (24.0 mg,
0.21 mmol), the intermediate compound was prepared. The crude intermediate product
was purified by basic HPLC. The clean fractions were combined and concentrated in
vacuo to leave the intermediate product as a colourless foam (17.0 mg, 44%). 10%
palladium on carbon (4.0 mg, 0.04 mmol) was added to a solution of the isolated
intermediate (17.0 mg, 0.026 mmol) in ethanol (2 mL) under an atmosphere of
hydrogen and the reaction mixture was stirred for 2 h at room temperature. The reaction
mixture was filtered through a Celite pad and concentrated in vacuo. The obtained
residue was dissolved in methanol and purified by basic HPLC. The clean fractions were
combined and concentrated in vacuo to leave the title product as a colourless non-
crystalline solid (8.0 mg, 62%).
H NMR (600 MHz, DMSO-d6) δ = 9.23 (s, 1H), 7.41 (d, J = 1.7 Hz, 1H), 6.82 (d, J =
1.7 Hz, 1H), 5.33 (hept, J = 6.8 Hz, 1H), 4.98 (d, J = 4.9 Hz, 1H), 4.35 (p, J = 5.3 Hz,
1H), 4.17 (d, J = 5.7 Hz, 1H) overlapping 4.14 (d, J = 9.2 Hz, 1H), 3.70 (d, J = 13.1 Hz,
1H), 3.41 (d, J = 13.0 Hz, 1H), 3.36 (m, 2H), 3.09 (ddd, J = 10.0, 8.1, 5.7 Hz, 1H),
3.05 (m, 1H), 2.82 (ddd, J = 10.0, 8.1, 6.3 Hz, 1H), 2.74 (ddt, J = 11.2, 3.5, 1.8 Hz,
1H), 2.63 (m, 1H), 2.24 (s, 3H), 2.22 (s, 3H), 2.12 (dd, J = 12.0, 4.0 Hz, 1H), 1.95 (m,
2H), 1.77 (dddd, J = 12.8, 8.1, 6.2, 4.8 Hz, 1H), 1.35 (dd, J = 6.6 Hz, 3H), 1.16 (d, J =
6.7 Hz, 3H). UPLC-MS Method 4: RT = 0.71 min.
Example 81: 2,2,2-trifluoroethyl (2S)[[3-[[5-[(2S,3R)hydroxypyrrolidinyl]-
1,3,4-oxadiazolyl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazine
carboxylate
Using a procedure as described in Example 80, using the product from Preparation 66
(29.0 mg, 0.06 mmol) and 2,2,2-trifluoroethanol (70.0 mg, 0.7 mmol), followed by the
intermediate deprotection with palladium on carbon and basic HPLC purification, the title
compound was isolated as a colourless non-crystalline solid. (4.0 mg, 14% overall)
H NMR (600 MHz, DMSO-d6) δ = 9.22 (s, 1H), 7.41 (d, J = 1.7 Hz, 1H), 6.82 (d, J =
1.7 Hz, 1H), 4.97 (d, J = 4.8 Hz, 1H), 4.68 (m, 2H), 4.35 (p, J = 5.4 Hz, 1H), 4.17 (d, J
= 5.7 Hz, 1H), 3.72 (d, J = 13.0 Hz, 1H), 3.38 (d, J = 4.9 Hz, 1H), 3.36 (m, 2H), 3.09
(ddd, J = 9.8, 8.0, 5.6 Hz, 1H), 2.80 (m, 2H), 2.64 (d, J = 11.3 Hz, 1H), 2.24 (s, 3H),
2.22 (s, 3H), 2.12 (dd, J = 11.4, 3.8 Hz, 1H), 1.95 (m, 2H), 1.77 (m, 1H), 1.17 (d, J =
6.7 Hz, 3H). UPLC-MS Method 4: RT = 0.68 min.
Example 82: [(1R)methylpropyl] (2S)[[3-[[5-[(2S,3R)hydroxypyrrolidinyl]-
1,3,4-oxadiazolyl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazine
carboxylate
Using a procedure as described in Example 80, using the product from Preparation 66
(30.0 mg, 0.06 mmol) and (2R)-butanol (90.0 mg, 1.21 mmol), followed by the
intermediate deprotection with palladium on carbon and basic HPLC purification, the title
compound was isolated as a colourless non-crystalline solid. (4.0 mg, 14% overall)
H NMR (600 MHz, DMSO-d6) δ = 9.23 (s, 1H), 7.41 (d, J = 1.7 Hz, 1H), 6.82 (d, J =
1.7 Hz, 1H), 4.98 (d, J = 4.8 Hz, 1H), 4.61 (hept, J = 6.2 Hz, 1H), 4.35 (p, J = 5.3 Hz,
1H), 4.17 (d, J = 5.8 Hz, 1H), 4.14 (t, J = 5.6 Hz, 1H), 3.71 (dt, J = 13.0, 2.7 Hz, 1H),
3.40 (m, 2H), 3.09 (ddd, J = 10.1, 8.1, 5.8 Hz, 1H), 2.96 (m, 1H), 2.82 (ddd, J = 10.0,
8.2, 6.3 Hz, 1H), 2.71 (m, 1H), 2.60 (dt, J = 11.1, 1.9 Hz, 1H), 2.24 (s, 3H), 2.22 (s,
3H), 2.08 (dd, J = 11.3, 3.9 Hz, 1H), 1.96 (m, 1H), 1.89 (td, J = 11.7, 3.5 Hz, 1H), 1.77
(dddd, J = 12.7, 8.1, 6.3, 4.9 Hz, 1H), 1.51 (m, 2H), 1.14 (m, 6H), 0.85 (t, J = 7.4 Hz,
3H). UPLC-MS Method 4: RT = 0.71 min.
Example 83: isopropyl (2S)[[2,5-dimethyl[[5-[(3S)oxopyrrolidinyl]-1,3,4-
oxadiazolyl]amino]phenyl]methyl]methyl-piperazinecarboxylate
Using a procedure similar to that described for Example 3, but with the product from
Preparation 27 (750 mg, 1.91 mmol) and (3S)oxopyrrolidinecarboxylic acid (295
mg, 2.29 mmol) the title compound was prepared. The obtained residue was purified by
silica gel (100-200 mesh) column chromatography eluting with a gradient of 0-15%
methanol in ethyl acetate. Clean fractions were evaporated under reduced pressure to
give title compound as a colourless non-crystalline solid (700 mg, 78%). The obtained
product (15 mg) was dissolved in ethyl acetate (0.1 mL) which crystallized immediately.
The crystalline material was collected and dried under pressure, before being used to
seed the remaining product (650 mg) in ethyl acetate (5 mL). The precipitated material
was collected and dried under pressure to give the title compound as a crystalline solid.
(625 mg, melting point 169-170°C, 93 %)
H NMR (600 MHz, DMSO-d6) δ = 9.33 (s, 1H), 7.80 (s, 1H), 7.39 (d, J = 1.7 Hz, 1H),
6.84 (d, J = 1.7 Hz, 1H), 4.77 (hept, J = 6.3 Hz, 1H), 4.11 (m, 1H), 3.85 (m, 1H), 3.70
(dt, J = 13.0, 2.6 Hz, 1H), 3.63 (m, 1H), 3.45 (dd, J = 9.7, 5.7 Hz, 1H), 3.38 (m, 2H),
2.95 (td, J = 12.9, 3.3 Hz, 1H), 2.70 (dp, J = 11.2, 1.8 Hz, 1H), 2.59 (m, 2H), 2.46 (dd,
J = 16.5, 6.7 Hz, 1H), 2.24 (s, 3H), 2.21 (s, 3H), 2.08 (dd, J = 11.3, 3.9 Hz, 1H), 1.90
(td, J = 11.7, 3.5 Hz, 1H), 1.17 (dd, J = 6.2, 1.0 Hz, 6H), 1.12 (d, J = 6.7 Hz, 3H).
UPLC-MS Method 5: RT = 1.79 min.
ROR-gamma binding assay
This assay is used to evaluate the binding affinity of compounds to the ligand-binding
pocket of the human RORgt nuclear receptor based on displacement of a radio-ligand.
The EC50 values are calculated using a four parameter fit. Compounds binding with high
affinity to RORgt will have low EC values.
The assay is a Scintillation Proximity Assay (SPA) that involves competition between an
unlabeled test compound and tritium-labeled 25-hydroxycholesterol for binding to
RORgT ligand binding domain (LBD) protein immobilized on the surface of SPA beads.
These beads contain a scintillant that emits light if excited by a radioactive particle, and
this light is detected using a scintillation counter. In this assay, tritium-labelled 25-
hydroxycholesterol is used as radiotracer.
400 nL of titrated test and reference compounds in DMSO were transferred by the Echo
liquid handling system to a 384-well assay plate followed by addition of 5 μL [3H]
Hydroxycholesterol (Perkin Elmer) and 35 μL diluted RORgT LBD protein with the
following amino acid sequence (HIS-FLG-tag): MAHHHHHHGS DYKDDDDKGS
SGASLTEIEH LVQSVCKSYR ETCQLRLEDL LRQRSNIFSR EEVTGYQRKS MWEMWERCAH
HLTEAIQYVV EFAKRLSGFM ELCQNDQIVL LKAGAMEVVL VRMCRAYNAD NRTVFFEGKY
GGMELFRALG CSELISSIFD FSHSLSALHF SEDEIALYTA LVLINAHRPG LQEKRKVEQL
QYNLELAFHH HLCKTHRQSI LAKLPPKGKL RSLCSQHVER LQIFQHLHPI VVQAAFPPLY
KELFSTETES PVGLSK (Purchased from Proteros Biostructures GmbH).
After 30 min of preincubation, 40 μL of HIS-TAG PVT SPA beads (Perkin Elmer) were
added. The plates were then incubated for minimum 4 hours at room temperature in
darkness before measuring the SPA signal using a MicroBeta plate scintillation counter.
Final assay conditions were: 50 mM HEPES pH 7.4, 150 mM NaCl, 5 mM MgCl2, 0.1%
BSA, 4 μg/well HIS-TAG PVT SPA Beads, 30 ng/well RORgT LBD (equal to a final
concentration of 12 nM), 15 nM [ H]Hydroxycholesterol, 0.5 % DMSO and varying
concentrations of test compound in a total volume of 80 μL/well. EC50 values were
calculated using a 4-parameter non-linear regression curve-fitting model.
The exemplified compounds were tested in the ROR-gamma binding assay.
Results are shown in Table 2.
Human PBMC IL-17A assay
This assay measures the IL-17A inhibitory potential of test compounds in Human
peripheral mononuclear cells.
Peripheral blood mononuclear cells (PBMC) were isolated from human buffy coats using
density grade centrifugation (Lymphoprep, Medinor), washed twice in PBS and frozen at
-150°C for later use.
Test compounds were diluted in DMSO and 70 nL of titrated test and reference
compounds were transferred by the Echo liquid handling system to a 384-well assay
plate in to give a final concentration of 0.1% DMSO in the wells.
The PBMC were thawed, washed and suspended in RPMI-1640 supplemented with
pen/strep, glutamax and 10 % bovine calf serum. The cells were mixed with
antiCD3/antiCD28-coated beads (1 cells pr one bead) (Milteney T-cell expansion kit),
and immediately thereafter the cells were pipetted to the plate at 130,000c/well. The
plate was incubated for 3 days in humidified air/CO2 (95%/5%) On day 3 the level of IL-
17A in the culture supernatant is measured using alpha-LISA kit (Perkin Elmer). Cell
viability was measured by adding 6 uL pr well Prestoblue© (Life Technologies) and
incubating for 2 hours followed by fluorescent measurement (Ex535/Em615). EC
values were calculated using a 4-parameter non-linear regression curve-fitting model.
Donors may be pre-screened in order to select PBMC with a high secretion of IL-17A.
The exemplified compounds were tested in the Human PBMC IL-17A assay.
Results are shown in Table 2.
Human whole blood IL-17A assay
The EC50 value reported from this assay is a measure of the potency of the tested
compound in inhibiting IL-17A levels in the blood after three days of incubation.
Test compounds were diluted in DMSO and 80 nL of titrated compound is transferred by
the Echo liquid handling system to a 384-well assay plate to give a final concentration of
0.1% DMSO in the wells.
Freshly drawn human peripheral blood stabilized with heparin was diluted 1:1 with X-
vivo 15 medium (Lonza) added pen/strep and glutamax. Staphylococcus enterotoxin B
(Sigma) at 300 ng/mL was added to the diluted blood just prior to pipetting into wells,
80 uL per well. The plates were incubated for 3 days at 37°C in humidified air/CO
(95%/5%). After 3 days of incubation, the level of IL-17A was measured using an alpha-
LISA kit (Perkin Elmer).
EC50 values were calculated using a 4-parameter non-linear regression curve-fitting
model.
The exemplified compounds were tested in the Human whole blood IL-17A assay.
Results are shown in Table 2.
Human liver microsomes (HLM) assay
Compounds of the invention were tested in the Human liver microsomes (HLM) assay.
Incubations of test compounds in DMSO, diluted with phosphate buffer, pH 7.4, at 0.5
μM were carried out with human liver microsomes (0.5 mg/mL). The percentage of
organic solvent in the incubations was 1%. The human liver microsomal suspension in
phosphate buffer was mixed with NADPH (1 mM) and preheated to 37 °C before test
compound was added. Aliquots were taken at 0, 5, 10, 20, 30 and 40 minutes, and
reactions were terminated by addition of cold acetonitrile containing analytical internal
standard (IS).
The results were expressed as apparent clearance (Clapp) (mL/min/kg) and hepatic
extraction ratio (E ) (%) calculated from the elimination rate constant (k) (min ) of test
compound depletion. Apparent clearance is a measure of compound elimination from the
liver.
Table 2
Example ROR-gamma Human Human
binding PBMC IL-17a Whole blood
(nM) (nM) IL-17A (nM)
1 40.2 3,030 NT
2 29 137 454
3 22.3 51.1 204
4 29.9 34.7 428
22.6 69.7 385
6 31.7 234 504
7 33 49.8 219
8 69 251 497
9 23.5 99.3 254
45.4 173 296
11 28.1 92.6 132
12 40.4 128 302
13 14.7 48.9 112
14 61.1 185 372
63.8 101 421
16 223 237 206
17 54.5 230 131
18 21.2 69.8 203
19 92.3 117 216
113 189 259
21 71.7 180 251
22 169 254 355
23 125 368 238
24 38.6 35.9 112
159 258 191
26 58.2 91.3 119
27 95.9 425 457
28 35.5 107 NT
29 37.8 117 422
31.2 93.6 239
31 32.4 63.5 231
32 26.4 101 392
33 23.3 45.2 126
34 24.6 24.8 83.7
33.9 106 499
36 84.1 366 451
37 40.8 43.7 426
38 49.7 58.5 403
39 29.2 38.2 377
40 21.2 212 365
41 91.1 215 373
42 48 34.2 359
43 53.9 63.5 332
44 22.7 26 330
45 42 39.9 330
46 37.1 103 322
47 26.6 63.2 307
48 37.2 191 296
49 90.5 218 275
50 31.6 86.5 272
51 64.4 216 266
52 42.1 134 256
53 68.2 93.9 247
54 16.3 28.1 176
55 39 62.3 36.8
56 36.5 51.9 92.2
57 23.8 46.5 96.7
58 54.4 373 215
59 25.7 123 211
60 38.3 106 195
61 42.3 106 101
62 20.7 67.6 103
63 34.8 62.1 187
64 50.6 131 191
65 47.9 58.7 107
66 54.8 77.6 140
67 62.2 47.2 597
68 103 182 552
69 70 308 NT
70 52.2 78.5 227
71 62 223 307
72 81.6 262 258
73 55.9 59.8 270
74 71.8 408 946
75 32.4 52.9 158
76 25.6 60.5 112
77 61.2 180 368
78 72.5 95.9 157
79 274 1,220 3,530
80 22.3 70 NT
81 110 1,520 NT
82 32 46 NT
83 67 123 240
The following are further embodiments of the invention or are described
herein:
Embodiment 1. A compound according to general formula (I)
wherein X represents N or CH;
R is selected from the group consisting of -CN, (C –C )alkyl, (C –C )cycloalkyl, (3-7
1 1 6 3 7
membered)heterocycloalkyl, (5-6 membered)heteroaryl, (C –C )cycloalkyl(C –C )alkyl,
3 7 1 4
(3-7 membered)heterocycloalkyl-(C –C )alkyl and (5-6 membered)heteroaryl-(C –
1 4 1
C4)alkyl, wherein said (C1–C6)alkyl, (C3–C7)cycloalkyl, (3-7 membered)heterocycloalkyl,
(5membered)heteroaryl, (C3–C7)cycloalkyl(C1–C4)alkyl, (3-7
membered)heterocycloalkyl-(C1–C4)alkyl and (5-6 membered)heteroaryl-(C1–C4)alkyl is
optionally substituted with one or more substituents independently selected from R ;
R is selected from the group consisting of halogen, cyano, (C –C )alkyl and (C –
2 1 4 3
C )cycloalkyl, wherein said (C –C )alkyl and (C –C )cycloalkyl is optionally substituted
7 1 4 3 7
with one or more substituents independently selected from –OH and halogen;
R3 is selected from the group consisting of halogen, cyano, (C1–C4)alkyl, (C1–
C4)haloalkyl and (C3–C7)cycloalkyl;
R is selected from the group consisting of (C –C )alkyl and (C –C )haloalkyl;
4 1 4 1 4
R5 is selected from the group consisting of (C1–C6)alkyl, (C3–C7)cycloalkyl, (C1–C6)alkyl-
(C3–C7)cycloalkyl, (C3–C7)cycloalkyl-(C1–C6)alkyl, (3-7 membered)heterocycloalkyl,
phenyl, (5-6 membered)heteroaryl and -ORa; wherein said (C1–C6)alkyl, (C3–
C7)cycloalkyl, (C1–C6)alkyl-(C3–C7)cycloalkyl, (C3–C7)cycloalkyl-(C1–C6)alkyl, (3-7
membered)heterocycloalkyl, phenyl, (5-6 membered)heteroaryl and -ORa is optionally
substituted with one or more substituents independently selected from R ;
represents the group consisting of –OH, -CN, halogen, =O, -S(O) R , -NR R , -
R6 2 b c d
NRcC(O)Rd, -C(O)NRcRd, -S(O)2NRcRd, -NRcS(O)2Rb, -ORb, -C(O)Rb, (C1–C4)alkyl,
hydroxy(C1–C4)alkyl, halo(C1–C4)alkyl, (C3–C7)cycloalkyl, (3-7
membered)heterocycloalkyl and (5-6 membered)heteroaryl;
R represents the group consisting of –OH, -CN, halogen, (C –C )alkyl, (C -C )cycloalkyl
7 1 4 3 7
and (C –C )alkyl-(C –C )cycloalkyl-;
1 6 3 7
Ra represents (C1–C6)alkyl, (C3–C7)cycloalkyl, (C1–C6)alkyl-(C3–C7)cycloalkyl- or (C3–C7)-
cycloalkyl(C1–C6)alkyl;
Rb represents (C1–C6)alkyl or (C3–C7)cycloalkyl;
Rc and Rd each independently represents H, (C1–C6)alkyl or (C3–C7)cycloalkyl;
or pharmaceutically acceptable salts, hydrates or solvates thereof.
Embodiment 2. The compound according to embodiment 1 wherein X represents N.
Embodiment 3. The compound according to any one of embodiments 1-2 wherein R1 is
selected from the group consisting of -CN, (C –C )alkyl, (C –C )cycloalkyl, (3-7
1 6 3 7
membered)heterocycloalkyl and 5- membered heteroaryl wherein said (C –C )alkyl, (C –
1 6 3
C )cycloalkyl, (3-7 membered)heterocycloalkyl and 5-membered heteroaryl is optionally
substituted with one or more substituents independently selected from R .
Embodiment 4. The compound according to any one of embodiments 1-3 wherein R1 is
selected from the group consisting of (C1–C6)alkyl, (C3–C7)cycloalkyl, (3-7
membered)heterocycloalkyl, wherein said (C1–C6)alkyl, (C3–C7)cycloalkyl, (3-7
membered)heterocycloalkyl is optionally substituted with one or more substituents
independently selected from R ; wherein R represents the group consisting of –OH,
halogen, =O, -S(O) R , -NR R , and -OR R represents methyl or ethyl; R and R
2 b c d b; b c d
independently represents hydrogen, methyl or ethyl.
Embodiment 5. The compound according to any one of embodiments 1-4 wherein R1 is
selected from the group consisting of (3-7 membered)heterocycloalkyl, wherein said
(3-7 membered)heterocycloalkyl is optionally substituted with one or more substituents
independently selected from R ; wherein R represents -S(O) R and R represents (C –
6 6 2 b b 1
C )alkyl.
Embodiment 6. The compound according to any one of embodiments 1-5 wherein R1 is
selected from the group consisting of (C1–C4)alkyl, wherein said (C1–C4)alkyl is
optionally substituted with one or more –OH.
Embodiment 7. The compound according to any one of embodiments 1-6 wherein R is
selected from (5-6 membered)heteroaryl, wherein said (5membered)heteroaryl is
optionally substituted with one or more substituents independently selected from (C –
C4)alkyl.
Embodiment 8. The compound according to any one of embodiments 1-7 wherein R1 is
selected from (3-7 membered)heterocycloalkyl, wherein said (3-7
membered)heterocycloalkyl is optionally substituted with one or more substituents
independently selected from (C –C )alkyl.
Embodiment 9. The compound according to any one of embodiments 1-8 wherein R
represents cyclopropyl, cyclobutyl, oxetanyl, azetidinyl and pyrrolidinyl, wherein said
cyclopropyl, cyclobutyl, oxetanyl, azetidinyl and pyrrolidinyl is optionally substituted
with one or more –OH or =O.
Embodiment 10. The compound according to any one of embodiments 1-9 wherein R is
selected from the group consisting of (C –C )alkyl and pyrrolidinyl, wherein said (C –
1 4 1
C )alkyl and pyrrolidinyl is optionally substituted with one or more –OH.
Embodiment 11. The compound according to any one of embodiments 1-10 wherein R1
is selected from the group consisting of methyl, ethyl, propyl and pyrrolidinyl, wherein
said methyl, ethyl, propyl and pyrrolidinyl is optionally substituted with one or more –
Embodiment 12. The compound according to any one of embodiments 1-11 wherein R
represents –CN, methyl, ethyl, propyl, cyclopropyl, cyclobutyl, oxetanyl,
tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl, oxazolidinyl, morpholinyl,
piperidinyl, triazolyl, pyrrazolyl, isoxazolyl, thiadiazolyl or oxadiazolyl, wherein said
methyl, ethyl, propyl, cyclopropyl, cyclobutyl, oxetanyl, tetrahydrofuranyl,
tetrahydropyranyl, azetidinyl, pyrrolidinyl, oxazolidinyl, morpholinyl, piperidinyl,
triazolyl, pyrrazolyl, isoxazolyl, thiadiazolyl or oxadiazolyl is optionally substituted with
one or more –OH, -S(O) CH , -NH , -CN, =O, fluoro, methyl, methoxy or hydroxymethyl,
2 3 2
Embodiment 13. The compound according to any one of embodiments 1-12 wherein R2
is selected from the group consisting of halogen and (C1–C4)alkyl, wherein said (C1–
C4)alkyl is optionally substituted with one or more substituents independently selected
from halogen.
Embodiment 14. The compound according to any one of embodiments 1-13 wherein R
represents (C –C )alkyl.
Embodiment 15. The compound according to any one of embodiments 1-14 wherein R2
represents methyl.
Embodiment 16. The compound according to any one of embodiments 1-15 wherein R2
and R both represent methyl.
Embodiment 17. The compound according to any one of embodiments 1-16 wherein
each of R2, R3 and R4 represent methyl.
Embodiment 18. The compound according to any one of embodiments 1-17 wherein X
represents N and each of R , R and R represent methyl.
2 3 4
Embodiment 19. The compound according to any one of embodiments 1-18 wherein R
represents chloro or difluoromethyl.
Embodiment 20. The compound according to any one of embodiments 1-19 wherein R2
represents chloro, methyl or difluoromethyl.
Embodiment 21. The compound according to any one of embodiments 1- 20 wherein R
represents (C –C )alkyl.
Embodiment 22. The compound according to any one of embodiments 1-21 wherein R3
represents methyl.
Embodiment 23. The compound according to embodiments 1-22 wherein R4 represents
(C1–C4)alkyl.
Embodiment 24. The compound according to any one of embodiments 1-23 wherein R
represents methyl.
Embodiment 25. The compound according to any one of embodiments 1-24 wherein R5 is
selected from the group consisting of (C1–C6)alkyl, (C3–C7)cycloalkyl, (C1–C6)alkyl-(C3–
C7)cycloalkyl, (C3–C7)cycloalkyl-(C1–C6)alkyl, phenyl and -ORa; wherein said (C1–
C )alkyl, (C –C )cycloalkyl, (C –C )alkyl-(C –C )cycloalkyl, (C –C )cycloalkyl-(C –
6 3 7 1 6 3 7 3 7 1
C )alkyl, phenyl and -OR is optionally substituted with one or more substituents
independently selected from R .
Embodiment 26. The compound according to any one of embodiments 1-25 wherein R5 is
selected from the group consisting of (C1–C6)alkyl, (C3–C7)cycloalkyl, (C1–C6)alkyl-(C3–
C7)cycloalkyl, (C3–C7)cycloalkyl-(C1–C6)alkyl and -ORa; wherein said (C1–C6)alkyl, (C3–
C )cycloalkyl, (C –C )alkyl-(C –C )cycloalkyl, (C –C )cycloalkyl-(C –C )alkyl and -OR is
7 1 6 3 7 3 7 1 6 a
optionally substituted with one or more substituents independently selected from R7;
wherein R represent halogen and R represents (C –C )alkyl.
7 a 1 6
Embodiment 27. The compound according to any one of embodiments 1-26 wherein R is
selected from the group consisting of (C1–C6)alkyl and -ORa; wherein said (C1–C6)alkyl
and -ORa is optionally substituted with one or more substituents independently selected
from R7; wherein Ra represents (C1–C6)alkyl and R7 represent halogen.
Embodiment 28. The compound according to any one of embodiments 1-27 wherein R is
selected from the group consisting of (C –C )alkyl and -OR ; wherein said (C –C )alkyl
1 6 a 1 6
and -OR is optionally substituted with one or more fluoro and wherein R represents
ethyl, propyl or isopropyl.
Embodiment 29. The compound according to any one of embodiments 1-28 wherein R5
represents phenyl; wherein said phenyl is optionally substituted with one or more
substituents independently selected from R .
Embodiment 30. The compound according to any one of embodiments 1-29 wherein R
represents phenyl; wherein said phenyl is optionally substituted with one or more
halogen.
Embodiment 31. The compound according to any one of embodiments 1-30 wherein R5
represents cyclopentyl; wherein said cyclopentyl is optionally substituted with one or
more fluoro.
Embodiment 32. The compound according to any one of embodiments 1-31 wherein R5
represents phenyl, propyl, butyl, ethoxy, iso-propyloxy, tert-butyloxy, cyclopropyl,
cyclobutyl, cyclopentyl, methylcyclopropyl or cyclobutylmethyl.
Embodiment 33. The compound according to any one of embodiments 1-32 wherein R5
represents phenyl, propyl, butyl, ethoxy, iso-propyloxy, tert-butyloxy, cyclopropyl,
cyclobutyl, cyclopentyl, methylcyclopropyl or cyclobutylmethyl; wherein said phenyl,
propyl, butyl, ethoxy, iso-propyloxy, tert-butyloxy, cyclopropyl, cyclobutyl, cyclopentyl,
methylcyclopropyl or cyclobutylmethyl is optionally substituted with one or more fluoro.
Embodiment 34. The compound according to any one of embodiments 1-33 wherein R6
represents the group consisting of –OH, -CN, halogen, =O, -S(O)2Rb, -NRcRd, -ORb, (C1–
C )alkyl and hydroxy(C –C )alkyl.
4 1 4
Embodiment 35. The compound according to any one of embodiments 1-34 wherein R
represents -OH, -CN, fluoro, -NH2, =O, -S(O) CH , methyl, methoxy or hydroxymethyl.
Embodiment 36. The compound according to any one of embodiments 1-35 wherein R6
represents –OH.
Embodiment 37. The compound according to any one of embodiments 1-36 wherein R
represents halogen.
Embodiment 38. The compound according to any one of embodiments 1-37 wherein R
represents fluoro.
Embodiment 39. The compound according to any one of embodiments 1-38 wherein R7
represents fluoro or –OH.
Embodiment 40. The compound according to any one of embodiments 1-39 wherein R
represents (C –C )alkyl optionally substituted with one or more halogen.
Embodiment 41. The compound according to any one of embodiments 1-40 wherein Rb
represents (C1–C6)alkyl.
Embodiment 42. The compound according to any one of embodiments 1-41 wherein Rb
represents methyl.
Embodiment 43. The compound according to any one of embodiments 1-42 wherein Rc
and Rd each independently represents H or (C1–C6)alkyl.
Embodiment 44. The compound according to any one of embodiments 1-43 wherein Rc
and Rd each independently represents H or methyl.
Embodiment 45. The compound according to any one of embodiments 1-44 wherein R
is selected from the group consisting of (C –C )alkyl and pyrrolidinyl, wherein said (C –
1 4 1
C4)alkyl and pyrrolidinyl is optionally substituted with one or more –OH; and wherein R2
represents halogen or (C1–C4)alkyl which is optionally substituted with one or more
halogen; R3 represents (C1–C4)alkyl; R4 represents (C1–C4)alkyl; R5 is selected from the
group consisting of (C1–C6)alkyl, (C3–C7)cycloalkyl, (C1–C6)alkyl-(C3–C7)cycloalkyl, (C3–
C )cycloalkyl-(C –C )alkyl and -OR ; wherein said (C –C )alkyl, (C –C )cycloalkyl, (C –
7 1 6 a 1 6 3 7 1
C6)alkyl-(C3–C7)cycloalkyl, (C3–C7)cycloalkyl-(C1–C6)alkyl and -ORa is optionally
substituted with one or more substituents independently selected from R ; wherein R
represent halogen and R represents (C –C )alkyl and X represents N; or
a 1 6
pharmaceutically acceptable salts, hydrates or solvates thereof.
Embodiment 46. The compound according to any one of embodiments 1-45 wherein R1
is selected from the group consisting of (C1–C4)alkyl and pyrrolidinyl, wherein said (C1–
C )alkyl and pyrrolidinyl is optionally substituted with one or more –OH; wherein X
represents N; wherein each of R , R and R represent methyl; and wherein R is selected
2 3 4 5
from the group consisting of (C –C )alkyl and -OR , said (C –C )alkyl and -OR optionally
1 6 a 1 6 a
being substituted with one or more substituents independently selected from R and
wherein R represents fluoro and R represents ethyl, propyl or isopropyl¸ or
pharmaceutically acceptable salts, hydrates or solvates thereof.
Embodiment 47. The compound according to any one of embodiments 46 wherein R1 is
selected from the group consisting of (C –C )alkyl, (C –C )cycloalkyl, (3-7
1 6 3 7
membered)heterocycloalkyl, wherein said (C –C )alkyl, (C –C )cycloalkyl, (3-7
1 6 3 7
membered)heterocycloalkyl is optionally substituted with one or more substituents
independently selected from R6; wherein R6 represents the group consisting of –OH,
halogen, =O, -S(O)2Rb, -NRcRd, and -ORb; Rb represents methyl or ethyl; Rc and Rd
independently represents hydrogen, methyl or ethyl; and wherein R2 represents halogen
or (C1–C4)alkyl which is optionally substituted with one or more halogen; R3 represents
(C1–C4)alkyl; R4 represents (C1–C4)alkyl; R5 is selected from the group consisting of
(C –C )alkyl, (C –C )cycloalkyl, (C –C )alkyl-(C –C )cycloalkyl, (C –C )cycloalkyl-(C –
1 6 3 7 1 6 3 7 3 7 1
C )alkyl and -OR ; wherein said (C –C )alkyl, (C –C )cycloalkyl, (C –C )alkyl-(C –
6 a 1 6 3 7 1 6 3
)cycloalkyl, (C –C )cycloalkyl-(C –C )alkyl and -OR is optionally substituted with one
C7 3 7 1 6 a
or more substituents independently selected from R7; wherein R7 represent halogen and
Ra represents (C1–C6)alkyl and X represents N; or pharmaceutically acceptable salts,
hydrates or solvates thereof.
Embodiment 48. The compound according to any one of embodiments 1-47 wherein R
is selected from the group consisting of (C –C )alkyl, (C –C )cycloalkyl, (3-7
1 6 3 7
membered)heterocycloalkyl, wherein said (C –C )alkyl, (C –C )cycloalkyl, (3-7
1 6 3 7
membered)heterocycloalkyl is optionally substituted with one or more substituents
independently selected from R6; wherein R6 represents the group consisting of –OH,
halogen, =O, -S(O)2Rb, -NRcRd, and -ORb; Rb represents methyl or ethyl; Rc and Rd
independently represents hydrogen, methyl or ethyl; and wherein R2 represents (C1–
C )alkyl which is optionally substituted with one or more halogen; R represents (C –
4 3 1
C4)alkyl; R4 represents (C1–C4)alkyl; R5 is selected from the group consisting of (C1–
C )alkyl, (C –C )cycloalkyl, (C –C )alkyl-(C –C )cycloalkyl, (C –C )cycloalkyl-(C –C )alkyl
6 3 7 1 6 3 7 3 7 1 6
and -OR ; wherein said (C –C )alkyl, (C –C )cycloalkyl, (C –C )alkyl-(C –C )cycloalkyl,
a 1 6 3 7 1 6 3 7
(C –C )cycloalkyl-(C –C )alkyl and -OR is optionally substituted with one or more
3 7 1 6 a
substituents independently selected from R7; wherein R7 represent halogen and Ra
represents (C1–C6)alkyl and X represents N; or pharmaceutically acceptable salts,
hydrates or solvates thereof.
Embodiment 49. The compound according to any one of embodiments 1-48 wherein R
is selected from the group consisting of (C –C )alkyl, (C –C )cycloalkyl, (3-7
1 6 3 7
membered)heterocycloalkyl, wherein said (C –C )alkyl, (C –C )cycloalkyl, (3-7
1 6 3 7
membered)heterocycloalkyl is optionally substituted with one or more substituents
independently selected from R6; wherein R6 represents the group consisting of –OH,
halogen, =O, -NH2 and -ORb; Rb represents methyl or ethyl; and wherein R2 represents
(C1–C4)alkyl which is optionally substituted with one or more halogen; R3 represents
(C –C )alkyl; R represents (C –C )alkyl; R is selected from the group consisting of
1 4 4 1 4 5
(C –C )alkyl, (C –C )cycloalkyl, (C –C )alkyl-(C –C )cycloalkyl, (C –C )cycloalkyl-(C –
1 6 3 7 1 6 3 7 3 7 1
C )alkyl and -OR ; wherein said (C –C )alkyl, (C –C )cycloalkyl, (C –C )alkyl-(C –
6 a 1 6 3 7 1 6 3
C7)cycloalkyl, (C3–C7)cycloalkyl-(C1–C6)alkyl and -ORa is optionally substituted with one
or more substituents independently selected from R7; wherein R7 represent halogen and
Ra represents (C1–C6)alkyl and X represents N; or pharmaceutically acceptable salts,
hydrates or solvates thereof.
Embodiment 50. The compound according to any one of embodiments 1-49 wherein R
is selected from the group consisting of -CN, (C –C )alkyl, (C –C )cycloalkyl, (3-7
1 6 3 7
–C )alkyl,
membered) heterocycloalkyl and 5- membered heteroaryl wherein said (C1 6
(C3–C7)cycloalkyl, (3-7 membered) heterocycloalkyl and 5-membered heteroaryl is
optionally substituted with one or more substituents independently selected from R6; R6
represents the group consisting of –OH, halogen, =O, -S(O)2Rb, -NRcRd, and -ORb; Rb
represents (C1–C4)alkyl; Rc and Rd independently represents H or (C1–C6)alkyl; and
wherein R represents halogen or (C –C )alkyl which is optionally substituted with one or
2 1 4
more halogen; R represents (C –C )alkyl; R represents (C –C )alkyl; X represents N;
3 1 4 4 1 4
R represents phenyl; wherein said phenyl is optionally substituted with one or more
substituents independently selected from R7; wherein R7 represents CN, halogen or (C1–
C4)alkyl¸ or pharmaceutically acceptable salts, hydrates or solvates thereof.
Embodiment 51. The compound according to any one of embodiments 1-50 wherein R1
is selected from (5-membered)heteroaryl, wherein said (5-membered)heteroaryl is
optionally substituted with one or more substituents independently selected from (C1–
C )alkyl; and wherein R represents halogen or (C –C )alkyl which is optionally
4 2 1 4
substituted with one or more halogen; R represents (C –C )alkyl; R represents (C –
3 1 4 4 1
C )alkyl; R is selected from the group consisting of (C –C )alkyl, (C –C )cycloalkyl, (C –
4 5 1 6 3 7 1
C6)alkyl-(C3–C7)cycloalkyl, (C3–C7)cycloalkyl-(C1–C6)alkyl and -ORa; wherein said (C1–
C6)alkyl, (C3–C7)cycloalkyl, (C1–C6)alkyl-(C3–C7)cycloalkyl, (C3–C7)cycloalkyl-(C1–C6)alkyl
and -ORa is optionally substituted with one or more substituents independently selected
from R ; wherein R represent halogen; R represents (C –C )alkyl and wherein X
7 7 a 1 6
represents N¸ or pharmaceutically acceptable salts, hydrates or solvates thereof.
Embodiment 52. The compound according to any one of embodiments 1-51 wherein R
is selected from the group consisting of (3-7 membered)heterocycloalkyl, wherein said
(3-7 membered)heterocycloalkyl is optionally substituted with one or more substituents
independently selected from R6; wherein R6 represents -S(O)2Rb and Rb represents (C1–
C4)alkyl; and wherein R2 represents halogen or (C1–C4)alkyl which is optionally
substituted with one or more halogen; R represents (C –C )alkyl; R represents (C –
3 1 4 4 1
C )alkyl; R is selected from the group consisting of (C –C )alkyl, (C –C )cycloalkyl, (C –
4 5 1 6 3 7 1
C )alkyl-(C –C )cycloalkyl, (C –C )cycloalkyl-(C –C )alkyl and -OR ; wherein said (C –
6 3 7 3 7 1 6 a 1
C6)alkyl, (C3–C7)cycloalkyl, (C1–C6)alkyl-(C3–C7)cycloalkyl, (C3–C7)cycloalkyl-(C1–C6)alkyl
and -ORa is optionally substituted with one or more substituents independently selected
from R7; wherein R7 represent halogen; Ra represents (C1–C6)alkyl and wherein X
represents N¸ or pharmaceutically acceptable salts, hydrates or solvates thereof.
Embodiment 53. A compound according to any one of embodiments 1-52 selected from
the list consisting of
-[3-[[(3S)benzoylmethyl-piperazinyl]methyl]chloromethyl-anilino]-
1,3,4-oxadiazolecarbonitrile,
[(2S)[[5-chloro[[5-(methoxymethyl)-1,3,4-oxadiazolyl]amino]methyl-
phenyl]methyl]methyl-piperazinyl]-phenyl-methanone,
[(2S)[[5-chloromethyl[(5-tetrahydrofuranyl-1,3,4-oxadiazol
yl)amino]phenyl]methyl]methyl-piperazinyl]-phenyl-methanone,
[(2S)[[5-chloromethyl[(5-tetrahydrofuranyl-1,3,4-oxadiazol
yl)amino]phenyl]methyl]methyl-piperazinyl]-phenyl-methanone,
[(2S)[[5-chloro[(5-cyclopropyl-1,3,4-oxadiazolyl)amino]methyl-
phenyl]methyl]methyl-piperazinyl]-phenyl-methanone,
[(2S)[[5-chloro[[5-(1-hydroxycyclopropyl)-1,3,4-oxadiazolyl]amino]methyl-
phenyl]methyl]methyl-piperazinyl]-phenyl-methanone,
3-[5-[3-[[(3S)benzoylmethyl-piperazinyl]methyl]chloromethyl-anilino]-
1,3,4-oxadiazolyl]propanenitrile,
3-[5-[3-[[(3S)benzoylmethyl-piperazinyl]methyl]chloromethyl-anilino]-
1,3,4-oxadiazolyl]propanenitrile,
1-[(2S)[[5-chloro[[5-(methoxymethyl)-1,3,4-oxadiazolyl]amino]methyl-
phenyl]methyl]methyl-piperazinyl]-2,2-difluoro-butanone,
[(2S)[[5-chloro[[5-(methoxymethyl)-1,3,4-oxadiazolyl]amino]methyl-
phenyl]methyl]methyl-piperazinyl]-(2-fluorophenyl)methanone,
[(2S)[[5-chloro[[5-(methoxymethyl)-1,3,4-oxadiazolyl]amino]methyl-
phenyl]methyl]methyl-piperazinyl]-(3,3-difluorocyclopentyl)methanone,
(2S)[(2S)[[5-chloro[[5-(methoxymethyl)-1,3,4-oxadiazolyl]amino]
methyl-phenyl]methyl]methyl-piperazinyl]methyl-butanone,
[(2S)[[5-chloro[[5-(methoxymethyl)-1,3,4-oxadiazolyl]amino]methyl-
phenyl]methyl]methyl-piperazinyl]-cyclobutyl-methanone,
[(2S)[[5-chloro[[5-(methoxymethyl)-1,3,4-oxadiazolyl]amino]methyl-
phenyl]methyl]methyl-piperazinyl]-cyclopentyl-methanone,
cyclobutyl-[(2S)[[2,5-dimethyl[(5-methyl-1,3,4-oxadiazol
yl)amino]phenyl]methyl]methyl-piperazinyl]methanone,
2-[5-[3-[[(3S)(cyclobutanecarbonyl)methyl-piperazinyl]methyl]-2,5-dimethyl-
anilino]-1,3,4-oxadiazolyl]acetonitrile,
2-[5-[3-[[(3S)(cyclopropanecarbonyl)methyl-piperazinyl]methyl]-2,5-dimethyl-
anilino]-1,3,4-oxadiazolyl]acetonitrile,
2-[5-[3-[[(3S)(3,3-difluorocyclopentanecarbonyl)methyl-piperazinyl]methyl]-
2,5-dimethyl-anilino]-1,3,4-oxadiazolyl]acetonitrile,
2-[5-[5-chloro[[4-(cyclopentanecarbonyl)methyl-piperazinyl]methyl]methyl-
anilino]-1,3,4-oxadiazolyl]acetonitrile,
cyclobutyl-[(2S)[[3-[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5-
dimethyl-phenyl]methyl]methyl-piperazinyl]methanone,
cyclobutyl-[(2S)[[3-[[5-[(1S)hydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5-
dimethyl-phenyl]methyl]methyl-piperazinyl]methanone,
2,2-difluoro[(2S)[[3-[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5-
dimethyl-phenyl]methyl]methyl-piperazinyl]butanone,
cyclopropyl-[(2S)[[3-[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5-
dimethyl-phenyl]methyl]methyl-piperazinyl]methanone,
[(2S)[[3-[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5-dimethyl-
phenyl]methyl]methyl-piperazinyl]-(2-methylcyclopropyl)methanone,
cyclopentyl-[(2S)[[3-[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5-
dimethyl-phenyl]methyl]methyl-piperazinyl]methanone,
(3,3-difluorocyclopentyl)-[(2S)[[3-[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazol
yl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinyl]methanone,
2-cyclobutyl[(2S)[[3-[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5-
dimethyl-phenyl]methyl]methyl-piperazinyl]ethanone,
cyclobutyl-[(2S)[[5-(difluoromethyl)[[5-[(1S)hydroxyethyl]-1,3,4-oxadiazol
yl]amino]methyl-phenyl]methyl]methyl-piperazinyl]methanone,
tert-butyl (2S)[[3-[[5-[(1S)hydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5-
dimethyl-phenyl]methyl]methyl-piperazinecarboxylate,
tert-butyl (2S)[[3-[[5-(3-hydroxycyclobutyl)-1,3,4-oxadiazolyl]amino]-2,5-
dimethyl-phenyl]methyl]methyl-piperazinecarboxylate,
tert-butyl (2S)[[2,5-dimethyl[[5-(3-methyltriazolyl)-1,3,4-oxadiazol
yl]amino]phenyl]methyl]methyl-piperazinecarboxylate,
tert-butyl (2S)[[2,5-dimethyl[[5-(2-methylpyrazolyl)-1,3,4-oxadiazol
yl]amino]phenyl]methyl]methyl-piperazinecarboxylate,
tert-butyl (2S)[[3-[(5-isoxazolyl-1,3,4-oxadiazolyl)amino]-2,5-dimethyl-
phenyl]methyl]methyl-piperazinecarboxylate,
tert-butyl (2S)[[2,5-dimethyl[[5-(1,2,5-thiadiazolyl)-1,3,4-oxadiazol
yl]amino]phenyl]methyl]methyl-piperazinecarboxylate,
tert-butyl (2S)[[2,5-dimethyl[[5-(4-methyl-1,2,5-oxadiazolyl)-1,3,4-oxadiazol-
2-yl]amino]phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[2,5-dimethyl[(5-methyl-1,3,4-oxadiazol
yl)amino]phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[3-[[5-[(1S)aminohydroxy-ethyl]-1,3,4-oxadiazolyl]amino]-
2,5-dimethyl-phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[3-[[5-(3-hydroxycyclobutyl)-1,3,4-oxadiazolyl]amino]-2,5-
dimethyl-phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[3-[[5-[(1S)aminopropyl]-1,3,4-oxadiazolyl]amino]chloro
methyl-phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[5-chloro[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazolyl]amino]
methyl-phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[5-chloromethyl[[5-(oxetanyl)-1,3,4-oxadiazol
yl]amino]phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[3-[[5-[(1S,2R)aminohydroxy-propyl]-1,3,4-oxadiazol
yl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[3-[[5-(cyanomethyl)-1,3,4-oxadiazolyl]amino]-2,5-dimethyl-
phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[5-(difluoromethyl)[[5-[(1S)hydroxyethyl]-1,3,4-oxadiazol
yl]amino]methyl-phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[5-chloromethyl[(5-tetrahydropyranyl-1,3,4-oxadiazol
yl)amino]phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[5-chloro[[5-(1-hydroxycyclopropyl)-1,3,4-oxadiazolyl]amino]-
2-methyl-phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[5-chloro[[5-[1-(hydroxymethyl)cyclopropyl]-1,3,4-oxadiazol
yl]amino]methyl-phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[5-chloromethyl[[5-(2,2,2-trifluorohydroxy-ethyl)-1,3,4-
oxadiazolyl]amino]phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[5-chloromethyl[[5-(2-oxopyrrolidinyl)-1,3,4-oxadiazol
yl]amino]phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[3-[[5-[(1S)aminoethyl]-1,3,4-oxadiazolyl]amino]-2,5-dimethyl-
phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[5-(difluoromethyl)[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazol
yl]amino]methyl-phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[2,5-dimethyl[[5-(5-oxopyrrolidinyl)-1,3,4-oxadiazol
yl]amino]phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[2,5-dimethyl[[5-[(5S)oxooxazolidinyl]-1,3,4-oxadiazol
yl]amino]phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[5-chloromethyl[[5-[(2S)oxoazetidinyl]-1,3,4-oxadiazol
yl]amino]phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[2,5-dimethyl[[5-(4-methyl-1,2,5-oxadiazolyl)-1,3,4-oxadiazol-
2-yl]amino]phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[2,5-dimethyl[[5-[(3S)-morpholinyl]-1,3,4-oxadiazol
yl]amino]phenyl]methyl]methyl-piperazinecarboxylate dihydrochloride,
isopropyl (2S)[[3-[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5-
dimethyl-phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[2,5-dimethyl[[5-[(2R)-3,3,3-trifluorohydroxy-propyl]-1,3,4-
oxadiazolyl]amino]phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[2,5-dimethyl[[5-(2-oxopiperidyl)-1,3,4-oxadiazol
yl]amino]phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[2,5-dimethyl[[5-(2-methylpyrazolyl)-1,3,4-oxadiazol
yl]amino]phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[3-[[5-[(2S)hydroxypropyl]-1,3,4-oxadiazolyl]amino]-2,5-
dimethyl-phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[3-[[5-[(2R)hydroxypropyl]-1,3,4-oxadiazolyl]amino]-2,5-
dimethyl-phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[3-[[5-[(1S)hydroxypropyl]-1,3,4-oxadiazolyl]amino]-2,5-
dimethyl-phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[5-chloro[[5-[(1S)hydroxyethyl]-1,3,4-oxadiazolyl]amino]
methyl-phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[5-chloro[[5-(3-hydroxycyclobutyl)-1,3,4-oxadiazolyl]amino]
methyl-phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[2,5-dimethyl[[5-[(2S)methylsulfonylpyrrolidinyl]-1,3,4-
oxadiazolyl]amino]phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[3-[[5-[(1S)hydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5-
dimethyl-phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[5-chloromethyl[[5-(5-oxopyrrolidinyl)-1,3,4-oxadiazol
yl]amino]phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[3-[[5-[(1R)aminoethyl]-1,3,4-oxadiazolyl]amino]-2,5-dimethyl-
phenyl]methyl]methyl-piperazinecarboxylate,
2,2,2-trifluoroethyl (2S)[[5-chloro[[5-(cyanomethyl)-1,3,4-oxadiazolyl]amino]-
2-methyl-phenyl]methyl]methyl-piperazinecarboxylate,
2,2,2-trifluoroethyl (2S)[[3-[[5-(3-hydroxycyclobutyl)-1,3,4-oxadiazolyl]amino]-
2,5-dimethyl-phenyl]methyl]methyl-piperazinecarboxylate,
ethyl (2S)[[3-[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5-dimethyl-
phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[3-[[5-[(1S)-1,2-dihydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5-
dimethyl-phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[5-chloromethyl[(5-morpholinyl-1,3,4-oxadiazol
yl)amino]phenyl]methyl]methyl-piperazinecarboxylate,
tert-butyl (2S)[[5-chloro[[5-(hydroxymethyl)oxazolyl]amino]methyl-
phenyl]methyl]methyl-piperazinecarboxylate,
[(1R)-2,2,2-trifluoromethyl-ethyl] (2S)[[3-[[5-[(1S)-1,2-dihydroxyethyl]-1,3,4-
oxadiazolyl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[2,5-dimethyl[[5-[(3R)-tetrahydrofuranyl]-1,3,4-oxadiazol
yl]amino]phenyl]methyl]methyl-piperazinecarboxylate,
isopropyl (2S)[[3-[[5-[(2S,3R)hydroxypyrrolidinyl]-1,3,4-oxadiazol
yl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinecarboxylate,
cyclopentyl-[(2S)[[3-[[5-[(2S,3R)hydroxypyrrolidinyl]-1,3,4-oxadiazol
yl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinyl]methanone,
(3,3-difluorocyclopentyl)-[(2S)[[3-[[5-[(2S,3R)hydroxypyrrolidinyl]-1,3,4-
oxadiazolyl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazin
yl]methanone,
[(1R)-2,2,2-trifluoromethyl-ethyl] (2S)[[3-[[5-[(2S,3R)hydroxypyrrolidinyl]-
1,3,4-oxadiazolyl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazine
carboxylate,
2,2,2-trifluoroethyl (2S)[[3-[[5-[(2S,3R)hydroxypyrrolidinyl]-1,3,4-oxadiazol-
2-yl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinecarboxylate,
[(1R)methylpropyl] (2S)[[3-[[5-[(2S,3R)hydroxypyrrolidinyl]-1,3,4-
oxadiazolyl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinecarboxylate
and
isopropyl (2S)[[2,5-dimethyl[[5-[(3S)oxopyrrolidinyl]-1,3,4-oxadiazol
yl]amino]phenyl]methyl]methyl-piperazinecarboxylate,
or pharmaceutically acceptable salts, hydrates or solvates thereof.
Embodiment 54. The compound according to any one of the embodiments 1-53 selected
from
[(1R)-2,2,2-trifluoromethyl-ethyl] (2S)[[3-[[5-[(1S)-1,2-dihydroxyethyl]-1,3,4-
oxadiazolyl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinecarboxylate,
or pharmaceutically acceptable salts, hydrates or solvates thereof.
Embodiment 55. The compound according to any one of the embodiments 1-54 wherein
said compound is [(1R)-2,2,2-trifluoromethyl-ethyl] (2S)[[3-[[5-[(1S)-1,2-
dihydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5-dimethyl-phenyl]methyl]methyl-
piperazinecarboxylate.
Embodiment 56. The compound according to any one of the embodiments 1-53 selected
from isopropyl (2S)[[2,5-dimethyl[[5-[(3R)-tetrahydrofuranyl]-1,3,4-oxadiazol-
2-yl]amino]phenyl]methyl]methyl-piperazinecarboxylate,
or pharmaceutically acceptable salts, hydrates or solvates thereof.
Embodiment 57. The compound according to any one of the embodiments 1-53 or 56
wherein said compound is isopropyl (2S)[[2,5-dimethyl[[5-[(3R)-tetrahydrofuran-
3-yl]-1,3,4-oxadiazolyl]amino]phenyl]methyl]methyl-piperazinecarboxylate.
Embodiment 58. The compound according to any one of the embodiments 1-53 selected
from isopropyl (2S)[[3-[[5-[(2S,3R)hydroxypyrrolidinyl]-1,3,4-oxadiazol
yl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinecarboxylate,
or pharmaceutically acceptable salts, hydrates or solvates thereof.
Embodiment 59. The compound according to any one of the embodiments 1-53 or 58
wherein said compound is isopropyl (2S)[[3-[[5-[(2S,3R)hydroxypyrrolidinyl]-
1,3,4-oxadiazolyl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazine
carboxylate.
Embodiment 60. The compound according to any one of embodiments 1-53 wherein said
compound is [(1R)-2,2,2-trifluoromethyl-ethyl] (2S)[[3-[[5-[(1S)-1,2-
dihydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5-dimethyl-phenyl]methyl]methyl-
piperazinecarboxylate, or pharmaceutically acceptable salts thereof.
Embodiment 61. The compound according to any one of embodiments 1-53 wherein said
compound is isopropyl (2S)[[3-[[5-[(2S,3R)hydroxypyrrolidinyl]-1,3,4-
oxadiazolyl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinecarboxylate,
or pharmaceutically acceptable salts thereof.
Embodiment 62. The compound according to any one of embodiments 1-53 wherein said
compound is isopropyl (2S)[[2,5-dimethyl[[5-[(2S)methylsulfonylpyrrolidin
yl]-1,3,4-oxadiazolyl]amino]phenyl]methyl]methyl-piperazinecarboxylate, or
pharmaceutically acceptable salts thereof.
Embodiment 63. The compound according to any one of embodiments 1-53 wherein said
compound is cyclopentyl-[(2S)[[3-[[5-[(2S,3R)hydroxypyrrolidinyl]-1,3,4-
oxadiazolyl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazin
yl]methanone, or pharmaceutically acceptable salts thereof.
Embodiment 64. The compound according to any one of the embodiments 1-63 selected
from isopropyl (2S)[[2,5-dimethyl[[5-[(2S)methylsulfonylpyrrolidinyl]-1,3,4-
oxadiazolyl]amino]phenyl]methyl]methyl-piperazinecarboxylate or
pharmaceutically acceptable salts, hydrates or solvates thereof.
Embodiment 65. The compound according to any one of the embodiments 1-63 wherein
said compound is isopropyl (2S)[[2,5-dimethyl[[5-[(2S)
methylsulfonylpyrrolidinyl]-1,3,4-oxadiazolyl]amino]phenyl]methyl]methyl-
piperazinecarboxylate.
Embodiment 66. The compound according to any one of the embodiments 1-63 selected
from cyclopentyl-[(2S)[[3-[[5-[(2S,3R)hydroxypyrrolidinyl]-1,3,4-oxadiazol
yl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinyl]methanone or
pharmaceutically acceptable salts, hydrates or solvates thereof.
Embodiment 67. The compound according to any one of the embodiments 1-63 wherein
said compound is cyclopentyl-[(2S)[[3-[[5-[(2S,3R)hydroxypyrrolidinyl]-1,3,4-
oxadiazolyl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazin
yl]methanone.
Embodiment 68. A compound according to any one of embodiments 1-67 for use as a
medicament.
Embodiment 69. A compound according to any one of embodiments 1-67 for use in
treatment of autoimmune or inflammatory diseases.
Embodiment 70. The compound for use according to embodiment 69 wherein the
autoimmune or inflammatory diseases is selected from psoriasis, psoriatic arthritis,
multiple sclerosis, rheumatoid arthritis, Crohns disease, ulcerative colitis, alopecia
areata, contact dermatitis, including irritative contact dermatitis and allergic contact
dermatitis, spondyloarthritis.
Embodiment 71. A compound according to any one of embodiments 1-67 for use in
treatment cancers, including prostate cancer and non-small cell lung cancer.
Embodiment 72. The compound for use according to embodiments 69-70
wherein the autoimmune or inflammatory diseases is psoriasis.
Embodiment 73. A pharmaceutical composition comprising a compound according to any
one of embodiments 1-67 together with a pharmaceutically acceptable vehicle or
excipient or pharmaceutically acceptable carrier(s).
Embodiment 74. The pharmaceutical composition according to embodiment 1-73
together with one or more other therapeutically active compound(s).
Embodiment 75. A method of preventing, treating or ameliorating psoriasis, the method
comprising administering to a person suffering from psoriasis an effective amount of one
or more compounds according to according to any one of embodiments 1-67, optionally
together with a pharmaceutically acceptable carrier or one or more excipients, optionally
in combination with other therapeutically active compounds.
Embodiment 76. A compound according to any one of embodiments 1-67 for use in
treatment of a disease, disorder or condition, which disease, disorder or condition is
responsive of modulation of RORgamma.
Embodiment 77. A compound according to general formula (II)
(II)
wherein
R2 is selected from the group consisting of halogen, cyano, (C1–C4)alkyl and (C3–
C )cycloalkyl, wherein said (C –C )alkyl and (C –C )cycloalkyl is optionally substituted
7 1 4 3 7
with one or more substituents independently selected from –OH and halogen;
R3 is selected from the group consisting of halogen, cyano, (C1–C4)alkyl, (C1–
C4)haloalkyl and (C3–C7)cycloalkyl;
R4 is selected from the group consisting of (C1–C4)alkyl and (C1–C4)haloalkyl;
R is selected from the group consisting of (C –C )alkyl, (C –C )cycloalkyl, (C –C )alkyl-
1 6 3 7 1 6
(C –C )cycloalkyl, (C –C )cycloalkyl-(C –C )alkyl, (3-7 membered)heterocycloalkyl,
3 7 3 7 1 6
phenyl, (5-6 membered)heteroaryl and -ORa; wherein said (C1–C6)alkyl, (C3–
C7)cycloalkyl, (C1–C6)alkyl-(C3–C7)cycloalkyl, (C3–C7)cycloalkyl-(C1–C6)alkyl, (3-7
membered)heterocycloalkyl, phenyl, (5-6 membered)heteroaryl and -ORa is optionally
substituted with one or more substituents independently selected from R7;
R represents the group consisting of –OH, -CN, halogen, (C –C )alkyl, (C -C )cycloalkyl
7 1 4 3 7
and (C –C )alkyl-(C –C )cycloalkyl-.
1 6 3 7
Embodiment 78. The compound according to embodiment 77 wherein R2 is selected from
the group consisting of halogen and (C1–C4)alkyl, wherein said (C1–C4)alkyl is optionally
substituted with one or more substituents independently selected from halogen;
R is selected from (C –C )alkyl;
3 1 4
R is selected from the group (C –C )alkyl;
4 1 4
R is selected from the group consisting of (C –C )alkyl, (C –C )cycloalkyl, phenyl and -
1 6 3 7
OR ; wherein said (C –C )alkyl, (C –C )cycloalkyl, phenyl and -OR is optionally
a 1 6 3 7 a
substituted with one or more substituents independently selected from halogen
Embodiment 79. The compound according to embodiments 77-78 , said compound being
selected from the list consisting of
tert-butyl (2S)[[3-(aminocarbamothioylamino)chloromethyl-phenyl]methyl]
methyl-piperazinecarboxylate,
1-amino[3-[[(3S)benzoylmethyl-piperazinyl]methyl]chloromethyl-
phenyl]thiourea,
isopropyl (2S)[[3-(aminocarbamothioylamino)chloromethyl-phenyl]methyl]
methyl-piperazinecarboxylate,
isopropyl (2S)[[3-(aminocarbamothioylamino)-2,5-dimethyl-phenyl]methyl]
methyl-piperazinecarboxylate,
tert-butyl (2S)[[3-(aminocarbamothioylamino)-2,5-dimethyl-phenyl]methyl]
methyl-piperazinecarboxylate,
1-amino[3-[[(3S)(cyclobutanecarbonyl)methyl-piperazinyl]methyl]-2,5-
dimethyl-phenyl]thiourea,
isopropyl (2S)[[3-(aminocarbamothioylamino)(difluoromethyl)methyl-
phenyl]methyl]methyl-piperazinecarboxylate,
1-amino[3-[[(3S)(cyclobutanecarbonyl)methyl-piperazinyl]methyl]
(difluoromethyl)methyl-phenyl]thiourea,
1-amino[3-[[(3S)(cyclopentanecarbonyl)methyl-piperazinyl]methyl]-2,5-
dimethyl-phenyl]thiourea.
Embodiment 80. A compound according to general formula (IX)
(IX)
wherein
R2 is selected from the group consisting of halogen, cyano, (C1–C4)alkyl and (C3–
C )cycloalkyl, wherein said (C –C )alkyl and (C –C )cycloalkyl is optionally substituted
7 1 4 3 7
with one or more substituents independently selected from –OH and halogen;
R3 is selected from the group consisting of halogen, cyano, (C1–C4)alkyl, (C1–
C4)haloalkyl and (C3–C7)cycloalkyl;
R is selected from the group consisting of (C –C )alkyl and (C –C )haloalkyl;
4 1 4 1 4
R is selected from the group consisting of (C –C )alkyl, (C –C )cycloalkyl, (C –C )alkyl-
1 6 3 7 1 6
(C –C )cycloalkyl, (C –C )cycloalkyl-(C –C )alkyl, (3-7 membered)heterocycloalkyl,
3 7 3 7 1 6
phenyl, (5-6 membered)heteroaryl and -OR ; wherein said (C –C )alkyl, (C –
a 1 6 3
C7)cycloalkyl, (C1–C6)alkyl-(C3–C7)cycloalkyl, (C3–C7)cycloalkyl-(C1–C6)alkyl, (3-7
membered)heterocycloalkyl, phenyl, (5-6 membered)heteroaryl and -ORa is optionally
substituted with one or more substituents independently selected from R7;
R represents the group consisting of –OH, -CN, halogen, (C –C )alkyl, (C -C )cycloalkyl
7 1 4 3 7
and (C –C )alkyl-(C –C )cycloalkyl-.
1 6 3 7
Embodiment 81. The compound according to embodiment 80 wherein
R2 is selected from the group consisting of halogen and (C1–C4)alkyl, wherein said (C1–
C4)alkyl is optionally substituted with one or more substituents independently selected
from halogen;
R is selected from (C –C )alkyl;
3 1 4
R4 is selected from the group (C1–C4)alkyl;
R5 is selected from the group consisting of (C1–C6)alkyl, (C3–C7)cycloalkyl, phenyl and -
ORa; wherein said (C1–C6)alkyl, (C3–C7)cycloalkyl, phenyl and -ORa is optionally
substituted with one or more substituents independently selected from halogen
Embodiment 82. The compound according to embodiments 80-81, said compound being
selected from the list consisting of
tert-butyl (2S)[(5-chloroisothiocyanatomethyl-phenyl)methyl]methyl-
piperazinecarboxylate,
[(2S)[(5-chloroisothiocyanatomethyl-phenyl)methyl]methyl-piperazinyl]-
phenyl-methanone,
isopropyl (2S)[(5-chloroisothiocyanatomethyl-phenyl)methyl]methyl-
piperazinecarboxylate,
isopropyl (2S)[(3-isothiocyanato-2,5-dimethyl-phenyl)methyl]methyl-piperazine-
1-carboxylate,
tert-butyl (2S)[(3-isothiocyanato-2,5-dimethyl-phenyl)methyl]methyl-piperazine-
1-carboxylate,
cyclobutyl-[(2S)[(3-isothiocyanato-2,5-dimethyl-phenyl)methyl]methyl-piperazin-
1-yl]methanone,
isopropyl (2S)[[5-(difluoromethyl)isothiocyanatomethyl-phenyl]methyl]
methyl-piperazinecarboxylate,
cyclobutyl-[(2S)[[5-(difluoromethyl)isothiocyanatomethyl-phenyl]methyl]
methyl-piperazinyl]methanone,
cyclopentyl-[(2S)[(3-isothiocyanato-2,5-dimethyl-phenyl)methyl]methyl-
piperazinyl]methanone.
In this specification where reference has been made to patent specifications, other
external documents, or other sources of information, this is generally for the purpose of
providing a context for discussing the features of the invention. Unless specifically stated
otherwise, reference to such external documents is not to be construed as an admission
that such documents, or such sources of information, in any jurisdiction, are prior art, or
form part of the common general knowledge in the art.
Claims (31)
1. A compound according to general formula (I) wherein X represents N or CH; 5 R is selected from the group consisting of -CN, (C –C )alkyl, (C –C )cycloalkyl, (3-7 1 1 6 3 7 membered)heterocycloalkyl, (5-6 membered)heteroaryl, (C3–C7)cycloalkyl(C1–C4)alkyl, (3-7 membered)heterocycloalkyl-(C1–C4)alkyl and (5-6 membered)heteroaryl-(C1– C4)alkyl, wherein said (C1–C6)alkyl, (C3–C7)cycloalkyl, (3-7 membered)heterocycloalkyl, (5membered)heteroaryl, (C3–C7)cycloalkyl(C1–C4)alkyl, (3-7 10 membered)heterocycloalkyl-(C –C )alkyl and (5-6 membered)heteroaryl-(C –C )alkyl is 1 4 1 4 optionally substituted with one or more substituents independently selected from R ; R is selected from the group consisting of halogen, cyano, (C –C )alkyl and (C – 2 1 4 3 C7)cycloalkyl, wherein said (C1–C4)alkyl and (C3–C7)cycloalkyl is optionally substituted 15 with one or more substituents independently selected from –OH and halogen; R is selected from the group consisting of halogen, cyano, (C –C )alkyl, (C – 3 1 4 1 C )haloalkyl and (C –C )cycloalkyl; 4 3 7 20 R4 is selected from the group consisting of (C1–C4)alkyl and (C1–C4)haloalkyl; R5 is selected from the group consisting of (C1–C6)alkyl, (C3–C7)cycloalkyl, (C1–C6)alkyl- (C3–C7)cycloalkyl, (C3–C7)cycloalkyl-(C1–C6)alkyl, (3-7 membered)heterocycloalkyl, phenyl, (5-6 membered)heteroaryl and -ORa; wherein said (C1–C6)alkyl, (C3– 25 C )cycloalkyl, (C –C )alkyl-(C –C )cycloalkyl, (C –C )cycloalkyl-(C –C )alkyl, (3-7 7 1 6 3 7 3 7 1 6 membered)heterocycloalkyl, phenyl, (5-6 membered)heteroaryl and -OR is optionally substituted with one or more substituents independently selected from R ; R6 represents the group consisting of –OH, -CN, halogen, =O, -S(O)2Rb, -NRcRd, - 30 NRcC(O)Rd, -C(O)NRcRd, -S(O)2NRcRd, -NRcS(O)2Rb, -ORb, -C(O)Rb, (C1–C4)alkyl, hydroxy(C1–C4)alkyl, halo(C1–C4)alkyl, (C3–C7)cycloalkyl, (3-7 membered)heterocycloalkyl and (5-6 membered)heteroaryl; R7 represents the group consisting of –OH, -CN, halogen, (C1–C4)alkyl, (C3-C7)cycloalkyl and (C –C )alkyl-(C –C )cycloalkyl-; 1 6 3 7 R represents (C –C )alkyl, (C –C )cycloalkyl, (C –C )alkyl-(C –C )cycloalkyl- or (C –C )- a 1 6 3 7 1 6 3 7 3 7 5 cycloalkyl(C1–C6)alkyl; Rb represents (C1–C6)alkyl or (C3–C7)cycloalkyl; R and R each independently represents H, (C –C )alkyl or (C –C )cycloalkyl; c d 1 6 3 7 or pharmaceutically acceptable salts, hydrates or solvates thereof.
2. The compound according to claim 1 wherein X represents N. 15
3. The compound according to any one of claims 1-2 wherein R1 is selected from the group consisting of -CN, (C –C )alkyl, (C –C )cycloalkyl, (3-7 membered) 1 6 3 7 heterocycloalkyl and 5- membered heteroaryl wherein said (C –C )alkyl, (C – 1 6 3 C )cycloalkyl, (3-7 membered) heterocycloalkyl and 5-membered heteroaryl is optionally substituted with one or more substituents independently selected from R6.
4. The compound according to any one of claims 1-3 wherein R2 represents chloro, methyl or difluoromethyl.
5. The compound according to any one of claims 1-4 wherein R represents methyl. represents methyl.
6. The compound according to any one of claims 1-5 wherein R4
7. The compound according to any one of claims 1-6 wherein R5 represents (C1– C6)alkyl, (C3–C7)cycloalkyl, (C1–C6)alkyl-(C3–C7)cycloalkyl, (C3–C7)cycloalkyl-(C1– 30 C6)alkyl, phenyl or -ORa; wherein said (C1–C6)alkyl, (C3–C7)cycloalkyl, (C1–C6)alkyl-(C3– C )cycloalkyl, (C –C )cycloalkyl-(C –C )alkyl, phenyl or -OR is optionally substituted 7 3 7 1 6 a with one or more substituents independently selected from R .
8. The compound according to any one of claims 1-7 wherein R6 represents –OH, -CN, 35 halogen, =O, -S(O)2Rb, -NRcRd, -ORb, (C1–C4)alkyl or hydroxy(C1–C4)alkyl.
9. The compound according to any one of claims 1-8 wherein R7 represents halogen.
10. The compound according to any one of claims 1-9 wherein Ra represents (C1– C )alkyl.
11. The compound according to any one of claims 1-10 wherein R represents (C – 5 C6)alkyl.
12. The compound according to any one of claims 1-11 wherein Rc and Rd each independently represents H or (C –C )alkyl. 10
13. A compound according to any one of claims 1-12 selected from the list consisting of 5-[3-[[(3S)benzoylmethyl-piperazinyl]methyl]chloromethyl-anilino]- 1,3,4-oxadiazolecarbonitrile, [(2S)[[5-chloro[[5-(methoxymethyl)-1,3,4-oxadiazolyl]amino]methyl- phenyl]methyl]methyl-piperazinyl]-phenyl-methanone, 15 [(2S)[[5-chloromethyl[(5-tetrahydrofuranyl-1,3,4-oxadiazol yl)amino]phenyl]methyl]methyl-piperazinyl]-phenyl-methanone, [(2S)[[5-chloromethyl[(5-tetrahydrofuranyl-1,3,4-oxadiazol yl)amino]phenyl]methyl]methyl-piperazinyl]-phenyl-methanone [(2S)[[5-chloro[(5-cyclopropyl-1,3,4-oxadiazolyl)amino]methyl- 20 phenyl]methyl]methyl-piperazinyl]-phenyl-methanone, [(2S)[[5-chloro[[5-(1-hydroxycyclopropyl)-1,3,4-oxadiazolyl]amino]methyl- phenyl]methyl]methyl-piperazinyl]-phenyl-methanone, 3-[5-[3-[[(3S)benzoylmethyl-piperazinyl]methyl]chloromethyl-anilino]- 1,3,4-oxadiazolyl]propanenitrile, 25 3-[5-[3-[[(3S)benzoylmethyl-piperazinyl]methyl]chloromethyl-anilino]- 1,3,4-oxadiazolyl]propanenitrile, 1-[(2S)[[5-chloro[[5-(methoxymethyl)-1,3,4-oxadiazolyl]amino]methyl- phenyl]methyl]methyl-piperazinyl]-2,2-difluoro-butanone, [(2S)[[5-chloro[[5-(methoxymethyl)-1,3,4-oxadiazolyl]amino]methyl- 30 phenyl]methyl]methyl-piperazinyl]-(2-fluorophenyl)methanone, [(2S)[[5-chloro[[5-(methoxymethyl)-1,3,4-oxadiazolyl]amino]methyl- phenyl]methyl]methyl-piperazinyl]-(3,3-difluorocyclopentyl)methanone, (2S)[(2S)[[5-chloro[[5-(methoxymethyl)-1,3,4-oxadiazolyl]amino] methyl-phenyl]methyl]methyl-piperazinyl]methyl-butanone, 35 [(2S)[[5-chloro[[5-(methoxymethyl)-1,3,4-oxadiazolyl]amino]methyl- phenyl]methyl]methyl-piperazinyl]-cyclobutyl-methanone, [(2S)[[5-chloro[[5-(methoxymethyl)-1,3,4-oxadiazolyl]amino]methyl- phenyl]methyl]methyl-piperazinyl]-cyclopentyl-methanone, cyclobutyl-[(2S)[[2,5-dimethyl[(5-methyl-1,3,4-oxadiazol yl)amino]phenyl]methyl]methyl-piperazinyl]methanone, 2-[5-[3-[[(3S)(cyclobutanecarbonyl)methyl-piperazinyl]methyl]-2,5-dimethyl- anilino]-1,3,4-oxadiazolyl]acetonitrile, 5 2-[5-[3-[[(3S)(cyclopropanecarbonyl)methyl-piperazinyl]methyl]-2,5-dimethyl- anilino]-1,3,4-oxadiazolyl]acetonitrile, 2-[5-[3-[[(3S)(3,3-difluorocyclopentanecarbonyl)methyl-piperazinyl]methyl]- 2,5-dimethyl-anilino]-1,3,4-oxadiazolyl]acetonitrile, 2-[5-[5-chloro[[4-(cyclopentanecarbonyl)methyl-piperazinyl]methyl]methyl- 10 anilino]-1,3,4-oxadiazolyl]acetonitrile, cyclobutyl-[(2S)[[3-[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5- dimethyl-phenyl]methyl]methyl-piperazinyl]methanone, cyclobutyl-[(2S)[[3-[[5-[(1S)hydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5- dimethyl-phenyl]methyl]methyl-piperazinyl]methanone, 15 2,2-difluoro[(2S)[[3-[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5- dimethyl-phenyl]methyl]methyl-piperazinyl]butanone, cyclopropyl-[(2S)[[3-[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5- dimethyl-phenyl]methyl]methyl-piperazinyl]methanone, [(2S)[[3-[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5-dimethyl- 20 phenyl]methyl]methyl-piperazinyl]-(2-methylcyclopropyl)methanone, cyclopentyl-[(2S)[[3-[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5- dimethyl-phenyl]methyl]methyl-piperazinyl]methanone, (3,3-difluorocyclopentyl)-[(2S)[[3-[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazol yl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinyl]methanone, 25 2-cyclobutyl[(2S)[[3-[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5- dimethyl-phenyl]methyl]methyl-piperazinyl]ethanone, cyclobutyl-[(2S)[[5-(difluoromethyl)[[5-[(1S)hydroxyethyl]-1,3,4-oxadiazol yl]amino]methyl-phenyl]methyl]methyl-piperazinyl]methanone, tert-butyl (2S)[[3-[[5-[(1S)hydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5- 30 dimethyl-phenyl]methyl]methyl-piperazinecarboxylate, tert-butyl (2S)[[3-[[5-(3-hydroxycyclobutyl)-1,3,4-oxadiazolyl]amino]-2,5- dimethyl-phenyl]methyl]methyl-piperazinecarboxylate, tert-butyl (2S)[[2,5-dimethyl[[5-(3-methyltriazolyl)-1,3,4-oxadiazol yl]amino]phenyl]methyl]methyl-piperazinecarboxylate, 35 tert-butyl (2S)[[2,5-dimethyl[[5-(2-methylpyrazolyl)-1,3,4-oxadiazol yl]amino]phenyl]methyl]methyl-piperazinecarboxylate, tert-butyl (2S)[[3-[(5-isoxazolyl-1,3,4-oxadiazolyl)amino]-2,5-dimethyl- phenyl]methyl]methyl-piperazinecarboxylate, tert-butyl (2S)[[2,5-dimethyl[[5-(1,2,5-thiadiazolyl)-1,3,4-oxadiazol yl]amino]phenyl]methyl]methyl-piperazinecarboxylate, tert-butyl (2S)[[2,5-dimethyl[[5-(4-methyl-1,2,5-oxadiazolyl)-1,3,4-oxadiazol- 2-yl]amino]phenyl]methyl]methyl-piperazinecarboxylate, 5 isopropyl (2S)[[2,5-dimethyl[(5-methyl-1,3,4-oxadiazol yl)amino]phenyl]methyl]methyl-piperazinecarboxylate, isopropyl (2S)[[3-[[5-[(1S)aminohydroxy-ethyl]-1,3,4-oxadiazolyl]amino]- 2,5-dimethyl-phenyl]methyl]methyl-piperazinecarboxylate, isopropyl (2S)[[3-[[5-(3-hydroxycyclobutyl)-1,3,4-oxadiazolyl]amino]-2,5- 10 dimethyl-phenyl]methyl]methyl-piperazinecarboxylate, isopropyl (2S)[[3-[[5-[(1S)aminopropyl]-1,3,4-oxadiazolyl]amino]chloro methyl-phenyl]methyl]methyl-piperazinecarboxylate, isopropyl (2S)[[5-chloro[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazolyl]amino] methyl-phenyl]methyl]methyl-piperazinecarboxylate, 15 isopropyl (2S)[[5-chloromethyl[[5-(oxetanyl)-1,3,4-oxadiazol yl]amino]phenyl]methyl]methyl-piperazinecarboxylate, isopropyl (2S)[[3-[[5-[(1S,2R)aminohydroxy-propyl]-1,3,4-oxadiazol yl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinecarboxylate, isopropyl (2S)[[3-[[5-(cyanomethyl)-1,3,4-oxadiazolyl]amino]-2,5-dimethyl- 20 phenyl]methyl]methyl-piperazinecarboxylate, isopropyl (2S)[[5-(difluoromethyl)[[5-[(1S)hydroxyethyl]-1,3,4-oxadiazol yl]amino]methyl-phenyl]methyl]methyl-piperazinecarboxylate, isopropyl (2S)[[5-chloromethyl[(5-tetrahydropyranyl-1,3,4-oxadiazol yl)amino]phenyl]methyl]methyl-piperazinecarboxylate, 25 isopropyl (2S)[[5-chloro[[5-(1-hydroxycyclopropyl)-1,3,4-oxadiazolyl]amino]- 2-methyl-phenyl]methyl]methyl-piperazinecarboxylate, isopropyl (2S)[[5-chloro[[5-[1-(hydroxymethyl)cyclopropyl]-1,3,4-oxadiazol yl]amino]methyl-phenyl]methyl]methyl-piperazinecarboxylate, isopropyl (2S)[[5-chloromethyl[[5-(2,2,2-trifluorohydroxy-ethyl)-1,3,4- 30 oxadiazolyl]amino]phenyl]methyl]methyl-piperazinecarboxylate, isopropyl (2S)[[5-chloromethyl[[5-(2-oxopyrrolidinyl)-1,3,4-oxadiazol yl]amino]phenyl]methyl]methyl-piperazinecarboxylate, isopropyl (2S)[[3-[[5-[(1S)aminoethyl]-1,3,4-oxadiazolyl]amino]-2,5-dimethyl- phenyl]methyl]methyl-piperazinecarboxylate, 35 isopropyl (2S)[[5-(difluoromethyl)[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazol yl]amino]methyl-phenyl]methyl]methyl-piperazinecarboxylate, isopropyl (2S)[[2,5-dimethyl[[5-(5-oxopyrrolidinyl)-1,3,4-oxadiazol yl]amino]phenyl]methyl]methyl-piperazinecarboxylate, isopropyl (2S)[[2,5-dimethyl[[5-[(5S)oxooxazolidinyl]-1,3,4-oxadiazol yl]amino]phenyl]methyl]methyl-piperazinecarboxylate, isopropyl (2S)[[5-chloromethyl[[5-[(2S)oxoazetidinyl]-1,3,4-oxadiazol yl]amino]phenyl]methyl]methyl-piperazinecarboxylate, 5 isopropyl (2S)[[2,5-dimethyl[[5-(4-methyl-1,2,5-oxadiazolyl)-1,3,4-oxadiazol- 2-yl]amino]phenyl]methyl]methyl-piperazinecarboxylate, isopropyl (2S)[[2,5-dimethyl[[5-[(3S)-morpholinyl]-1,3,4-oxadiazol yl]amino]phenyl]methyl]methyl-piperazinecarboxylate dihydrochloride, isopropyl (2S)[[3-[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5- 10 dimethyl-phenyl]methyl]methyl-piperazinecarboxylate, isopropyl (2S)[[2,5-dimethyl[[5-[(2R)-3,3,3-trifluorohydroxy-propyl]-1,3,4- oxadiazolyl]amino]phenyl]methyl]methyl-piperazinecarboxylate, isopropyl (2S)[[2,5-dimethyl[[5-(2-oxopiperidyl)-1,3,4-oxadiazol yl]amino]phenyl]methyl]methyl-piperazinecarboxylate, 15 isopropyl (2S)[[2,5-dimethyl[[5-(2-methylpyrazolyl)-1,3,4-oxadiazol yl]amino]phenyl]methyl]methyl-piperazinecarboxylate, isopropyl (2S)[[3-[[5-[(2S)hydroxypropyl]-1,3,4-oxadiazolyl]amino]-2,5- dimethyl-phenyl]methyl]methyl-piperazinecarboxylate, isopropyl (2S)[[3-[[5-[(2R)hydroxypropyl]-1,3,4-oxadiazolyl]amino]-2,5- 20 dimethyl-phenyl]methyl]methyl-piperazinecarboxylate, isopropyl (2S)[[3-[[5-[(1S)hydroxypropyl]-1,3,4-oxadiazolyl]amino]-2,5- dimethyl-phenyl]methyl]methyl-piperazinecarboxylate, isopropyl (2S)[[5-chloro[[5-[(1S)hydroxyethyl]-1,3,4-oxadiazolyl]amino] methyl-phenyl]methyl]methyl-piperazinecarboxylate, 25 isopropyl (2S)[[5-chloro[[5-(3-hydroxycyclobutyl)-1,3,4-oxadiazolyl]amino] methyl-phenyl]methyl]methyl-piperazinecarboxylate isopropyl (2S)[[2,5-dimethyl[[5-[(2S)methylsulfonylpyrrolidinyl]-1,3,4- oxadiazolyl]amino]phenyl]methyl]methyl-piperazinecarboxylate, isopropyl (2S)[[3-[[5-[(1S)hydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5- 30 dimethyl-phenyl]methyl]methyl-piperazinecarboxylate, isopropyl (2S)[[5-chloromethyl[[5-(5-oxopyrrolidinyl)-1,3,4-oxadiazol yl]amino]phenyl]methyl]methyl-piperazinecarboxylate, isopropyl (2S)[[3-[[5-[(1R)aminoethyl]-1,3,4-oxadiazolyl]amino]-2,5-dimethyl- phenyl]methyl]methyl-piperazinecarboxylate 35 2,2,2-trifluoroethyl (2S)[[5-chloro[[5-(cyanomethyl)-1,3,4-oxadiazolyl]amino]- 2-methyl-phenyl]methyl]methyl-piperazinecarboxylate, 2,2,2-trifluoroethyl (2S)[[3-[[5-(3-hydroxycyclobutyl)-1,3,4-oxadiazolyl]amino]- 2,5-dimethyl-phenyl]methyl]methyl-piperazinecarboxylate, ethyl (2S)[[3-[[5-[(1R)hydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5-dimethyl- phenyl]methyl]methyl-piperazinecarboxylate, isopropyl (2S)[[3-[[5-[(1S)-1,2-dihydroxyethyl]-1,3,4-oxadiazolyl]amino]-2,5- dimethyl-phenyl]methyl]methyl-piperazinecarboxylate, 5 isopropyl (2S)[[5-chloromethyl[(5-morpholinyl-1,3,4-oxadiazol yl)amino]phenyl]methyl]methyl-piperazinecarboxylate, tert-butyl (2S)[[5-chloro[[5-(hydroxymethyl)oxazolyl]amino]methyl- phenyl]methyl]methyl-piperazinecarboxylate, [(1R)-2,2,2-trifluoromethyl-ethyl] (2S)[[3-[[5-[(1S)-1,2-dihydroxyethyl]-1,3,4- 10 oxadiazolyl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinecarboxylate, isopropyl (2S)[[2,5-dimethyl[[5-[(3R)-tetrahydrofuranyl]-1,3,4-oxadiazol yl]amino]phenyl]methyl]methyl-piperazinecarboxylate, isopropyl (2S)[[3-[[5-[(2S,3R)hydroxypyrrolidinyl]-1,3,4-oxadiazol yl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinecarboxylate, 15 cyclopentyl-[(2S)[[3-[[5-[(2S,3R)hydroxypyrrolidinyl]-1,3,4-oxadiazol yl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinyl]methanone, (3,3-difluorocyclopentyl)-[(2S)[[3-[[5-[(2S,3R)hydroxypyrrolidinyl]-1,3,4- oxadiazolyl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazin yl]methanone, 20 [(1R)-2,2,2-trifluoromethyl-ethyl] (2S)[[3-[[5-[(2S,3R)hydroxypyrrolidinyl]- 1,3,4-oxadiazolyl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazine carboxylate, 2,2,2-trifluoroethyl (2S)[[3-[[5-[(2S,3R)hydroxypyrrolidinyl]-1,3,4-oxadiazol- 2-yl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinecarboxylate, 25 [(1R)methylpropyl] (2S)[[3-[[5-[(2S,3R)hydroxypyrrolidinyl]-1,3,4- oxadiazolyl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinecarboxylate isopropyl (2S)[[2,5-dimethyl[[5-[(3S)oxopyrrolidinyl]-1,3,4-oxadiazol yl]amino]phenyl]methyl]methyl-piperazinecarboxylate, or pharmaceutically acceptable salts, hydrates or solvates thereof.
14. The compound according to any one of claims 1-13 wherein said compound is [(1R)- 35 2,2,2-trifluoromethyl-ethyl] (2S)[[3-[[5-[(1S)-1,2-dihydroxyethyl]-1,3,4- oxadiazolyl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinecarboxylate, or pharmaceutically acceptable salts thereof.
15. The compound according to any one of claims 1-13 wherein said compound is isopropyl (2S)[[3-[[5-[(2S,3R)hydroxypyrrolidinyl]-1,3,4-oxadiazol yl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinecarboxylate, or pharmaceutically acceptable salts thereof.
16. The compound according to any one of claims 1-13 wherein said compound is isopropyl (2S)[[2,5-dimethyl[[5-[(2S)methylsulfonylpyrrolidinyl]-1,3,4- oxadiazolyl]amino]phenyl]methyl]methyl-piperazinecarboxylate, or pharmaceutically acceptable salts thereof.
17. The compound according to any one of claims 1-13 wherein said compound is cyclopentyl-[(2S)[[3-[[5-[(2S,3R)hydroxypyrrolidinyl]-1,3,4-oxadiazol yl]amino]-2,5-dimethyl-phenyl]methyl]methyl-piperazinyl]methanone, or pharmaceutically acceptable salts thereof.
18. A compound according to any one of claims 1-17 for use as a medicament.
19. Use of a compound according to any one of claims 1-17 in the manufacture of a medicament for treatment of autoimmune or inflammatory diseases.
20. Use according to claim 19, wherein the autoimmune or inflammatory disease is psoriasis.
21. A pharmaceutical composition comprising a compound according to any one of 25 claims 1-17 together with a pharmaceutically acceptable vehicle or excipient or pharmaceutically acceptable carrier(s).
22. The pharmaceutical composition according to claim 21 together with one or more other therapeutically active compound(s).
23. Use of a compound according to according to any one of claims 1-17, optionally together with a pharmaceutically acceptable carrier or one or more excipients, in the manufacture of a medicament for preventing, treating or ameliorating psoriasis, wherein the medicament is optionally formulated for administration in combination with other 35 therapeutically active compounds.
24. Use of a compound according to any one of claims 1-17 in the manufacture of a medicament for treatment of a disease, disorder or condition, which disease, disorder or condition is responsive of modulation of RORgamma. 5
25. A compound according to general formula (II) (II) wherein R is selected from the group consisting of halogen and (C –C )alkyl, wherein said (C – 2 1 4 1 10 C )alkyl is optionally substituted with one or more substituents independently selected from halogen; R3 is selected from (C1–C4)alkyl; 15 R4 is selected from the group (C1–C4)alkyl; R is selected from the group consisting of (C –C )alkyl, (C –C )cycloalkyl, phenyl and - 5 1 6 3 7 OR ; wherein said (C –C )alkyl, (C –C )cycloalkyl, phenyl and -OR is optionally a 1 6 3 7 a substituted with one or more substituents independently selected from halogen.
26. The compound according to claim 25, said compound being selected from the list consisting of tert-butyl (2S)[[3-(aminocarbamothioylamino)chloromethyl-phenyl]methyl] methyl-piperazinecarboxylate, 25 1-amino[3-[[(3S)benzoylmethyl-piperazinyl]methyl]chloromethyl- phenyl]thiourea, isopropyl (2S)[[3-(aminocarbamothioylamino)chloromethyl-phenyl]methyl] methyl-piperazinecarboxylate, isopropyl (2S)[[3-(aminocarbamothioylamino)-2,5-dimethyl-phenyl]methyl] 30 methyl-piperazinecarboxylate, tert-butyl (2S)[[3-(aminocarbamothioylamino)-2,5-dimethyl-phenyl]methyl] methyl-piperazinecarboxylate, 1-amino[3-[[(3S)(cyclobutanecarbonyl)methyl-piperazinyl]methyl]-2,5- dimethyl-phenyl]thiourea, isopropyl (2S)[[3-(aminocarbamothioylamino)(difluoromethyl)methyl- phenyl]methyl]methyl-piperazinecarboxylate, 5 1-amino[3-[[(3S)(cyclobutanecarbonyl)methyl-piperazinyl]methyl] (difluoromethyl)methyl-phenyl]thiourea, 1-amino[3-[[(3S)(cyclopentanecarbonyl)methyl-piperazinyl]methyl]-2,5- dimethyl-phenyl]thiourea. 10
27. A compound according to general formula (IX) (IX) wherein R2 is selected from the group consisting of halogen and (C1–C4)alkyl, wherein said (C1– C )alkyl is optionally substituted with one or more substituents independently selected from halogen; 20 is selected from (C –C )alkyl; R3 1 4 R4 is selected from the group (C1–C4)alkyl; R5 is selected from the group consisting of (C1–C6)alkyl, (C3–C7)cycloalkyl, phenyl and - 25 OR ; wherein said (C –C )alkyl, (C –C )cycloalkyl, phenyl and -OR is optionally a 1 6 3 7 a substituted with one or more substituents independently selected from halogen.
28. The compound according to claim 27, said compound being selected from the list consisting of 30 tert-butyl (2S)[(5-chloroisothiocyanatomethyl-phenyl)methyl]methyl- piperazinecarboxylate, [(2S)[(5-chloroisothiocyanatomethyl-phenyl)methyl]methyl-piperazinyl]- phenyl-methanone, isopropyl (2S)[(5-chloroisothiocyanatomethyl-phenyl)methyl]methyl- piperazinecarboxylate, isopropyl (2S)[(3-isothiocyanato-2,5-dimethyl-phenyl)methyl]methyl-piperazine- 1-carboxylate, 5 tert-butyl (2S)[(3-isothiocyanato-2,5-dimethyl-phenyl)methyl]methyl-piperazine- 1-carboxylate, cyclobutyl-[(2S)[(3-isothiocyanato-2,5-dimethyl-phenyl)methyl]methyl-piperazin- 1-yl]methanone, isopropyl (2S)[[5-(difluoromethyl)isothiocyanatomethyl-phenyl]methyl] 10 methyl-piperazinecarboxylate, cyclobutyl-[(2S)[[5-(difluoromethyl)isothiocyanatomethyl-phenyl]methyl] methyl-piperazinyl]methanone, cyclopentyl-[(2S)[(3-isothiocyanato-2,5-dimethyl-phenyl)methyl]methyl- piperazinyl]methanone.
29. The compound according to any one of claims 1-18 and 25-28 substantially as herein described with reference to any example thereof.
30. Use according to any one of claims 19, 20, 23 and 24 substantially as herein 20 described with reference to any example thereof.
31. The pharmaceutical composition according to claim 21 or 22, substantially as herein described with reference to any example thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16020268.5 | 2016-07-13 | ||
EP16020268 | 2016-07-13 | ||
PCT/EP2017/067390 WO2018011201A1 (en) | 2016-07-13 | 2017-07-11 | Heteroaromatic modulators of the retinoid-related orphan receptor gamma |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ749301A NZ749301A (en) | 2021-03-26 |
NZ749301B2 true NZ749301B2 (en) | 2021-06-29 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2426407T3 (en) | Pyrrolo [2,3-d] pyrimidine compounds | |
EA031223B1 (en) | COMPOUNDS THAT INHIBIT Mcl-1 PROTEIN | |
JP2019527718A (en) | TLR7 / 8 antagonists and their use | |
KR20200012833A (en) | 11,13-modified saxitoxin for pain treatment | |
JP2023065588A (en) | Tlr7/8 antagonists and uses thereof | |
US10934282B2 (en) | Heteroaromatic modulators of the retinoid-related orphan receptor gamma | |
KR102653190B1 (en) | Highly active STING protein agonist compounds | |
JP2021533125A (en) | TLR7 / 8 antagonists and their use | |
KR20110113755A (en) | Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer | |
CA3110436C (en) | High activity sting protein agonist | |
EP3148963A1 (en) | 1 -(cyclopent-2-en-1 -yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as cxcr2 inhibitors | |
US20220339160A1 (en) | Adenosine receptor antagonist | |
EP3929188A1 (en) | Pd-l1 antagonist compound | |
NZ749301B2 (en) | Heteroaromatic modulators of the retinoid-related orphan receptor gamma | |
CA3160606A1 (en) | Pd-l1 antagonist compound | |
KR20180050408A (en) | Non-steroidal glucocorticoid receptor modulators for local drug delivery | |
US20220267350A1 (en) | Adenosine receptor antagonist | |
WO2020035556A1 (en) | Novel heteroaromatic modulators of the retinoid-related orphan receptor gamma | |
CN116348117A (en) | HPK1 kinase inhibitor compounds | |
WO2020035557A1 (en) | Novel heteroaromatic modulators of the retinoid-related orphan receptor gamma |